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ABSTRACT OF THESIS
Measurement of PG and TX synthesis in reproductive
tissues of the rat were carried out using radioimmunoassay.
The study was in 3 main parts.
1. Measurement of PG and TX synthesis by ovarian tissue in
relation to ovulation. Between pro-oestrus and oestrus,
PGE-2, PGF-2a, 6-keto-PGF-loc production increased but there
was a preferential increase in PGE-2. This was not due
to altered arachidonic acid availability, decreased PGE-2
metabolism or increased conversion of PGF-2otto PGE-2. It
is proposed that increased ovarian cyclooxygenase activity
could increase the ratio of PGE-2 to the other PGs and
TX at the time of ovulation.
2. Measurement of PG and TX synthesis by the hypothalamus in
relation to LH release. PG and TX production by ME
homogenates showed a diurnal variation, being high at
06:00h and low at 18:00h. There was an extra peak in
PGE-2 production at 18:OOh on pro-oestrus which is the
time of LH release in the rat. Treatment of long-term
OVX oestrogen-primed rats with progesterone, stimulated
PGE-2 production by the ME. While 2-hydroxy oestradiol
had no effect, NA stimulated PG and TX production by the
ME. Since there are similarities in ME PGE-2 production
and plasma progesterone concentrations it is proposed
that progesterone stimulates PGE-2 synthesis in this
tissue - possibly by causing NA release from noradrenergic
nerve endings.
PG and TX production by AH-POA homogenates peaked at
22:OOh on each day. However, there was no clear
correlation between PG and TX production by the AH-POA and
LH release.
PG synthesis by the brain has been proposed to be
essential for LH release in the rat. This hypothesis was
tested by examining the effect of a PG synthesis
inhibitor, Froben, on the pro-oestrous LH surge. Froben
completely inhibited the surge in 33% of treated animals
and delayed the surge in the remaining animals. These
results are in support of a physiological role for PGs in
LH release.
Measurement of PG and TX synthesis by the uterus during
the oestrous cycle and in relation to the effects of
ageing on the process of implantation. Uterine PG
and TX production increased on pro-oestrus and peaked
at 02:OOh on oestrus. Endometrial PGF-2a and TXB-2
showed the greatest percentage increase. Treatment
of long-term OVX oestrogen-primed rats with progesterone
stimulated uterine PGF-2a and TXB-2 production suggesting
that ovarian steroids may be the physiological stimulus
for uterine PG and TX synthesis. It is speculated that
the peak in uterine PG and TX production at 02 :00h
on oestrus may be associated with changes in uterine
motility at that time.
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The failure of the uterus to support pregnancy may be
a factor which contributes to the reduced fertility of aged
animals. Since PGs have been implicated in the process
of blastocyst implantation the hypothesis that aged uteri show
a deficiency in PG synthesis was tested. Uterine PGE-2
synthesis was reduced in the aged animal and there was a
diminished response to oestrogen and progesterone treatment
with ageing. Reduced PGE-2 synthesis may have significant
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GENERAL INTRODUCTION
Prostaglandins (PGs) have several characteristics which
allow them to be distinguished from the classical hormones.
Firstly, it appears that most, if not all, cell types
have the capacity to synthesize PGs. In the female
reproductive tract, PGs have been identified in the ovary,
uterus, decidual tissue, menstrual fluid, placenta and amniotic
fluid (see Poyser, 1981).
A second distinguishing feature of PGs is that they
are not stored in tissues (with the only exception of PGs
stored in primate seminal vesicles) and their synthesis must
therefore immediately precede their release into tissue fluids
or into the circulation. Many stimuli, including simple
mechanical damage^cause PG release (Pace-Asciak and Wolfe,
1968; Flower and Blackwell, 1976).
A third distinguishing feature of PGs is their short
half-life. PGE and PGF are effectively metabolized in the
circulation by one passage of the blood through the lungs
(Ferreira and Vane, 1967). This short half-life suggests
that they may act as local mediators or modulators of cell
function but are not hormones by the classical definition
since they cannot circulate in biologically active
concentrations. Thromboxane A-2 (TXA-2) is rapidly hydrolyzed
into the almost inactive TXB-2 with a half-life of about 30
sec in aqueous solution. PGI-2 escapes lung metabolism and has
recently been proposed as a circulating hormone (Moncada,
Korbut, Bunting and Vane, 1978).
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Chemically, the PGs are 20-carbon fatty acids consisting
of 2 side chains of 7 and 8 carbon atoms respectively, linked
by a cyclopentane ring. PGs of the 2-series are derived from
arachidonic acid which is obtained from the diet or
synthesized from another dietary fatty acid linoleic acid.
The first stage in the biosynthesis of PGs of the 2-series
requires the release of free arachidonic acid from cholesterol
esters, phospholipids or triglycerides by the action of the
appropriate esterases and lipases. Arachidonic acid is then
converted by the action of a membrane-bound enzyme complex
(PG synthetase) initially by the cyclooxygenase component
into PGH-2, an unstable endoperoxide intermediate. PGH-2 is then
converted by other enzymes and factors in the PG synthetase
complex into the different PGs and TX. The latter compound is
distinguished chemically by the presence of an oxygen atom in the
ring system. Lipoxygenation of arachidonic acid gives rise to
another group of compounds, the leukotrienes.
Since PGs were first identified in seminal fluid (von
Euler, 1932) much attention has been directed towards their
connection with reproductive function. The particular
reproductive processes which have been the subject for study
in this thesis are ovulation and the release of gonadotroph!'ns.
In addition, uterine PG and TX production either during the
oestrous cycle or by uterine tissue which has been sensitized
for the decidual cell response has been investigated.
3
The unifying aim of these studies is to investigate the
physiological significance of PG and TX in these processes
and also to investigate the regulation of PG and TX synthesis
by reproductive tissues in the rat.
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Prostaglandins and Ovulation
The involvement of PGs in ovulation was first proposed by
Armstrong (1970), as an extension of the hypothesis of Pharris
and Wyngarden (1969). The latter authors suggested that PGF-2a
could precipitate luteolysis by virtue of its potent venoconstrictive
activity (Du Charme and Weeks, 1968). Luteolysis was proposed
to arise as the result of luteal ischaemia. Armstrong (1970)
proposed that luteinizing hormone (LH), by increasing cholesterol
esterase activity (Behrman and Armstrong, 1969) may cause
increased release of arachidonic acid from cholesterol arachidonate
and hence may increase PGF-2o: production. He suggested that the
increased PGF-2o; 1 evels, acting in concert with increased capillary
permeability in response to LH (Zachariae, 1958) may cause
intrafol 1 icular fluid accumulation and hence follicular rupture.
Further support for the hypothesis that PGs are involved in
ovulation arose from the observation that inhibitors of PG
synthesis can block ovulation. Indomethacin (Armstrong and Grinwich,
1972) or aspirin (Orczyk and Behrman, 1972) administered to rats
at the time of the LH surge, blocks ovulation. Since exogenous
LH did not overcome this block it was concluded that indomethacin
was not acting by preventing LH release from the brain but rather,
inhibited ovulation by a direct action on the ovary (Armstrong and
Grinwich, 1972). Tsafriri, Lindner, Zor and Lamprecht (1972)
confirmed that the anti-ovulatory action of indomethacin was by
a direct action on the ovary, preventing follicular rupture while
permitting ovum maturation.
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In rabbits, indomethacin prevented ovulation when injected either
30 min before administering exogenous LH (Grinwich, Kennedy and
Armstrong, 1972) or 8h after mating (O'Grady, Caldwell, Auletta
and Speroff, 1972). Indomethacin neither interfered with
follicular 1uteinization in the rabbit (Grinwich et al., 1972),
nor prevented the elevation of progesterone levels to the usual
post-ovulatory range (O'Grady et al., 1972), suggesting that
indomethacin affects only the physical process of ovulation,
while follicular development and secretory potential remain
intact. Likewise, indomethacin inhibited human chorionic
gonadotropin'n (hCG) - induced ovulation in the Rhesus monkey,
without interfering with follicular maturation or inhibiting
steroid production (Wallach, de la Cruz, Hunt, Wright and
Stevens, 1975). These initial findings were confirmed for
several other species including mice (Lau, Saksena and Chang,
1972) marmoset monkeys (Maia, Barbosa and Continho, 1978) and
pigs (Ainsworth, Tsang, Downey, Barker, Marcus and Armstrong,
1979). The only study in women, using aspirin to block PG
synthesis failed to demonstrate ovulation blockade (Chaudhuri
and Elder, 1976). However, the dosage of aspirin may have been
insufficient to block RG synthesis in the ovarian follicles, a
paramete'r which was not assessed in the study. The toxicity
of indomethacin in all of these experiments is an unknown
factor, and the action of the drug as an inhibitor of PG
synthesis, may not be its only effect. However, since these
early observations, it has been reported that superovulation,
induced by pregnant mare serum gonadotrophs (PMSG) or hCG in
immature rats is inhibited by anticyclooxygenase antiserum
in spite of continued ovarian progesterone production (Satoh,
Fukoka, Wu, Mitsuhashi, Kinoshita and Sakamoto, 1981).
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These studies indicate that ovarian PG synthesis is necessary
for ovulation to occur.
Effects of PG administration on ovulation
In rats in which ovulation had been blocked by indomethacin,
PGE-2 administration overcame this block in the majority of
animals treated (Tsafriri et al., 1972). In nembutal-treated
rats (where the LH surge is prevented), PGE-2 treatment during
the afternoon of pro-oestrus, induced final maturation of the
ovum as well as ovulation (Tsafriri et al., 1972). However it
had previously been shown that indomethacin will block ovulation
while ovum maturation proceeds normally. These observations
suggest that, although PGE-2 can mimic LH in inducing ovum
maturation and ovulation, the former process does not require
endogenous PG production (Tsafriri et al., 1972). In monkeys
(Wallach, Bronson, Hamada, Wright and Stevens, 1975) and rabbits
(Diaz-Infante, Wright and Wallach, 1974), exogenously
administered PGF-2o;can reverse the inhibitory effect of
indomethacin on ovulation induced by gonadotroph!'n.
A species difference is apparent when considering which PG
is most effective in causing ovulation. Treatment of rabbits
with PGE-2 actually delayed hCG-induced ovulation (Richman,
Wright and Wallach, 1972) whereas PGE-2 was most effective in
causing ovulation in the rat (Tsafriri et al., 1972). More
recently, it has been shown that PGF-2o: alone induced ovulation
in the absence of gonadotropin'n in the isolated perfused rabbit
ovary (Wallach, Wright and Hamada, 1978; Kobayashi, Santutti,
Wright and Wallach, 1981).
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Ovarian PG Synthesis
During the process of ovulation, the endogenous levels of
PGs in the ovary undergo marked changes. Follicles isolated from
rabbits at various times between the ovulatory LH surge and
ovulation showed a striking increase in PG levels as ovulation
approached (Le Maire, Yang, Behrman and Marsh, 1973). PGF and
PGE levels were similar although PGF levels had increased 50-fold
whereas PGE levels had only increased 11-fold.
In a study, extended to include follicles obtained from
rabbits up to 48h after hCG injection, Yang, Marsh and Le Maine
(1974) found that PGF levels fell rapidly after ovulation whereas
PGE levels continued to rise for several hours after ovulation
before declining. This suggests differential roles for these
two PGs in ovulation in the rabbit. Moreover, the increase in
both PGs was confined to the follicles which went on to ovulate
(Yang et al., 1974).
Indomethacin administration just prior to hCG or LH
treatment, or after mating abolished the increase in PG levels
in rabbit follicles as well as preventing ovulation (Yang et al.,
1973). Armstrong, Grinwich, Moon and Zamecnik (1974)
demonstrated that the anti-ovulatory action of indomethacin was
local by micro-injection of indomethacin into rabbit follicles.
As well as blocking ovulation, the injection prevented the
LH-induced increase in follicular PGF. Additionally they
demonstrated that while treatment with PGF antiserum blocked
ovulation, PGE antiserum was only partially effective
(Armstrong et al., 1974). This further suggests that PGF may
be more important than PGE in mediating LH-induced ovulation
at the follicular level in the rabbit.
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Levels of PGE and PGF in rat ovaries increased to reach
a peak at 05.00h on oestrus, i.e. shortly after the time of
ovulation (Bauminger and Lindner, 1975). PGF levels increased
6-fold whereas PGE levels increased 30-fold. There was a
concomitant increase in PG synthetase levels. By lO.OOh on
oestrus, levels of PGE, PGF and PG synthetase had declined to
basal values. Administration of nembutal prevented the pre¬
ovulatory rise of both PGE and PGF. LH administration restored
the rise in PGE and PGF levels (Bauminger and Lindner, 1975),
suggesting that LH stimulates PG synthesis by the ovary.
Intrafollicular PGE and PGF levels also increased towards
the time of ovulation in the rat (Le Mai re, Leidner and Marsh,
1975). Early on pro-oestrus, PG levels were low and PGF levels
exceeded PGE levels. Towards the time of ovulation, the levels
of both PGE and PGF increased and at the time of ovulation, PGE
levels exceeded PGF levels. Within 4h both PGE and PGF levels
had returned to basal, and the ratio of PGE to PGF had reverted
back in favour of PGF (Le Mai re et al., 1975).
Pre-ovulatory increases in ovarian PG levels have also been
demonstrated for other species. In the pig, PGF and PGE levels
in follicular fluid increased a few hours prior to ovulation
(Tsang, Ainsworth, Downey and Armstrong, 1979). Ovulation and
the increase in PG levels were prevented by indomethacin
treatment (Ainsworth et al., 1979) and, as in the rabbit, PGF-2o:
but not PGE-2 overcame the inhibition of ovulation by
indomethacin (Ainsworth et al., 1979; Downey and Ainsworth,
1980). In guinea-pigs, ovarian synthesis of PGE-2 and PGF-2o6
increased markedly 3 days before ovulation and reached a peak on
the day of ovulation. PGF levels exceeded PGE levels throughout
the pre-ovulatory period (Sharma, Wilson and Pugh, 1976).
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In the ewe, follicular PGE and PGF levels were increased 8h
after the initiation of the LH surge, again PGE-2 showing a
greater percentage increase in the pre-ovulatory period (Murdoch,
Dailey and Inskeep, 1981). Increased levels of PGF-^x have been
observed in venous blood draining the human ovary containing the
developing follicle when compared to the inactive ovary (Askel ,
Stiromberg and Hammond, 1977). The concentration of PGF-2a was
higher in corpora lutea immediately after ovulation than at any
time during the luteal phase (Swanston, Mcnatty and Baird, 1977).
Similarly the concentrations of PGF-2o: in fluid taken from
pre-ovulatory follicles was higher than in fluid taken from
three less mature follicles (Edward, 1973). In a large-scale
study, PGF-2q! concentrations measured in human follicular fluid
rose 2 to 3 days before ovulation, and reached a peak at the
time of ovulation, before falling after mid-cycle (Darling,
Jogee and Elder, 1982). These observations are consistent with
the proposal that PGs play a role in the ovulatory process at
the fol1icular level.
The stimulus for ovarian PG synthesis
The stimulus for ovarian PG synthesis appears to be
gonadotrophs since in all these species, the increase in PG
concentrations follows either the ovulatory surge of LH or the
exogenous administration of LH or hCG. Indeed, injection of
antiserum to LH suppressed PG synthesis by ovarian homogenates,
whereas simultaneous injection of LH or addition of LH to the
homogenates restored PG synthesis (Chasalow and Pharriss, 1972).
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Bauminger and Lindner (1975) also reported that pre-treatment
of rats with antiserum to the /3-subunit of LH prevented both
the increase in PG levels and the increase in PG synthetase
levels which normally occur between late pro-oestrus and early
oestrus . PG synthetase levels in granulosa cells are also
increased 4 to 8h after the ovulatory LH surge. This increase
in PG synthetase levels can be stimulated by treating PMSG-primed
rats with hCG (Clark, Chainy, Marsh and Le Mai re, 1979).
In addition to LH, follicle stimulating hormone (FSH)
stimulated follicular PGF and PGE synthesis in the rat (Bauminger
et al., 1975). This effect was not due to contamination with
LH, as a stimulatory effect of FSH was still present after
treatment of the gonadotrophs preparation with antiserum to
the sub-unit of LH.
In follicles isolated from rabbits at oestrus PGE synthesis
could be stimulated by LH or hCG whereas FSH, prolactin or bovine
serum albumin were without effect (Marsh, Yang and Le Maire,
1974). The synthesis of PGF in bovine follicular tissue in vitro
was stimulated by LH (Shemesh and Hansel, 1975), and human
follicular tissue synthesizes PGF in vitro after exposure to
gonadotrophin (Plunkett, Moon, Zamecnik and Armstrong, 1975).
More recently, Veldhuis, Klase and Demers (1982) reported that
LH elicited a dose-dependent increase in 6-keto-PGF-loC
accumulation in granulosa cells isolated from mature swine
Graafian follicles, while FSH, prolactin, adrenaline, oestradiol-
17/3 and PGE - 2 were devoid of this activity. LH also stimulated
6-keto-PGF-lo: synthesis by rat granulosa cells incubated in
vitro (Koos and Clark, 1982). All these studies indicate that
LH released from the anterior pituitary gland is the
physiological stimulus for increased PG production by the ovary.
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Luteinizing hormone-releasing hormone (LHRH) may mimic the
actions of LH on the ovary. Analogues of LHRH have been reported
to stimulate follicular luteinization (Hseuh, Wang and Erickson,
1980) oocyte maturation (Hseuh et al , 1980; Hillensjo and
Le Maire, 1980) and progesterone accumulation (Knecht, Katz and
Catt, 1981; Jones and Hseuh, 1981). Furthermore, an LHRH-1ike
peptide has been identified in ovarian follicular fluid (Ying,
Ling, Bohlen and Guilleman, 1981). Therefore LHRH may be the
intra-ovarian stimulant of PG synthesis. In a study of the
effects of LHRH and LHRH analogues on ovarian granulosa cell
PG synthesis, Clark, Thibier and Marsh (1980a), observed that
these compounds, when added in vitro to cell incubates from
PMSG-treated rats, stimulated PGE and PGF accumulation. A
stimulatory effect of an LHRH analogue [D-Alab,des-Gly-NH2'° ]
LHRH-ethylamide on ovarian PGE synthesis was also observed when
administered to hypophysectomised PMSG-treated immature rats
(Ekholm, Clark, Magnusson, Isaksson and Le Maire, 1982). Thus
although the physiological role of locally produced LHRH-like
peptides is unclear, they may control ovulation, in addition to
LH, by stimulating ovarian PG synthesis. Indeed ovulation
induced by[D-Ala " , des-Glyn-NH2'° ]
LHRH ethylamide in PMSG-treated rats was blocked by indomethacin
administra-tion (Ekholm et al., 1982).
Involvement of cAMP in ovarian PG synthesis
.Kuehl, Humes, Tarnoff, Cirillo and Ham (1970) suggested
initially that PGs function as a necessary intermediate in the
effect of LH upon ovarian adenosine 3' 5' monophosphate (cAMP)
production. They observed a dose-related increase in cAMP
production by mouse ovaries in response to PGE-1.
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The PG-induced increase in cAMP was blocked by a PG antagonist,
7-oxa-13-prostynoic acid, and in addition the antagonist blocked
LH-induced cAMP formation. However, when the time courses of
the accumulation of ovarian cAMP and PGE in response to LH were
compared, no changes in ovarian PGE content could be detected
after injection of LH at a time when cAMP accumulation was
markedly enhanced (Rigler, Peake and Ratner, 1976). Moreover,
indomethacin did not inhibit the LH-induced rise in cAMP
(Raj, 1974). These results suggest that it is unlikely that PGs
are mediators of LH action on follicular cAMP production as
suggested by Kuehl et al, (1970). It is more likely that the
converse is true, in that cAMP mediates the stimulation of
ovarian PG accumulation by LH. cAMP added to incubates of
ovarian follicles from rabbits (Marsh, Yang and Le Mai re, 1974)
and rats (Clark, Marsh and Le Maire, 1978a) mimics the effect of
LH in stimulating the synthesis of both PGE and PGF. This effect
was specific for cAMP, as other nucleotides such as adenosine
triphosphate (ATP), adenosine diphosphate (ADP), 3' adenosine
monophosphate (3' AMP), 5' AMP, cyclic guanosine monophosphate
(cGMP) and 0 '-monobutyryl cAMP did not stimulate PGE
accumulation (Clark et al., 1978<). However, a cAMP analogue Nfa
-monobutyryl cAMP produced a similar increase in PGE accumulation
to that seen with LH (Clark et al., 1978a). Although Clark et
al., (1978a) did not observe a stimulation of PGE synthesis with
cGMP, it has been reported that 8-bromo- cGMP increases PGE
production by isolated rat Graafian follicles during a 6h
incubation (Zor, Strulovici, Nimrod and Lindner, 1977).
Information concerning the influence of LH on cGMP levels is
conflicting however.
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Whereas hCG has been reported to stimulate ovarian cGMP levels
(Rao and Carman, 1973), other workers report that LH decreased
cGMP levels in rat ovaries in vitro (Ratner, 1976). Therefore,
it is difficult to interpret the effects of 8-bromo-cGMP on
ovarian PGE accumulation.
Ovarian PGE synthesis is also stimulated by two other agents
which elevate follicular cAMP levels, namely, 1-methyl-3 isobutyl
xanthine (Zor et al., 1977) and cholera toxin (Clark et al.,
1978a). With the exception of the anomalous result of Zor et
al., (1977), these results suggest that the stimulation of
follicular PG synthesis is specific for cAMP-like nucleotides.
The increase in PGE accumulation by cAMP in rat follicles
occurred after 3h which is similar to the time course of PG
stimulation by LH (Clark et al., 1978a). In the mouse, cAMP
stimulated ovarian PG production (Kuehl, Cirillo, Ham and
Humes, 1972), and likewise in pig follicles, increased cAMP
levels preceded the pre-ovulatory increase in follicular PG
production (Tsang et al., 1979).
As well as the stimulation of ovarian PGE synthesis by cAMP,
it has already been stated that PGE in turn stimulates cAMP
formation (Kuehl et al., 1970) indicating that a positive
feedback mechanism may operate. Quenching of this feedback
mechanism could be brought about by the refractoriness of ovarian
tissue to PGE which has been observed after continued exposure to
this PG (Zor, Lamprecht, Misulovin, Koch and Lindner, 1976).
All these results suggest that LH-induced PG production
within the' follicle is mediated by cAMP. However, increased
ovarian cAMP levels do not appear to be a pre-requisite for
increased PG synthesis.
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Concanavalin A induced PGE production isolated Graafian
follicles after a 2h incubation with no detectable rise in
cAMP levels until 6h of incubation (Strulovici, Weinstein and
Zor, 1981). Moreover, colchicine blocked the effect of
Concanavalin A on cAMP formation with no inhibition of follicular
PGE synthesis (Strulovici et al., 1981). Additional support for
a cAMP-independent mechanism for ovarian PGE synthesis came
from the observation that [D-Ala6 , des-Gly-NH2 °] LHRH-ethylamide
stimulated PGE accumulation in rat granulosa cells without an
associated effect on cAMP accumulation in these cells (Clark et
al., 1980a).
PG synthesis and ovarian steroid secretion
It has been suggested (Le Maire and Marsh, 1975) that the
effect of LH and cAMP on PG synthesis might be mediated by
increasing steroidogenesis. However, Bauminger, Lieberman and
Lindner (1975), have shown that stimulation of PG accumulation
in rat follicles by LH and FSH was unimpaired during suppression
of progesterone and oestrogen synthesis by aminoglutethimide.
Consequently, increased steroid production is not necessary for
increased PG production in the ovary.
The mechanism of LH-stimulated PG synthesis in the ovary
When considering the time course of follicular cAMP and PGE
accumulation in response to LH, it is apparent that the two
responses differ markedly.
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Whereas cAMP accumulation was augmented within minutes (Marsh,
Mills and Le Mai re, 1972) there was a delay of 2 to 3h between
the exposure to LH (in vivo or in vitro) and the earliest
detectable increases in follicular PGs (Bauminger and Lindner,
1975). This lag period suggests that macromolecular synthesis
may participate in the mechanism of the LH-stimu!ated PG
accummulation. To test this hypothesis, Clark, Marsh and
Le Mai re (1976) incubated follicles from PMSG-treated rats
with LH in the presence of various concentrations of the
protein synthesis inhibitor puromycin. The LH-stimulated
PGE accumulation was lowered in the presence of lO^uM puromycin
and was completely inhibited at a concentration of lOOyuM.
Puromycin aminonucleoside, which does not inhibit protein
synthesis (Nathans and Neidle, 1963) had no effect on LH-
stimulated PGE accumulation (Clark et al., 1976). Further
studies showed that both the LH- and cAMP-induced increased in
follicular PGE production were blocked by inhibitors of protein
and nucleic acid synthesis (Zor et al., 1977). Indeed it has
been known for several years that protein and ribonucleic acid
(RNA) synthesis inhibitors will suppress ovulation (Pool and
Lipner, 1964; 1966). This effect of protein synthesis inhibitors
could be explained by their inhibitory effects on ovarian PG
synthesis. Increases in follicular RNA and protein synthesis
precede ovulation (Mills, 1975). Although the proteins affected
have not been identified, one of them may be PG synthetase.
Bauminger and Lindner (1975) have observed an increase in ovarian
PG synthetase activity in the rat ovary immediately before
ovula tion. They found a 50 to 80% increase in activity of the
enzyme and this was associated with the pre-ovulatory increases
in ovarian PG concentrations.
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In granulosa cells from immature PMSG-treated rats, LH was
found to stimulate PG synthetase activity approximately 5-fold
(Clark, Marsh and Le Maire, 1978b). A similar marked
stimulation of granulosa cell PG synthetase activity was observed
5h and lOh after in vivo exposure of immature PMSG-treated rats
to hCG (Clark, Chainy, Marsh and Le Maire, 1979). These authors
also found that in mature rats, granulosa cell PG synthetase
activity increased late on pro-oestrus by approximately 10-fold,
concomitantly with a 5-fold increase in follicular fluid PG
levels. It is apparent that an increase in PG synthetase
concentrations does take place following the LH surge, but prior
to ovulation.
Mechanism of PG-induced follicular rupture
PG synthesis in ovulatory follicles may be important in
the connective tissue decomposition and subsequent thinning
of the follicle wall. A comparison of the ultrastructure of
ovulatory follicles with follicles from indomethacin-treated
rabbits showed that, by 9h after coitus (near the time of
ovulation), the tissue at the apex of normal follicles begins
to thin opt, whereas follicles from indomethacin-treated
animals showed no signs of thinning as late as 12h post-coitus
(Espey, Coons, Marsh and Le Maire, 1981). In fact the normal
transformation of follicular fibroblasts from a quiescent to
a proliferative state was inhibited in indomethacin-treated
animals and it has been suggested that the normal elevation
in PGs might be necessary to stimulate the synthesis or release
of proteolytic enzymes from the fibroblasts (Espey et al., 1981).
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In support of this suggestion, PGE-1 and PGE-2, but not
PGF-2o:, have been shown to stimulate the production of the
enzyme, plasminogen activator, from rat granulosa cells
(Strickland and Beers, 1976). LH also stimulates granulosa cells
to produce this enzyme in vitro, although FSH is more active in
this respect. Plasminogen activator converts the inactive
protein plasminogen to plasmin which is capable of weakening the
follicular wall (Strickland and Beers, 1976).
In addition to the enzymatic weakening of the follicular
wall, a role for smooth muscle contractions in follicular
rupture has been proposed. The wall of the Graafian follicle
has contractile properties (Guttmacher and Guttmacher, 1921) and
the theca externa layer of rat Graafian follicles contains the
contractile proteins actin and myosin (Walles, Groschel-Stewart,
Owman, Sjoberg and Unsicker, 1978). In rabbits, ovarian
contractility is reduced by indomethacin and is restored
following PGF-2a administration (Diaz-Infante, Wright and
Wallach, 1974). It was proposed that, by stimulating ovarian
contractility, follicular rupture would be promoted. However,
in another study in rabbits, no association between ovarian
contractility, ovulation and the number of ovulation points
could be found (Demers and Gable, 1976).
Figure 1 shows a model for the biochemical mechanism of
ovulation.
LH/FSH
Figure 1. A model for the biochemical mechanism
of ovulation in the rat.
PL = phospholipids
AA = arachidonic acid
PGM = PG metabolites
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Summary and aims
In summary, PGs (particularly PGE-2) mimic many of the
biological actions of LH on the ovary - ovum maturation,
1uteinization, cAMP accumulation and steroidogenesis - but PGs
are not essential for these processes. However, PGs appear to be
indispensable for the process of follicular rupture. PGE-2 seems
to be the PG involved in ovulation in the rat, while PGF-2ais
involved in ovulation in other species.
Many features of the control of ovarian PG biosynthesis
remain unexplained. For example, the cellular mechanism which
brings about an apparently directional synthesis of PGs in the
rat requires investigation. In addition, the study of ovarian
PG synthesis has largely been confined to the E-series PGs,
and therefore the study of other cyclo-oxygenase products
of arachidonic acid metabolism in the ovary is required.
The majority of evidence suggests that LH stimulates an
increase in ovarian PG synthetase. However another possibility
is that the site of action of LH may be at the level of
catabolism of the PGs. In this case LH may inhibit PG breakdown
thereby increasing the accumulation of these substances.
The Experiments described in Section 2.1 were aimed at the
study of ovarian PGE-2, PGF-2a, 6-keto-PGF-lo: and TXB-2
synthesis during the oestrous cycle and at the elucidation of the
control of their synthesis by the rat ovary.
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PGs and Gonadotroph!"n Secretion
The secretion of anterior pituitary hormones is under
specific control by hypothalamic releasing factors, and by the
feedback action of gonadal, adrenal and thyroid hormones. The
releasing factors are themselves released from nerve endings
in the median eminence (ME) (Pelletier, Labrie, Puviani, Arimura
and Schally, 1974) and are transported to their site of action by
the hypophysial portal vascular system.
In the rat (Sarkar,.Chiappa, Fink and Sherwood, 1976)
and monkey (Neil 1, Dailey, Tson, Patton and Tindrill, 1976) it
has been demonstrated that the pre-ovulatory LH surge coincides
with a surge of luteinizing hormone-releasing hormone (LHRH) in
hypophysial portal blood. The LHRH surge depends upon the pre¬
ovulatory surge of circulating oestradiol-17/3 (Sarkar and Fink,
1979).
Much evidence is accumulating which suggests an involvement
of PGs in the control of gonadotropin'n release from the brain
and it has been postulated that PGs are an essential link between
the stimulatory effect of oestradiol and the LH surge (Craig,
1975).
PG synthesis by the brain
Hypothalamic tissue contains a relatively higher
concentration of PGs than other regions of the brain (Holmes and
Horton, 1968). These authors also found that, in general,
the concentration of PGF was greater than PGE.
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In agreement, Wolfe, Pappius and Marion (1976) found that
incubates of rat, cat and human cerebral cortex slices
synthesized more PGF-2o: than PGE-2. Moreover, noradrenaline
(NA), added in vitro, stimulated the formation of PGF-2o:in
slices and homogenates. In addition to PGE-2 and PGF-2o;, PGH-2
was converted to PGD-2 and 6-keto-PGF-lo: by rat brain homogenates
(Pace-Asciak and Nashat, 1976). Subsequent studies have shown
PGD-2 to be the major PG formed in rat brain (Saeed Abdel-Halim,
Hamberg, Sjoquist and Anggard, 1977; Saeed Abdel-Halim and
Anggard, 1979). Higher concentrations of PGD-2 were formed in
the pineal body, hypothalamus and pituitary gland than elsewhere
in rat brain (Narumiya, Ogorochi and Hayaishi, 1982).
Using a bioassay technique, Cseh, Szabo, Lang and Palkovits
(1978), demonstrated that PG concentrations were higher in the
hypothalamus than in other areas of the rat brain. PGF-2o:
levels exceeded PGE-2 levels in most tissues with the exception
of the median eminence (ME) where PGE-2 predominated. Moreover,
in the median eminence, PGE-2 concentrations were approximately
10-fold higher than elsewhere in the brain. Using
radioimmunoassay (RIA), Ojeda, Naor and McCann (1978) were able to
confirm the results of Cseh et al , (1978). They showed that the
PGE content of the ME was much higher than in the remainder of
the medial basal hypothalamus (MBH) in both male and female rats.
However, no difference in PGE content of the ME, MBH or anterior
pituitary gland was observed between male and female animals.
When considering the 'newer1 arachidonic acid
cyclooxygenase metabolites, it has been reported that TXB-2
formation by incubates of guinea pig and rat cerebral cortex was
5-6 fold greater than that of PGF-2o; or PGE-2 (Wolfe, Rostworoski
and Marion, 1976).
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However, divergent results exist as other workers report that
rat brain homogenates synthesize less TXB-2 than PGF-2a (Saeed
Abdel-Halim et al., 1977). The reason for differences in these
results is at present unclear, as both groups used a similar
GC-MS technique. The formation of 6-keto-PGF-loc in homogenates
of mouse, rat and rabbit brain was low in relation to that of
PGD-2, PGE-2 and PGF-2oc, but 6-keto-PGF-locwas the major PG
present in cerebral blood vessels (Saeed Abdel-Halim, Lindner,
Cseh and Anggard, 1980). Likewise, in the rat, 6-keto-PGF-lot
formation by homogenates of isolated brain microvessels was much
higher than in whole cortical homogenates, suggesting that
6-keto-PGF- let synthesis by the brain is of vascular, rather than
of neuronal origin (Birkle, Wright, Ellis and Ellis, 1981).
Information is lacking on the regional distribution of 6-keto-
PGF-lCtand TXB-2 in the brain.
Since PG synthesis by brain tissue has been demonstrated,
the proposal that PGs produced by the brain may be involved in
gonadotrophs secretion has gained support. In particular, the
higher concentration of PGE in the ME compared to other areas of
the brain suggests that PGE synthesis by this tissue (which is
also rich in releasing factors (Krulich, Quijada, Wheaton, Illner
and McCann', 1977) may play a role in the physiological control of
hypothalamo-pituitary function.
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Effects of indomethacin on ovulation
Indomethacin can block ovulation by a direct action on the
ovary (see earlier). In addition, indomethacin may also block
ovulation by inhibiting LH release (Orczyk and Behrman, 1972).
Ovulation in rats was blocked by indomethacin given as a single
injection 6h before the expected LH surge and this block was
overridden by LH administered 3h after the indomethacin (Orczyk
and Behrman, 1972). This dose of indomethacin reduced the
hypothalamic and pituitary PGF levels. This experiment suggests
that indomethacin blocked ovulation by preventing the release
of LH. However, the site of the blocking action of indomethacin
could have been either at the hypothalamic or pituitary level.
Support for a hypothalamic site of action of PG synthesis
inhibitors arose from experiments demonstrating that an aspirin-
induced blockade of ovulation was consistently reversed by LHRH
given twice to rats either 3h and 4h or 2h and 3h after aspirin
administration. However, LHRH did not reverse indomethacin-
induced ovulation block (Behrman, Orczyk and Greep, 1972). This
is inconsistent with the effects of LH on indomethacin-blocked
ovulation as reported by Orczyk and Behrman (1972) and suggests
that aspirin may exert its blocking effect on ovulation primarily
at the hypothalamic level, whereas indomethacin appears to block
ovulation at both the ovarian and hypothalamic levels. The fact
that indomethacin was equally effective in blocking ovulation
when given to rats before or after the pre-ovulatory LH surge
(Armstrong and Grinwich, 1972) argues primarily for an ovarian
site of action for indomethacin.
24
However, the latter authors noted a considerably higher incidence
of follicular 1uteinization and loss of uterine lumenal fluid
when indomethacin administration was delayed until 16:00h,
i.e. after the LH surge. The lack of follicular luteinization
or of evidence for progesterone secretion (as indicated by loss
of uterine lumen fluid) in rats which received indomethacin
before the critical period for LH release, suggests that LH
secretion was inhibited by indomethacin. Obviously, the timing
of indomethacin administration in relation to the LH surge is
crucial as to the overall effects produced.
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Effects of indomethacin on LH release
Although it is clear that inhibitors of PG synthesis are
capable of interfering with ovulation probably by inhibiting
LH release, in studies so far, indomethacin has failed to
suppress the pre-ovulatory LH surge (Tsafriri, Koch and Lindner,
1973; Sato, Taya, Jyujo and Igarashi, 1974). However, on the
basis of these two "indomethacin experiments" alone, it is not
possible to rule out an involvement of PGs in LH release as
the lack of effect of indomethacin treatment on the LH surge
in these two studies might be attributable to its relatively
poor uptake into the CNS (Hucker, Zacchei, Cox, Brodie and
Cantwell, 1966). Although no reports are available demonstrating
suppression of the pro-oestrous LH surge, indomethacin will
suppress plasma LH concentrations in ovariectomized rats (Ojeda,
Harms and McCann, 1975; Sato, Jyujo, Hirono and Iesaka, 1975).
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The intravenous injection of indomethacin 3 to 4 days after
ovariectomy failed to alter the pulsatile pattern of LH release
in rats, but a subcutaneous injection of indomethacin 20h before
blood sampling reduced the pulsatile rhythm of LH. A higher
dose given 30h prior to blood sampling completely abolished
the LH pulsatile rhythm (Ojeda et al., 1975). In further
support of a hypothalamic site of action of indomethacin, Harms,
Ojeda and McCann (1973), Spies and Norman, (1973), Harms, Ojeda
and McCann (1974) and Ojeda et al., (1975) reported that
indomethacin did not affect the LHRH-induced LH surge in
ovariectomized rats. In male rats, indomethacin reduced LH
concentrations in intact animals (Saksena, Lau, Bartke and Chang,
1975) and suppressed the rise in plasma LH levels following
orchidectomy (Ojeda et al., 1975).
Concerning species other than the rat, indomethacin given
subcutaneously every 4h for 48h abolished the oestradiol-induced
LH surge in anoestrous sheep (Roberts, Carlson and McCracken,
1976). A hypothalamic action of indomethacin in preventing
the LH surge was concluded, as LHRH-induced LH release was
unimpaired during indomethacin treatment (Roberts, Glew and
McCracken, 1975). In monkeys, indomethacin inhibited oestradiol-
induced LH release (Carlson, Wong and Perrin, 1977c}. The
administration of aspirin to bulls abolished the episodic
release of LH and this block was reversed by giving PGF-2q:
(Haynes, Kiser, Hafs and Marks, 1977).
In contrast to the effects on plasma LH levels, indomethacin
given to ovariectomized rats actually raised FSH levels but had
no effect on the post-castration rise in plasma FSH in male rats.
Indomethacin abolished the LH surge and partially inhibited the
rise in plasma FSH following the injection of oestradiol and
progesterone into ovariectomised rats (Ojeda et al., 1975).
This result suggests that this treatment regime of oestrogen
and progesterone stimulates PG synthesis in the hypothalamus
and that this stimulation of PG synthesis is necessary for LH
and FSH release. It must be noted, however, that in these
studies, relatively high doses of indomethacin were employed
(12.5 to 50 mgkg 1 body weight). Hypothalamic PG synthesis
-1
has been shown to be inhibited by as little as 1.5 mgkg
indomethacin (Orczyk and Behrman, 1972).
Effects of indomethacin on pituitary responsiveness to LHRH
Pituitary responsiveness to LHRH increased following
indomethacin treatment in the ewe (Roberts et al ., 1976), in
the rat, (Sandberg, Fawcett, Illner and McCann, 1975) and in
women with amenorrhoea or oligomenorrhoea (Craig, Ginsburg,
Gore and Isaacs, 1975). The mechanism whereby indomethacin
exerts a facilitatory effect is not known. One possible
explanation is that indomethacin also suppresses the formation
of a PG which reduces pituitary responsiveness to LHRH. In this
regard, PGD-2 has been shown to inhibit pulsatile LH release in
orchidectomized male rats (Kinoshita, Nakai, Katakami, Imura,
Shimizu and Hayaishi, 1982). Another possibility is that a
lipoxygenase product is involved in sensitizing the pituitary
gland to LHRH. Thirdly, it is widely known that indomethacin
inhibits phosphodiesterase activity and therefore would reduce
cyclic nucleotide degradation (Ciosek, Ortel, Thamassi and
Newcombe, 1974; Zor, Koch and Naor, 1976).
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Cyclic nucleotides have been implicated in the mechanism by
which LHRH stimulates gonadotroph!'n release (Labrie, Pelletier,
Borgeat, Drouin, Ferland and Belanger, 1975).
In contrast, a longer term schedule of indomethacin
treatment depressed pituitary responsiveness to exogenous
LHRH in ovariectomised rats (Sato et al., 1975). Clearly
the effect of indomethacin depends upon the hormonal status
of the animals as pituitary responsiveness is depressed in
ovariectomi zed rats but is enhanced in intact rats.
Effects of indomethacin injection into the brain
The intraventricular administration of 10 jjg indomethacin
or its implantation into the MBH of ovariectomized rats decreased
the plasma LH levels by approximately 60% and 50% respectively
(Ojeda et al., 1975). Eicosatetraynoic acid, another PG
synthesis inhibitor, was effective in depressing LH levels
following intraventricular injection, but the effect was less
sustained than that of indomethacin. Microinjection of aspirin
into the anterior hypothalamic area (AHA) of rats, interfered
with progesterone-induced ovulation in 87% of animals (Labhsetwar
and Zolovick, 1973). Simultaneous injection of PGF-2o: restored
the incidence of ovulation, suggesting that aspirin blocks
ovulation by preventing PG synthesis in the hypothalamus. The
possibility that aspirin had diffused to the pituitary gland and
acted therein, was excluded by demonstrating that an
intrapituitary injection of aspirin was ineffective in blocking
ovulation.
28
In a separate study Linton and Whitehead (1980) reported that
indomethacin injected into two different brain areas, namely
the AHA and the pre-optic area (POA), blocked ovulation.
The PGI-2 synthetase inhibitor, 15-hydroperoxy-arachidonic
acid, and the TXA-2 synthetase inhibitor, imidazole, were both
ineffective in this respect, suggesting that PGI-2 and TXA-2
are not involved in LH release.
All these studies suggest that, providing the PG synthesis
inhibitors are acting solely by inhibiting PG synthesis, that
hypothalamic PGs are required for LH release. However, it still
has to be demonstrated that the inhibition of hypothalamic PG
synthesis can block the pro-oestrous LH surge.
Effects of PGs on gonadotrophin release
Numerous reports have indicated that PGs injected
systemically or intraventricularly, can elicit gonadotrophs
release. PGE given subcutaneously or intraventricular^, on
the afternoon of pro-oestrus to phenobarbitone-blocked rats
overcame the block and caused an LH surge (Tsafriri et al.,
1973; Spies and Norman, 1973). In the latter study, PGE-1
was more potent than PGE-2 or PGF-2a . Similarly, Harms,
Ojeda and McCann (1974) demonstrated that intravenous PGE-2
produced a slight increase in plasma LH levels in ovariectomized
rats. However, when injected into the 3rd ventricle, PGE-2
induced a much greater increase in .plasma LH levels, as well as
a smaller increase in plasma FSH levels.
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When ovulation in rats was blocked by intraventricular
phentolamine, a further intraventricular injection of PGE-2
overcame the effect of the ex-receptor antagonist (Linton,
Perkins and Whitehead, 1977). PGE-1 was less effective and
PGF-2cx completely ineffective in this respect (Linton et al ,
1977). Intracarotid injections of PGE-1 into ovariectomized
oestrogen-pretreated rats were followed by a rapid increase in
plasma LH levels which were maintained for up to 30h with no
change in FSH levels (Batta, Zanisi and Martini, 1973). In
male rats, intracarotid PGE-1 (Batta et al., 1973), subcutaneous
PGE-1 or PGE-2 (Castracane and Saksena, 1974), or intravenous
PGE-2 (Chobsieng, Naor, Koch, Zor and Lindner, 1975) increased
circulating LH levels. The infusion of PGE-2 into non-receptive
or pseudopregnant rabbits produced a 2-to 4-fold increase in
plasma LH levels (Carlson, Wong and Perrin, 1977b). In cycling
or ovariectomized oestrogen-treated monkeys, PGE-1 or PGE-2
stimulated LH release (Batta, Niswender and Brackett, 1978).
The effects of systemically administered PGF-2cx on LH
release seem more variable. Thus, PGF-2o; induced an increase
in LH levels in pentobarbitone-blocked pro-oestrous rats
(Spies and Norman, 1973), ovariectomized oestrogen-treated rats
(Batta et' al., 1973), and pseudopregnant oestrogen-treated
rabbits (Carlson et al., 1977b) and hamsters (Saksena, Lau and
Chang, 1974). In ovariectomized, oestrogen-treated monkeys
(Batta et al., 1978) or in male monkeys (Kimball et al., 1979),
injection of PGF-2cx increased plasma LH levels. In human
females, the intravenous infusion of PGF-2ot (up to 250yug min 1 )
during the luteal phase resulted in a transient elevation in
plasma LH concentrations (Hi 11ier, Dutton and Corker, 1973).
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However, other workers have reported that PGF-2o; infusion
_ ^
(50 jugmin ') in similar women, produced a transient fall in
plasma LH levels (Elias, Newton and Collins, 1975). These
conflicting results in women may relate to the differing infusion
rates of PGF-2Q!.
PGF-2a injected into the 3rd ventricles of ovariectomized
rats failed to affect LH levels (Harms et al., 1973). Likewise,
a subcutaneous injection of PGF-2o: into ovariectomized hamsters
(Labhsetwar, 1973) or ovariectomized sheep (Chamley and Christie,
1973) failed to elicit LH release. Systemic injection of PGF-2a
into male rats (Batta et al., 1974; Warberg, Eskay and Porter,
1976) and humans (Craig, 1975) did not affect LH levels. In
heifers, the systemic administration of PGF-2a increased plasma
LH levels, but not until 1.5 to 6h after administration (Louis,
Stellflug, Tucker and Hafs, 1974). Results of this type suggest
that part of the effect of PGF-2oi on LH release is subsequent
to alterations in gonadal steroid production as the effect is
absent in either males or ovariectomized females. Alternatively,
the failure of PGF-2o: to enhance LH release in ovariectomized
animals may be due to a poor pituitary responsiveness to LHRH.
Experiments in cycling Rhesus monkeys (Carlson et al ., 1977a)
and rats (Carlson and Kehl , 1979) have demonstrated that PGE-2
and PGF-2a were most effective in stimulating LH release during
the late follicular phase and at pro-oestrus respectively.
However, these results are perhaps not surprising since the PGs
are thought to act via the release of LHRH from the hypothalamus,
and pituitary responsiveness to the releasing hormone itself is
highest on these days (Aiyer, Chiappa and Fink, 1974).
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Although in the rat, PGE-2 appears to be more effective
than PGF-2Q! in stimulating LH release, intracarotid infusion
of PGF-2ain the cycling ewe caused a rapid increase in plasma
LH (Roberts, Carlson and McCracken, 1976). Since this effect
was absent in ovariectomized animals (Chamley and Christie,
1973) PGF-2o: probably acted at the hypothalamic level and not
by altering gonadal steroid production.
There is general agreement that PGF-lo: does not affect
LH (Harms et al., 1973; Ojeda et al., 1974; Warberg, Eskay and
Porter, 1976) or FSH (Harms et al., 1973; Ojeda et al., 1974)
release from the pcbuitarvj cjiand. The work of Warberg et al.,
(1975) has included ten different PGs which were ranked
according to their LH-stimulating potency as PGE-2 =, PGF-2cy
= PGF-2/3> PGA-2 = PGB-2 = PGE-1 = PGF-1/3>PGA-1 = PGB-1 = PGF-lcc =
vehicle. From these findings it was concluded that the cis-
double bond at the 5, 6 position and the 11-hydroxyl group
are essential for this supra-pituitary stimulation of LH
secretion. Ojeda et al., (1976) confirmed that PGA-2 and
PGB-2 given intraventricularly into ovariectomized oestrogen-
treated rats were less potent than PGE-2. Also the injection
of two endoperoxide analogues (U-44069 and U-46619) into the
3rd ventricle was followed by a transient increase in plasma
LH levels with no effect on FSH levels.
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Site of action of PGs in eliciting LH release
Substantial evidence exists to show that PGs do not
stimulate LH release by a direct action on the pituitary gland.
In male rats (Chobsieng et al., 1975) and in pro-oestrous
rats (Drouin, Ferland and Labrie, 1976) prior administration of
antiserum to LHRH prevented the increase in circulating LH
levels following intravenous injection of PGE-2. The direct
infusion of PGE-2 into hypophysial portal vessels of male
rats failed to cause LH release, whereas the intraventricular
infusion of PGE-2 stimulated a 2-to 3-fold increase in the
concentration of LHRH in hypophysial portal plasma (Eskay
et al., 1975). An increase in circulating LHRH was found after
injection of PGE-2 into the 3rd ventricle of conscious
ovariectomized rats (Ojeda, Wheaton and McCann, 1975).
In vitro studies with pituitary glands also demonstrated
that PGs do not act directly on the gland to cause LH release.
Neither PGE-1 nor PGE-2 altered the time-course of basal, or
LHRH-induced LH release from cultured pituitary glands (Drouin
et al., 1976). Similarly addition of LHRH to cultured
hemipituitary glands from male rats stimulated cAMP accumulation
and LH release, but did not affect either PGE-2 levels or PG
synthetase activity in the glands (Naor, Koch, Bauminger and Zor,
1975). Moreover, the stimulatory action of LHRH on these
parameters was not impaired during PG synthetase inhibition with
aspirin or indomethacin.
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In contrast, however, Sato, Hirono, Jyujo, Iseka, Taya and
Igarashi (1975) favour a pituitary site of action of PG
based on their observation that PGE-1, PGE-2 and PGF-2o: could
elevate plasma LH levels upon intraventricular injection into
rats with M.E. lesions, or upon intrapituitary injection
into intact rats. However, failure to observe altered LH
secretion following intrapituitary injection of PGs has also
been described (Harms et al., 1974, Spies and Norman 1973,
and Hedge, 1977). These discrepancies may be due to different
doses of PGs employed.. Sato et al., (1975) used 50 jug and
100 jug whereas most other studies used about 5 jug. It seems
therefore, that although under certain circumstances PGs can act
directly on the pituitary gland to evoke gonadotrophs release,
their primary and most important site of action is within
the hypothalamus.
Hypothalamic sites of action of PGs in eliciting gonadotrophs
release
By implanting crystalline PGs into the hypothalamus of
ovariectomized rats, Ojeda, Jameson and McCann (1977a) have
defined more clearly the anatomical sites at which PGs evoke
LH release. When PGE-2 was placed in the arcuate nucleus -
median eminence region (ARH-ME), a 4-to 5-fold increase in
plasma LH levels ensued within 60 min. PGE-2 placed more
dorsally, close to the ventromedial nucleus, caused a similar
increase in plasma LH levels but only after 2h. When implanted
in the caudal portion of the ARH-ME or dorsally in the ventro¬
medial hypothalamus (VMH) and dorso-medial nuclei, PGE-2 barely
increased plasma LH 1evels}whereas its implantation into the
anterior portion of the ARH-ME clearly elevated plasma LH levels.
The POA or anterior ventral portion of the anterior hypothalamic
area are other important sites at which PGE-2 act as here the
PGE-2 induced a large increase in plasma LH levels within 20 min
of injection. Areas where PGE-2 implants were relatively
ineffective include the para ventricular nuclei and the dorsal
portion of the AHA. PGF-Ikappeared less potent than PGE-2 as a
smaller increase in LH levels followed the implantation of PGF-2o:
into the ARH-ME or POA. The finding that PGs are effective in
releasing LH when implanted in the ARH-ME is significant as this
area is rich in LHRH-containing nerve endings (Ibata, Watanabe,
Kimura, Sano, Sin, Hashimurcj and Imagawa, 1978). Studies of this
type are useful in that they overcome the problem of pulmonary
metabolism of PGs administered intravenously. It is difficult,
however, to assess the results of the implant experiments
quantitatively as the amount of PG diffusing into the tissues is
unknown. Using a similar technique, the hypothalamic areas where
PGs stimulate FSH release have been outlined (Ojeda, Jameson and
McCann, 1977b). The results indicate that PGE-2 and PGF-2a act
mainly on the POA and AHA regions and that PGE-2 is more
effective than PGF-2o; in this respect.
Information on the sites of action of PGs within the
hypothalamus in other species is lacking.
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Interaction of PGs and neurotransmitters
There have been few attempts to determine the possible
relationships between PGs and some of the hypothalamic
neurotransmitters thought to regulate gonadotrophs secretion.
It has been reported, however, that the inhibition of
progesterone-induced ovulation by aspirin injected into the
hypothalamus can be reversed by either PGF-2o: or dopamine
(DA) (Labhsetwar and Zolovick, 1973). Furthermore NA, DA or
adrenaline stimulated PGE formation by rat brain synaptosomes.
(Hillier, Roberts and Woolard, 1976). In addition PGE-2 in
turn has been shown to facilitate NA release from rat brain
synaptosomes (Roberts and Hillier, 1976) indicating that PGE-2
may exert a positive feedback on NA release on central nerve
terminals. Although these findings are consistent with an
interaction between PGs and the dopaminergic and noradrenergic
systems, pharmacological evidence has been provided to suggest
that PGE-2 acts directly on LHRH secreting neurons. Thus,a
or/3-adrenergic receptor antagonists, dopaminergic, serotonergic
or muscarinic receptor antagonists failed to inhibit the LH
release induced by intraventricular injection of PGE-2 in
ovariectomized rats (Harms et al., 1976). Moreover, PGE-2 will
overcome the ovulatory block induced by phentolamine (Linton et
al., 1976) and nembutal (Tsafriri et al., 1973; Spies and Norman,'
1973). However, PGE-2 failed to stimulate rat hypothalamic
synaptosomes to release LHRH (Linton, Bennet and Whitehead,
1979). It is possible, therefore, that PGs stimulate LHRH
release by acting on the cell bodies of the LHRH neurones.
Indeed, iontophoretically applied PGE-2, increased the firing
rate of hypothalamic neurones (Poulain and Carette, 1974-). It
would be interesting to study the effects of PGs applied
iontophoretically to specific hypothalamic areas involved in
LHRH release.
PG synthesis by the brain in relation to the LH surge
The demonstration that endogenous PG levels change
concomitantly with alterations in LH and LHRH secretion have
further substantiated the idea that PGs play a physiological
role in the control of gonadotroph!'n release. In the ewe,
Roberts, Carlson and McCracken (1976) have shown a temporal
association between the release of. PGF-2a; and of LH from the
brain. Thus, circulating PGF-2o; 1evels varied in a pulsatile
manner and LH release was also pulsatile. The arterio-venous
difference in PGF-2a concentrations across the brain showed that
significant amounts of PGF-2o; were released by the brain.
Furthermore, an infusion of oestradiol resulted in an initial
suppression of the PGF-2a pulses, followed by a distinct rise in
their amplitude at a time coincident or slightly prior to the
steroid- 'induced LH surge. While these experiments do not prove
that PGF-2a mediates the LH surge, they are consistent with this
suggestion.
In the rat, the ME of both male and female animals showed
a higher PGE content than either the MBH or the anterior
pituitary gland (Ojeda et al., 1978). No sex differences were
observed.
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The elevated content of PGE in the ME is associated with a
5 to 6-fold greater capacity of the tissue to release PGE
in vitro compared to the MBH of male rats (Ojeda, Negro-Vilar,
McCann, 1979). The in vitro addition of indomethacin, which
completely suppressed basal PGE release by both the MBH and ME,
also depressed basal LHRH release from these tissues, suggesting
that PG synthesis is required for basal LHRH release to occur.
NA or DA added in vitro, elicited both LHRH and PGE release
with NA being the more potent catecholamine. Moreover, the
in vitro suppression of PG synthesis by indomethacin, completely
abolished the release of LHRH from the ME induced by DA or NA.
In contrast, indomethacin did not prevent release of LHRH induced
by PGE-2 (Ojeda, Negro-Vilar and McCann, 1979). These results
suggest that the stimulatory effect of DA and NA on LHRH release
by the ME and MBH is mediated by PGs. When comparing
catecholamine induced PGE release, NA, DA and adrenaline are
more effective in causing release of PGE from the ME than from
the MBH (Ojeda et al., 1979). It should be noted that since
the ME contains the terminals of LHRH n^arones, that high
concentrations of LHRH coincide with areas which have a high
capacity to release PGE in response to NA. NA-induced PGE-2
and LHRH in vitro from the ME of male rats requires activation
A
of an Ot-adrenergic receptor as the effect of NA was blocked by
phentolamine. Neither propanolol nor pimozide had any effect
on NA-induced PGE-2 or LHRH release, indicating that stimulation
of ^-adrenergic or dopaminergic receptors are not involved
(Ojeda, Negro-Vilar and McCann, 1982).
Since the effect of PGE-2 on LH release cannot be prevented
by monoaminergic receptor blockers (Harms et al ., 1976) but
the effect of catecholamines on LHRH release is inhibited by
preventing PG synthesis, it appears that PGE-2 mediates the
effect of catecholamines on hypothalamic LHRH release.
These observations may explain the inhibitory effect of
OC-antagonists on LH release and ovulation (see Barraclough
and Wise, 1982).
There is a diurnal variation in the response of rat ME
fragments to NA or PGE-2 on met-oestrus, pro-oestrus and
oestrus. (De Paolo, Ojeda, Negro-Vilar and McCann, 1982).
The release of PGE-2 in response to NA was higher at 13.OOh
than at 16.OOh on each day. However, on di-oestrus the NA-
induced PGE-2 release showed no diurnal variation. Since, with
the exception of di-oestrus, fluctuations in NA-induced PGE-2
release from the ME were independent of the day of the cycle,
it is unlikely that these changes were secondary to cyclical
changes in steroid hormones. As it has been suggested that
the release of LHRH caused by NA is mediated by PGE-2 (Harms
et al., 1976) it would be expected that the responsiveness of
the LHRH terminals to NA should parallel the NA induced PGE-2
response during the cycle. This did not appear to be the case
however, as on pro-oestrus, NA-induced LHRH secretion in the
ME increased between 13.OOh and 16.OOh, which is the converse
trend for NA-induced PGE-2 secretion. Cyclical changes in
NA-induced LHRH release more closely resembled the changes in
the response of the LHRH terminals to PGE-2. Therefore, it
seems likely that the response of the ME to NA with respect
to LHRH release is dependent upon the response to PGE-2 and not
on the amount of PGE-2 released by NA (De Paolo et al ; 1982).
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Progesterone given at 09.30h on pro-oestrus advanced both
the onset of the LH surge and the in vitro response of the LHRH
terminals to PGE-2 (De Paolo et al., 1982). As well as a
diurnal pattern of responsiveness of the ME to PGE-2, a similar
diurnal rhythm in plasma progesterone levels occurs during the
rat oestrous cycle with highest levels at 03.00h and lowest
at lO.OOh on each day (Mann and Barraclough, 1973). Thus
progesterone may alter the responsiveness of the LHRH terminals
to PGE-2, although this suggestion remains speculative at
present. A diagramatic representation of the involvement of PGs
in hypothalamic LHRH release is shown in Figure 2.
Summary and Aims
In conclusion, the concept that PGs (particularly PGE-2)
are involved in the physiology of LHRH secretion has gained
support in recent years. There are, however, several unresolved
issues. The possibility of cyclical changes in hypothalamic
PG production has not been investigated. A major argument
against the hypothesis that PGs are essential for LH release
arises from the failure to demonstrate that inhibition of
hypothalamic PG synthesis results in suppression of the
pre-ovulatory LH surge. It is possible that the use of a more
specific inhibitor of PG synthesis or perhaps a PG antagonist
could suppress the LH surge and this area requires investigation.
Lastly, if PGs are an essential link between the positive
feedback effect of oestradiol and the LH surge, it may be
possible to demonstrate that the steroid will affect hypothalamic
PG synthesis. The experiments described in section2.Z.were aimed
at testing these possibilities.
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Figure 2. Possible sites of action of PGs in





Functional significance of uterine PG synthesis
The presence of PGE and PGF in uterine tissue of many
species has been widely demonstrated (see Norton and Poyser,
1976). The majority of studies on uterine PG synthesis concern
the increased production of PGF-2qi towards the end of the cycle
in relation to luteolysis. There is also a significant increase
in endometrial PGF-2a production during the luteal phase of the
menstrual cycle in women (Downie, Poyser and Wunderlich, 1974;
Le Vitt, Tobon and Josimovich, 1975; Singh, Baccarini and Zuspan,
1975,Maathius and Kelly, 1978). However, luteal regression in
women does not require uterine PGF-2qi synthesis as ovarian
activity continues after hysterectomy (Whitelaw, 1958) or in
cases of congenital absence of a uterus (Fraser, Baird, Hobson,
Miotic and Hunter, 1973). As in the human, uterine PG synthesis
is not required for luteal regression during the rat oestrous
cycle although uterine PGF-2o; synthesis may be required for
luteolysis in the pseudopregnant rat (Chatterjee, 1973).
' In addition to PGE and PGF, Poyser and Scott (1980) have
identified PG 1-2, PGD-2 and TXA-2 in the uterus during the
oestrous cycle of the rat. In fact PGI-2 (measured as
6-keto-PGF-lQ') was the major PG produced by the uterus of the
rat (Fenwick et al., 1977; Poyser and Scott, 1980), sheep (Jones,
Poyser and Wilson, 1977) and human (Abel and Kelly, 1979).
It is possible that these PGs play a role in uterine physiology
during the oestrous cycle.
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Uterine PG synthesis during the oestrous cycle
Saksena, Shaikh and Shaikh (1973) found that, in rats,
uterine tissue concentrations of PGF correlated with PGF
concentrations in uterine venous plasma in that they were highest
on met-oestrus and also showed a smaller peak on pro-oestrus.
In general however, other workers (see below) have reported
highest uterine tissue PG levels on pro-oestrus or oestrus in the
rat. The anomalous result of Saksena et al., (1973) may be
attributed to the frequency of sampling (once on met-oestrus
and di-oestrus, twice on oestrus and four times on pro-oestrus).
In sheep, more frequent sampling (every 2h) from the utero-
ovarian vein revealed the presence of pulses of PGF-2o(. lasting
up to 2h and, which increased in amplitude towards the end of the
oestrous cycle (Barcikowski, Carlson, Wilson and McCracken,
1974). Clearly, the variation in the pattern of uterine PG
production depends greatly on the resolution of the experimental
sampling.
In the rat, there is general agreement (except for the
report by Saksena et al., 1973) that uterine levels of PGF
and PGE are highest on pro-oestrus or between pro-oestrus
and early oestrus (Ham, Cirillo, Zanetti and Kuehl, 1975;
Ishikawa and Fuchs, 1978; Poyser and Scott, 1980; Van Orden
Goodale, Baker and Farley, 1980; Thaler-Dao, Saintot, Ramonatxo,
Chavis and Crastes de Paulet, 1982). PG1-2 and PGD-2 synthesis
by rat uterine homogenates, measured between 10:OOh and 12:OOh
on each day, paralled that of PGE-2 and PGF-2o: in being highest
on oestrus and lowest on pro-oestrus with no change in the ratios
of PGs formed (Poyser and Scott, 1980).
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However, Thaler-Dao et al ., (1982) report an additional peak in *
uterine PGE-2 synthesis at 15:OOh on di-oestrus. Also in
contrast to the results of Poyser and Scott (1980), Ham et al.,
(1975) found that PGF synthesis increased at the expense of PGE
synthesis and, during di-oestrus, PGE synthesis exceeded that of
PGF by 3-fold. It is difficult to compare these conflicting
reports as differing methodologies were employed. Poyser and
Scott (1980) incubated uterine homogenates with no added co-
factors, whereas Ham et al., (1975) used a microsomal preparation
and added arachidonic acid and glutathione. Likewise Thaler-Dao
et al ., (1982) added arachidonic acid, glutathione and adrenaline
to uterine homogenates. Consequently the addition of a
co-factor (i.e. glutathione) which promotes PGE synthesis may
upset the natural pattern of PG synthesis by the uterus.
B. Pregnant uterus
In the pregnant rat, the endometrium is the major site for
PGF-2o; synthesis while the myometrium synthesizes mainly PGI-2
(Williams, Sneddon and Harney, 1974; Williams, Dembinska-Kiec,
Zmuda and Gryglewski, 1978). The significance of myometrial
PGI-2 production is at present unknown. Myometrial blood vessels
are unlikely to be the main source of PGI-2 as PGI-2 synthesis
by uterine arteries and veins did not change significantly during
pregnancy in the rat, whereas myometrial PGI-2 synthesis
increased markedly towards the end of gestation (Williams et al.,
1978). Although PGI-2 itself was not oxytocic, oxytocin-induced
contractions of the pregnant rat uterus were potentiated by
PGI-2 (Williams et al., 1979) and thus PGI-2 may play a role in
stimulating myometrial activity at parturition.
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Both the endometrium and myometrium produce PGE-2 while the
endometrium is a major site for PGD-2 synthesis in the pregnant
rat (Downing and Williams, 1977).
Uterine PG synthesis and implantation
In a study of PG production by the rat uterus during
pseudopregnancy, Fenwick et al., (1977) found highest production
of both PGF and PGE on day 5 after mating. This day is when
blastocyst implantation takes place and hence the suggestion
is that PGs may be involved in this process.
Indomethacin inhibited implantation in rats (Gavin,
Dominguez Fernandez-Tejerina, Montanes de las Heras and Vijil
Maeso, 1974) mice (Saksena, Lau and Chang, 1976), hamsters
(Evans and Kennedy, 1978) and rabbits (Hoffmann, Di Pietro and
McKenna, 1978).
One of the earliest signs of blastocyst implantation is the
appearance of localized sites of increased endometrial vascular
permeability (Psychoyos, 1973). These sites can be visualized
experimentally by intravenous injection of Evans blue dye.
Indomethacin administrati on effectively inhibited the uterine
dye site response in ovariectomized rats treated with exogenous
steroids, adequate for the initiation of implantation
(Kennedy, 1977) and delayed the appearance of uterine dye sites
in pregnant rats (Phillips and Poyser, 1981b). When PG synthesis
at implantation sites in rats was examined, PGF, PGE and PGI-2
levels were found to be higher than in surrounding endometrial
tissue with PGI-2 being present in greatest concentration
(Kennedy, 1977; Kennedy and Zamecnik, 1978).
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Similarly, PGE levels were high at implantation sites in the
hamster (Evans and Kennedy, 1978). Since PGE-2 but not PGI-2
or PGF-2a increased vascular permeability in the rat uterus
(Kennedy, 1979a) this suggests that PGE-2 mediates this process
during implantation.
Increased endometrial vascular permeability is thought
to be pre-requisite for the decidual cell reaction (Psychoyos,
1973). Decidualization of endometrial stromal cells can be
obtained during a limited period of pregnancy, pseudopregnancy
or experimentally by artificial stimuli such as uterine
scratching or injection of oil or phosphate-buffered saline
containing gelatin (PBSG). Kennedy (1979b) showed that increased
endometrial vascular permeability which normally follows the
unilateral injection of PBSG, was inhibited by indomethacin and
in addition, uterine concentrations of PGE and PGF were elevated
following PBSG-injection. Moreover, the intraluminal injection
of PGE-2 resulted in increased endometrial vascular permeability
in rats in which endometrial PG production had been inhibited.
Artificial deciduogenic stimuli (trauma or the injection of
sesame oil) increased the uterine content of PGE and PGF in mice
(Jonsson, Rankin, Ledford and Baggett, 1978; Rankin, Ledford,
Jonsson and Baggett, 1979). In addition, artificially-induced
decidualization was inhibited by indomethacin treatment in rats
(Castracane, Saksena and Shaikh, 1974; Sananes, Baulieu and Le
Goascogne, 1976; Tobert, 1976) and in mice (Rankin et al., 1979).
All these results suggest that PG synthesis by the endometrium
in these species is essential for increased vascular permeability
and the subsequent decidualization of the endometrium during
the implantation process.
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There is evidence that PGs affect the decidual cell reaction
per se, and not solely by inducing increased vascular
permeability. When indomethacin administration was delayed
until 8h after the artificial stimulus (by which time increased
vascular permeability had already occurred), decidualization was
still inhibited (Tobert, 1976). PGF-2a el i ci ted a decidual
response when instilled into the uterus of prepubertal rats
(Sananes et al., 1976), and in pseudopregnant rabbits, the
insertion of implants containing PGE-2, PGF-2o: or arachidonic
acid into the uterus elicited a decidual response. Similar
implants releasing histamine or oestradiol had a slight effect
in some animals, while dibutyryl cAMP was inactive (Hoffman
et al., 1977).
PG synthetase activity in deciduomata, induced by
traumatization of the pseudopregnant rat uterus, was 7-to 10-fold
higher than in untraumatized tissue (Anteby, Bauminger and
Lindner, 1975). PGE-2 concentrations in the deciduomata
exceeded those in control tissue by 10-to 20-fold on the third
or fourth day after decidual induction and by about 5-fold
on the ninth and tenth day. However, PGF concentrations did not
differ between decidualized and non-decidualized tissue (Anteby
et al., 1975).
PGF-2c* production by the pregnant rat uterus was lower on
day 5 compared with the pseudopregnant rat uterus (Fenwick et al,
1977) which indicates that the presence of a blastocyst has an
effect on uterine PG synthesis. However, PGE-2 and 6-keto-PGF-lo:
production by homogenates of pregnant rat uterus were highest
on day 5 as in pseudopregnancy (Phillips and Poyser, 1981b).
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This day 5 peak in uterine PG synthesis in the pregnant rat
coincides with the time at which the uterus is most sensitive
to deciduogenic stimuli (De Feo, 1963). However, when
ovariectomized rats were treated with oestradiol and progesterone
so that they were at the equivalent of days 4, 5 or 6 of
pseudupregnancy, uterine concentrations of PGE and PGF did not
differ between the three days in response to intrauterine PBSG.
In contrast, endometrial vascular permeability was highest
in animals on the equivalent of Day 5 of pseudopregnancy
(Kennedy, 1979b). It appears therefore that the timing of
uterine sensitivity to deciduogenic stimuli is not related to
the ability to respond to such stimuli with increased PG
production. Alternatively, changes in the uterine PG receptor
population may be related to the changes in sensitivity to
deciduogenic stimuli. In support of this suggestion, Kennedy
(1979b) showed that when PGE-2 was administered into the uterine
lumen of indomethacin-treated rats on the equivalent of days 4,
5 or 6 of pseudopregnancy, the greatest change in endometrial
vascular permeability (as indicated by the uterine radioactivity
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levels after intravenous I-1 a be!led bovine serum albumin)
was in animals on day 5. Using a receptor binding assay,
Kennedy (1982) has recently demonstrated greater PGE receptor
numbers in rats on the equivalent of day 5 of pseudopregnancy,
compared with other days.
The suggestion that PGI-2 may be the mediator of
decidual ization has come from Rankin et al., (1979) who found
that tranylcypromine, an inhibitor of PGI-2 synthesis (Gryglewski
et al., 1976) inhibited decidualization in mice.
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However, the selectivity of the inhibitory action of
tranylcypromine has been questioned (Rajtar and de Gaetario,
1979) and also the inhibition has not been overidden with
PGI-2. Nevertheless, uterine levels of 6-keto-PGF-la were
elevated following the application of an artificial
deciduogenic stimulus to the sensitized rat uterus (Kennedy,
1979). In addition, 6-keto-PGF-la: was the major PG produced
by uterine homogenates from rats in early pregnancy or
pseudopregnancy (Phillips and Poyser, 1981b). 6-Keto-PGF-la ,
PGF-2a, and PGE-2 production peaked on day 5 of pseudopregnancy,
whereas only 6-keto-PGF-laand PGE-2 peaked on day 5 of pregnancy
(Phillips and Poyser, 1981b). However, PGI-2 failed to increase
endometrial vascular permeability following the application of an
artificial stimulus to the rat uterus sensitized for the decidual
cell reaction (Kennedy, 1979a). Failure to observe an effect of
PGI-2 may be due to the instability of this PG at neutral pH.
Injection of PGF-2yinto the uterine lumen of rats had no effect
on endometrial vascular permeability although the intralumenal
infusion of the same PG from an osmotic mini pump resulted in
increased vascular permeability and subsequent uterine
decidualization (Kennedy and Lukash, 1982). Clearly the mode of
administration of PGs is important and the infusion of PGI-2 in a
similar manner requires investigation.
In indomethacin-treated rabbits, PGE-2 or PGF-2a only
partially overcame the reduction in the number of implanted
blastocysts (Hoffmann, 1978).
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Similarly, in indomethacin-treated mice, the administration of
PGE-2 or PGF-2o: alone or in combination resulted in implantation
only in 60% of the mice (Lau, Saksena and Chang, 1973). If,
however, the mice were treated with PGF-2o; and histamine, then a
100% success rate for implantation was achieved (Saksena, Lau
and Chang, 1976). A role for histamine was further supported
by the observation that the histamine H-, and H2. receptor
antagonists, mepyramine and burimamide reduced the number of
implantation sites in rats (Brandon and Willis, 1977). It is
possible that an interaction between histamine and PGs is
involved in implantation. An analogy between the process
of implantation and the inflammatory response is apparent.
Acute inflammation is also characterised by both vasodilation
and increased vascular permeability and the involvement of PGs
and histamine is well documented (see Williams, 1977).
Another observation regarding implantation, is that
ageing of the uterus is associated with decreased frequency of
blastocyst implantation in many species. In ageing hamsters,
a diminished local oedema in the endometrial stroma at
implantation sites has been reported (Sorger and Soderwall,
1981). Since PGs are implicated in the production of an
'inflammatory response1 at implantation sites, this has
stimulated the study of the uterine PG production in uterus
sensitized for the decidual cell reaction in the aged animal.
(These studies are described in more detail in Section 2.4).
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c) The control of uterine PG synthesis
Oestrogen appears to be a potent stimulant for uterine
PG synthesis. The secretion of PGF into the utero-ovarian
vein increased significantly following oestrogen treatment of
guinea pigs (Blatchley, Donovan, Poyser, Horton, Thompson
and Los, 1971). Similarly, oestrogen treatment of hamsters
(Saksena and Harper, 1972), ovariectomized mice (Saksena and Lau,
1973), monkeys (Demers, Yoshinaga and Greep, 1974) and rats
(Ryan, Clark, Van Orden, Farley, Edvinsson, Sjoberg Van Orden,
and Brody, 1974) increased uterine levels of PGF. Oestradiol- 17(3
infused into the arterial supply of the autotransplanted sheep
uterus increased PGF-2Q! 1 eve!s in utero-ovarian venous plasma
100-fold within 90 min (Barcikowski et a 1.., 1974). Ham et al.,
(1975) found that oestradiol treatment of ovariectomized rats
stimulated uterine PGF-2a synthesis but reduced PGE-2 synthesis.
Co-administration of progesterone with oestradiol completely
inhibited the stimulatory effect of oestrogen on PGF synthesis in
the rat uterus (Ham et al., 1975). In contrast, a stimulatory
role for progesterone in the production of PGE and PGF by the rat
uterus was demonstrated by Castracane and Jordan (1975). After
two days of progesterone priming, the PGF and PGE levels in
uterine venous plasma of ovariectomized rats were higher than in
unprimed animals. Furthermore, progesterone priming prolonged the
stimulatory effect of oestradiol on PG production. In the study
of Ham et al., (1975) no progesterone priming was employed and
this may account for differences in results between the groups.
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It has been shown that progesterone is required for
oestradiol-stimulated PGF production by the sheep uterus
(Barcikowski et al., 1974). They showed that, although
peaks of oestradiol in utero-ovarian plasma occurred throughout
the cycle in ewes, it was not until days 13 and 14 (i.e. after
progesterone priming) that small peaks of PGF-2a were associated
with the oestradiol peaks. Similarly, prior treatment with
progesterone greatly enhanced the effect of oestrogen on
uterine PGF release in ovariectomized sheep (Scaramuzzi et al .,
1977) and guinea pigs (Blatchley and Poyser, 1974). However,
in ovariectomized guinea-pigs, prior treatment with progesterone
failed to affect the stimulatory effect of oestradiol treatment
on PGF-2a synthesis by uterine homogenates (Naylor and Poyser,
The disparity in results reported by various groups
probably arises from the variations in the dose regimes of
steroids used. It would seem important to attempt to replicate
the plasma levels and sequential order of hormones in the
circulation during the oestrous cycle. However, many of these
studies have involved treating animals with progesterone followed
by oestrogen. While this regime mimics the in vivo situation
in many animals including the guinea pig and sheep, it does
not do so for the rat.
The temporal pattern of changes in plasma steroid hormOnes
during the rat oestrous cycle have been characterized by many
workers (Goldman, Kamberi, Sitteri and Porter, 1969; Barraclough,
Collu, Massa and Martini, 1971; Feder, Brown-Grant and Corker,
1971; Naftolin, Brown-Grant and Corker, 1972; Butcher,




Figure 3 shows the plasma concentrations of LH, progesterone
and oestradi ol-17(3 throughout the 4-day oestrous cycle of the
rat. Oestradiol rises on the evening of met-oestrus and reaches
a peak on the morning of pro-oestrus, before falling to a nadir
on the morning of the next met-oestrus. Nequin et al., (1979)
found that progesterone was not released on pro-oestrus prior
to the LH surge, but rather, began to rise between 12:OOh and
18:00h on pro-oestrus to reach a peak at 22:00h on that night.
However, other workers (Feder et al., 1971; Karla and Karla,
1974) report that during pro-oestrus plasma progesterone levels
increase slowly from 09:30h to 13:30h then more rapidly after
LH release to peak at 21:00h. It has been suggested that this
rise in circulating progesterone on the morning of pro-oestrus
facilitates LH release (Feder et al., 1971). Therefore in
the rat, the effect of progesterone given after oestrogen on
uterine PG synthesis requires re-evaluation.
Following ovariectomy, PGI-2 production by chopped strips
of rat uteri increased (Gimeno, Batta, Lazzari and Gimeno,
1980). Subsequent injection of oestradiol* progesterone or
both into ovariectomized rats diminished uterine PGI-2
production (Gimeno et al., 1980). In this study, however,
50ug of oestradiol was administered 24h before the animal was
killed. Since oestradiol is normally released from the ovary
over a period of 48h it would have been more instructive to
have assessed the effects of this dose of oestrogen later than
24h after administration. Likewise, 4mg of progesterone was
given 48h and 24h before sacrifice, whereas in the cycling rat,
the ovulatory surge in plasma progesterone is relatively
























Thaler-Dao et al., (19824 found that in the cycling rat,
a rise in uterine PGE-2 and PGF-2o: production occurred 5h after
the highest value for plasma oestradiol and was superimposed on
the peak of plasma progesterone. This suggests that oestradiol
output by the ovary could stimulate uterine PGF-2a and PGE-2
synthesis but that in addition progesterone could facilitate
this process.
In contrast to the cyclical fluctuations in uterine
PGF-2a and PGE-2 production, uterine PGI-2 production did not
change during the oestrous cycle (Thaler-Dao et al., 19824.
This observation suggests that the synthesis of each of PGE-2,
PGF-2a and PGI-2 by the uterus is modulated independently
(possibly by activating PGH-2 reductase, PGH-2 isomerase or
PGI-2 synthetase) and not via a common intermediate such as
the phospholipase or cycloxygenase enzymes.
Mechanism of action of oestrogen and progesterone in
stimulating uterine PG synthesis
There are several ways in which ovarian steroids could
modulate uterine PG production. Since PGs are not stored in
tissues, it is likely that the steroid hormones affect PG
synthesis either by a) induction of lipases, thereby providing
arachidonic for PG synthesis. In this regard it is interesting
to note that in the ewe, progesterone administration caused the
appearance of lipid droplets in the endometrium which decreased
following oestrogen treatment (Brinsfield and Hawk, 1973)
b) direct induction of PG synthetase.
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There is evidence that oestradiol treatment increases the
level of PG synthetase in the uterus of the rat (Ham et al.,
1975) and guinea-pig (Naylor and Poyser, 1975; Wlodawer,
Kindall and Hamberg, 1976; Thaler-Dao, 1982).
c) affecting co-factor availability thereby providing optimal
conditions for enzyme and substrate interaction.
Protein synthesis is required for oestradiol-induced
PG synthesis in the guinea pig uterus, as intra-uterine
administration of actinomycin D abolished the increase in uterine
PG synthesis which normally occurs at the end of the oestrous
cycle (Poyser, 1979). Inhibition of ovarian oestradiol output
following treatment with the oestrogen antagonist Tamoxifen
was probably responsible for the attenuation of the increase
in uterine PGF, PGD and PGE production normally seen on day 5
of pseudopregnancy in the rat (Fenwick et al., 1977). Tamoxifen
also antagonizes the effects of oestrogen at the tissue receptor
level (Harper and Walpole, 1967). These findings suggest that
oestrogen release and receptor activation is required for the
stimulation of uterine PG synthesis.
PG synthesis by the endometrium and myometrium
Most of the preceeding studies have concerned PG synthesis
by the whole uterus. However, the uterus contains two types
of tissue (the endometrium and myometrium) which differ greatly
in structure. There is general agreement that the main site of
PGI-2 synthesis is the rnyometrium, whereas the endometrium
synthesizes mainly PGF-2Q: and PGD-2 (Williams, Sneddon and
Harney, 1974; Williams, Dembinska-Kiec and Zmuda, 1978; Abel and
Kelly, 1979; Alwachi, Bland and Poyser, 1980; Poyser, 1983). The
study by Abel and Kelly (1979) demonstrated that in vitro, human
endometrial tissue synthesized less PGI-2 when incubated separate
from the rTiyometriurn.
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The differential PG production by endometrial and myometrial
tissue may reveal differing roles for PGs in these tissues,
although there may be an interaction between the two tissue
types.
Summary and aims
Uterine PG synthesis has been widely investigated. However,
many of the studies which have been described have involved
relatively infrequent measurements of only PGE and PGF synthesis.
In the experiments described in section 2.3 uterine synthesis
of PGE-2, PGF-2q:, 6-keto-PGF-la and TXB-2 has been studied at
4-hourly intervals throughout the rat oestrous cycle. In
addition PG and TX production by the separated endometrium and
myometrium has been measured. As to the control of uterine
PG synthesis, it has been pointed out that existing studies
showing an effect of ovarian steroids on uterine PG synthesis
have used steroid treatments which do not attempt to mimic
the physiological situation. Consequently, the effects of
oestrogen and progesterone on uterine PG synthesis has been
re-examined.
The experiments described in section 2.4 were performed to
investigate the hypothesis that diminished uterine PG synthesis
in the aged animal could be responsible for the failure of
the uterus to support blastocyst implantation which has
previously been described in aged animals.
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The control of PG biosynthesis in reproductive tissues
In the preceeding pages, the evidence for and against the
involvement of PGs in several reproductive processes has been
reviewed. The information largely deals with the effects of
indornethacin on these processes and the pharmacological effects
of PGs. In addition, evidence has been presented to show that
PG synthesis by the uterus and ovary (and possibly the
hypothalamus) changes throughout the oestrous cycle. The
stimulus for PG synthesis in the ovary, appears to be LH and
in the uterus, oestrogen and progesterone. However, relatively
little is known of precisely how these hormones exert their
actions on the PG synthetic pathway.
It has already been mentioned that PGs are not stored
in tissues and therefore by controlling PG synthesis, a hormone
could affect PG release. In addition, during PG synthesis
the cyclooxygenase enzyme is destroyed (Lands, Le Tellier and
Vanderhoek, 1973) and thus fresh enzyme must be synthesized
for further PG release. Indeed there is evidence that protein
synthesis is an integral part of LH-induced (Clark et al., 1976)
and estrogen-induced (Poyser, 1979) PG synthesis by the ovary
and uterus, respectively. In addition, PG synthetase levels
have been shown to increase during periods of increased PG
production by the ovary and uterus (Bauminger and Linder, 1975;
Anteby et al., 1975, Wlodawer et al., 1976). However, when the
synthesis of several PGs in the ovary (Bauminger and Lindner,
1975) and in the uterus (Poyser and Scott, 1980; Thaler- Dao et
al, 1982) is considered, it is apparent that the ratios of
products changes during the oestrous cycle.
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This suggests that there must be specific mechanisms which
direct PG synthesis towards the production of one PG in
preference to another. It is possible that this is achieved
by controlling the relative quantities of the specific enzymes
and/or co-factors which convert the endoperoxides into PGs.
Fig 4 shows the pathway for PG and TX synthesis and
breakdown and outlines the various stages at which control
of PG synthesis could be exerted. In addition to controlling
PG synthetase levels, changes in PG levels in tissues could be
brought about by altering PG metabolism. There is evidence
that PGE-2 metabolism in rat lung tissue is increased in
pregnancy and is decreased by oestradiol treatment (Blackwell
and Flower, 1975). Also PGE-2 and PGF-2a levels may be
altered by the variations in activity of the enzyme PGE-2-9-
ketoreductase which has been identified in ovarian tissue
(Watson, Shepherd and Dodson, 1979; Shepherd and Dodson, 1980)
as well as in rat brain incubates (Wolfe, Pappius and Marion,
1976).
It is widely held that the release of arachidonic acid
is the rate-limiting step for PG synthesis in tissues (see Vogt,
1978). Indeed, the levels of free arachidonic acid are too
low for continued PG synthesis in the guinea pig uterus
(Leaver and Poyser, 1980). Consequently arachidonic acid
release from some bound source commonly assumed to be
phospholipids, is necessary to allow PG synthesis to occur.
However it is difficult to imagine that alterations in
phospholipase activity per se, can account for the changes
in PG ratios within tissues.
metabolites
Figure 4. The biochemical pathways for PG and TX synthesis and
metabolism showing possible stages at which hormonal
control could be exerted.
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In the following sections, several aspects of PG and TX
synthesis by the ovary, uterus and hypothalamus have been
studied. These include:
a) the measurement of PG and TX levels in tissues. This gives
information on the endogenous concentrations of PGs and reflects
which PGs the tissue synthesizes in vivo
b) the measurement of PG synthetic capacity following
homogenization of the tissue. This procedure liberates
arachidonic acid which is then present in excess amounts in the
homogenate. The relative amounts of PGs and TX which have been
synthesized at the end of the incubation period, gives
information about the activity of the enzymes which convert
the arachidonic acid into PGs and TX
c) metabolism of PGE-2 and PGF-2a and
d) the measurement of the interconversion of PGE-2 and PGF-2a.
This gives a measure of the activity of the PGE-2-9-ketoreductase
e) release of PGs from the superfused uterus. This gives an
enzyme. indication of which PGs are released from uterine tissue
after synthesis within the cells of the uterus.
It is anticipated that these studies wi IT provide" iurtner* ~
insight into the significance of, and into the control of, PG
biosynthesis in these reproductive tissues.
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SECTION 1. MATERIALS AND GENERAL METHODS
This thesis presents work which has largely involved the
measurement of PGs and thromboxane in the uterus, ovaries,
median eminence and hypothalamus of female rats.
PGs and thromboxane have been extracted from homogenized
tissues or superfusates into organic solvents and have been
measured by RIA. Where possible, the PGs and thromboxane were
identified by combined gas chromatography and mass spectrometry
(GC-MS). The experimental results have been divided into four
sections. This section describes the general procedures for
extracting, measuring and identifying PGs and thromboxane which




Chloroform (analar) B.D.H. Chemicals Ltd.
1,2-Dichloroethane (HPLC grade) Rathbone Chemicals
Ethanol J. Boroughs Ltd.
2-Ethoxyethanol (analar) B.D.H. Chemicals Ltd.
♦Ethyl acetate (reagent grade) B.D.H. Chemicals Ltd.
Glacial acetic acid (analar) B.D.H. Chemicals Ltd.
Hexane (analar) B.D.H. Chemicals Ltd.
Methanol (analar) B.D.H. Chemicals Ltd.
♦Petroleum spirit, b.p 40-60°C
(reagent grade) B.D.H. Chemicals Ltd.
Toluene Koch Light Laboratories Ltd.
(♦) These solvents were re-distilled prior to use.
Radioactive compounds
(5,6,8,11,12,14,15 (n)-3H) Prostaglandin E-2 (Sp. act. 160 Ci
mmol 1 )
Amersham International.
(5,6,8,11,12,14,15 (n)-3H) Prostaglandin F-2a; (sp. act. 160 Ci
mmol 1 )
Amersham International.
(5,8,9,11,12,14,15 (n)-3H) 6-keto-Prostaglandin F-lc* (sp. act,
150 Ci mmol 1)
Amersham International.
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(5,6,8,9,11,12,14,15 (n)-3H) Thromboxane B-2 (sp. act. 100
Ci mmol 1 ).
New England Nuclear Inc.
-1
All radioactive compounds were stored at 5 /jCi ml in methanol
at -20°C.
Other Chemicals
Most authentic PGs, thromboxanes and their metabolites were
the gift of Dr. J. Pike, Upjohn Company, Kalamazoo, U.S.A.
PGH-2 was prepared by chemical synthesis by Dr. R.L. Jones and











Sigma Chemical Company, U.K.
Boots Company, U.K.
Evans Medical Ltd., U.K.
Sigma, Chemical Company, U.K.
Sigma Chemical Company, U.K.
Sigma Chemical Company, U.K.
Sigma Chemical Company, U.K.
May & Baker Ltd., U.K.
Krebs1 solution was made up daily as required in 11 quantities
2g Glucose
2.Ig Sodium dihydrogen phosphate
6.9g Sodium Chloride
1.4 ml 10% Magnesium sulphate
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1.6 ml 10% Potassium dihydrogen orthophosphate i^O'E /
2.5 ml 1 M Calcium chloride (l S6q^)
3.5 ml 10% Potassium chloride
All reagents were supplied by B.D.H. Chemicals Ltd., U.K.





B.D.H. Chemicals Ltd., U.K.
Hopkin and Williams Ltd., U.K.
Sigma Chemical Company, U.K.
Fisons, U.K.
Tris (hydroxymethyl) methylamine B.D.H. Chemicals Ltd., U.K.
Diluents for Radioimmunoassay
Diluent 1 0.05M Tris buffer pH 8.0
-1
0.1 gl Sodium azide
1.0 gl 1 Gelatin
Diluent 2 0.05M Phosphate buffer pH 7.5
-1
0.1 gl Sodium azide
-i
1.0 gl Gelatin
Diluent 3 0.05M Tris buffer pH 6.8
0.1 gl sodium azide
-1
1.0 gl Gelatin
Scintillation fluid I 10.5 g PPO
1.51 Toluene
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Scintillation fluid II 10.5 g PPO
1.5 1 Toluene
0.9 1 2-ethoxyethanol
Donkey anti-rabbit serum (DARS) Wellcome Reagents Ltd., and
Scottish Antibody Production
Unit, U.K.
Normal rabbit serum (NRS) was obtained from male New Zealand
white rabbits by the method of Dighe, Emslie, Henderson and
Simon, 1975.
SECTION 1.2 EXTRACTION OF PSS AND TX FROM BIOLOGICAL FLUID
Section 1.2a Solvent extraction of PGs and TX
PGs were extracted from homogenates using the method
described by Poyser (1972). The pH of the homogenate was
first lowered to 4 to 4.5 by the dropwise addition of IN HCL.
The homogenates were then partitioned three times 'with two
volumes of redistilled ethyl acetate. The ethyl acetate
fractions were combined and evaporated to dryness under reduced
pressure at 45°C on a rotary evaporator. Residues were
redissolved in known volumes of ethyl acetate and stored at
-20°C until assayed.
66
Section 1.2b Recovery of tritiated PGE-2, PGF-2a? , 6-keto-PGF-la;
and TXB-2 from tissue homogenates
Method
Four albino Wistar rats were killed by decapitation. Each
uterus was removed and divided into 4 segments each weighing
approximately 120 mg. Each segment was homogenized in 2 ml
Krebs1 solution using a Fisons glass homogenizer, and the
homogenate was added to a 25 ml flask. The homogenizer was
washed with two 1 ml volumes of Krebs1 solution and the washings
3
added to the flask. 0.2 juCi of H PGF-2o: was added to one flask
and also to 4 scintillation vials. These scintillation vials
acted as counting standards. The other three flasks contained
3 3H 3H
0.2 yuCi H PGE-2, 0.2 ^uCi ^6-keto-PGF-la: and 0.2 ^Ci ^XB-2
respectively. Counting standards were also set up as for the
flask with 3H PGF-2o:. The homogenates were incubated for 90 min
at 37°C in a Grant shaking water bath gassed with 5% COi in
Oz. Homogenates were then extracted as described in section
1.2a.
After taking each sample to dryness, the residue was
redissolved in 2 ml ethyl acetate. The ethyl acetate was
transferred to a scintillation vial and evaporated to dryness
under nitrogen at 45°C. 10 ml scintillation fluid I was added
to each vial and the radioactivity monitored using the sample
channels ratio method. The percentage recovery was calculated
from the formul a:
% recovery = disintegrations per min (dpm) per vial x 100
average dpm of counting standards
Results
The percentage recoveries (mean + s.e.m., n=4) at pH 4
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were 96.3 ± 0.53% for PGF-2a, 89.7 ± 1.44% for PGE-2, 81.5 ±
2.01% for 6-keto-PGF-la. and 95.1 ± 1.3% for TXB-2.
It is presumed that similar recovery values would be
obtained after extraction of PGs from ovarian and brain tissue.
Conclusion
Extracting PGs by the method described in section 1.2a
gives high recovery for PGF-2a, PGE-2, 6-keto-PGF-lo: and
TXB-2. PG concentrations measured in tissue homogenates have
not been corrected for procedural losses.
SECTION 1.3 MEASUREMENT OF PGS BY RADIOIMMUNOASSAY
Section 1.3a PGE-2 Radioimunoassay
Introduction
PGE-2 antiserum was raised byDr. K.K. Dighe in rabbits
immunized with prostaglandin-bovine serum albumin conjugates
using the procedure described by Dighe, Jones and Poyser (1978).
The double antibody method was used for the separation of free-




Standard solutions were made up in diluent 2 from a stock
-1
solution of 1 jjg ml PGE-2 in methanol.
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Standard PG solutions were dispensed in triplicate into plastic
tubes as detailed in Table 1.
Table 1. Concentrations of PGE-2 standards used in setting
up a PGE-2 standard curve together with the volume
















1 0.04 0.5 0.02
0.02 0.5 0.01
Tubes were also set up in quadruplicate for counting
standards, zero standards and non-specific binding standards.
Zero standards contained 0.5 ml diluent 2 and non-specific
binding standards contained 0.5 ml of 10 ng ml 1 standard PGE-2.
One tube was also set up for background counting.
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Before use, the methanol containing radioactive PGE-2
(tracer) was evaporated to dryness at 45°C under a stream of
air. The residue was redissolved in diluent 2 to give a
-i _1
concentration of approximately 0.26 juCi ml (0.6 ng ml ).
Antiserum was diluted in diluent 2. The dilution of antiserum
chosen was that which bound 60% of tracer PGE-2 in the absence
of non-radioactive standard PG. All tubes were treated as in
Fig. 5.
The counting standards indicate the average amount of
radioactivity (i.e. the average number of counts) added to each
tube. The zero standards indicate the binding of the tracer PG
to the antibody in the absence of non-radioactive PG. Non¬
specific binding is assessed by calculating the degree of
binding of tracer in the presence of excess non-radioactive
prostaglandin which is present in sufficient amounts to
3
completely prevent binding of H-PGE-2 to the specific sites on
the antibody. If the non-specific binding exceeded 10% in any
assay, the assay was repeated.
Preparation of samples for radioimmunoassay
Tissue homogenates were extracted into ethyl acetate as
described previously (section 1.2a). Two different volumes
of 50 to 500 /il were dispensed in duplicate, (to check for
parallelism between volumes) and the ethyl acetate was blown
off under a stream of air at 45°C. A volume of 0.5 ml of
diluent 2 was added to each tube and the tubes treated according
to Fig. 5. In addition to the assay tubes, four tubes were set
up containing 0.5 ml ethyl acetate.
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All tubes
Counting standards Blow off ethyl acetate at 45°C under
a stream of air




Add 50 /Jl H-PGE-2 tracer
Add 50 jj] PGE-2 antiserum (1:400
di 1 ution )
vortex mix and incubate for 2h
at room temperature
Add 50 1 NRS (1:140 dilution)
Add ^0 /Jl DARS (1:15 dilution)
vortex mix and incubate for 16h at
4°C
Centrifuge at 1300 x g for 30 min at 4°C
Decant supernatant and discard
*
Add 0.2 ml scintillation fluid II
vortex mix
Add 2.8 ml scintillation fluid II
place all tubes in scintillation
vi al s
Liquid scintillation counting
Fig. 5. Procedure for setting up a PGE-2 standard curve and
assay.
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These tubes monitored any possible interference of a residue in
the ethyl acetate with the binding of tracer to antibody. If any
binding did occur, the assay was repeated. Two standard PG
solutions were also set up in duplicate at the end of the assay
tubes. These tubes were used to calculate the interassay
coefficient of variation. The tubes were treated as in Fig. 5.
The vials were monitored for radioactivity in a Nuclear
Chicago Liquid Scintillation counter, counting each vial for
4 min. Counts from the liquid scintillation counter were
recorded on paper tape which was fed into a PDP 8 computer,
programmed to calculate the percentage binding. The percentage
of tracer bound was calculated using the formula:
% bound = sample counts - background counts x 100
average counting standard counts - background counts
The computer applied a logistic curve fitting formula to the
observed values of percentage tracer bound in the standard
curve and calculated the best fitting curve. Two sets of
values, observed and calculated, were compared, and, cf the
variation between them was less than 5%, the curve was judged to
be acceptable.
Results
The standard curves of 6 consecutive PGE-2 assays are shown
in Fig. 6 (mean _+ s.e.m.). The detection limit of the assay,
defined as the amount of standard PG required to give a 10%
fall in binding from the zero standard, was 40 pg. The gradient
of the linear portion of the standard curve for PGE-2 was 11.5%
measured over a doubling of the concentration of PGE-2 per tube.
If the gradient is less than 8%, small differences in PGE-2
concentrations in samples, produce changes in binding of tracer












If the gradient of the standard curve was less than 8%, the assay
was repeated. The intra-assay coefficient of variation was
calculated from the formula:-
intra assay standard deviation of
coefficent of variation = sample quadruplicate x 100
mean value of sample
quadruplicate
The intra-assay coefficient of variation for the PGE-2
radioimmunoassay was 9.2%, and the working range of the assay
was 40-500 pg. The inter-assay coefficient of variation was
calculated from the results obtained by incorporating a known
amount of PGE-2 into each assay, using the formula.
Inter-assay coefficient of variation = standard deviation of
PGE-2 standard xlOO
mean of PGE-2 standard
The inter-assay coefficient of variation for the PGE-2 assay
was 12.6%.
The accuracy of this assay was assessed by adding known
amounts 0, 50, 200, 500 and 1000 ng of PGE-2 to 20 ml Krebs'
solution, extracting the PG as described in Section 1.2a and
measuring the amount of PGE-2 recovered by radioimunoassay. The
mean values obtained were respectively (mean _+ s.e.m., n=3)
0, 45 _+ 7 ng, 208 _+ 19 ng, 490 _+ 37 ng and 987 _+ 35 ng. This
shows that the PGE-2 assay can measure PGE-2 extracted from
Krebs' solution with sufficient accuracy.
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Cross reactivity of the PGE-2 antiserum
Method
A standard curve for PGE-2 was set up. In parallel,
standard curves for different PGs and PG metabolites were
prepared. The percentage cross reactivity of the antiserum
was determined by finding the concentration of PG or PG
metabolite which produced a 10% fall in binding obtained with
the zero standard. The following calculation-was then applied:
% cross reactivity= concentration of PGE-2 giving a 10% (or30°/oy
fall in zero-binding x 100
concentration of PG or PG metabolite
giving a 10% fall in zero-binding
Results
The cross reactivities of antiserum obtained from rabbit 5,
7 bleed with various prostanoids are given in Table 2.
Conclusion
The PGE-2 antibody cross reacts significantly with PGE-1,
PGA-2 and PGB-2. Samples obtained by extraction of tissue
homogenates were therefore subjected to further analysis by
gas chromatography-mass spectometry (GC-MS) to determine if
these samples contained significant quantities of PGE-1,
PGA-2 and PGB-2 which might interfere with the measurement of
PGE-2 in them. The GC-MS analysis is described in Section 1.4.
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Table 2. Cross reactivities of prostanoids with PGE-2 antiserum
-falUn zero
from rabbit 5, 7 bleed, measured at J0% binding of
A
tracer.
















Section 1.3b PGF-2o: Radioimmunoassay
Introduction
Samples were assayed for PGF-2o: using an antiserum raised
in rabbits immunized with a PGF-2o:-bovine serum albumin conjugate
(Dighe, Emslie, Henderson, Rutherford and Simon, 1975).
Method
Reagents: Diluent 1
3 -1 -1 '
H-PGF-2Q! 0.26 jjCi ml (0.6 ngml ) in diluent 1
PGF-2Q! antiserum (rabbit 6, 4^ bleed) 1:1500 dilution
in diluent 1.
NRS 1:140 dilution in diluent 1
DARS 1:15 dilution in diluent 1.
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PGF-2q: Standard Curve and Assay
A standard curve for PGF-2a was set up as for PGE-2.
Standard solutions of PGF-2a were made up in diluent 1 in
-1 -1
concentrations from 0.2 ng ml to 5.12 ngml . Standards were
dispensed in triplicate into tubes in 0.5 ml volumes. Counting
standards, non-specific binding standards and zero standards
were set up in quadruplicate. One tube was also set up for
background counting. All tubes were treated as in Fig. 7.
Results
Fig. 8 shows the standard curve for the PGF-2a
radioimmunoassay drawn from the results of 6 consecutive assays
(mean _+ s.e.m.). The detection limit was 40 pg PGF-2od. Intra-
and inter-assay coefficients of variation were 8.6% and 11.1%
respectively. The gradient of the standard curve measured over
a doubling of the concentration of PGF-2Q; in the tube was 13%
and the working range of the assay was 40 to 500 pg. The
accuracy of the assay was demonstrated by adding known amounts
of PGF-2a, 0, 50, 200, 500 and 1000 ng PGF2o: to 20 ml Krebs'
solution, extracting the PGF-2o: using the method described in
Section 1.2a and measuring the amount of PGF-2a by
radioimmunoassay. The values obtained were 0, 52 _+ 2 ng, 187




Blow off ethyl acetate at 45°C under
a stream of air
Add 50 /Jl PGF-2a: antiserum (1:1500
dilution)
vortex mix and incubate for 1 hour
at room temperature
Add 50 /j1 NRS (1:140 dilution)
Add 50 /Jl DARS (1:15 dilution)
vortex mix and incubate for 16hr
at 4°C
Centrifuge at 1300 x g for 30min at
Decant supernatant and discard
i
Add 0.2 ml scintillation fluid II
vortex mix
Add 2.8 ml scintillation fluid II








Add 50 /Jl 3H-PGF-2a tracer

















The cross reactivities of antiserum from rabbit 6, 4th
bleed with other prostanoids as determined by Miss I. Ramsay
are given in Table 3.
Table 3. Cross reactivities of prostanoids with PGF-2o:
antiserum from rabbit 6, 4thbleed, measured at
-fa IX ui zeyo
30% binding of tracer.
Prostanoid % cross reactivity at














The PGF-2o: antibody cross reacts compLeb-ly with PGF-lo:.
Samples obtained by extraction of tissue homogenates were
therefore subjected to further analysis by GC-MS to determine
if these samples contained significant quantities of PGF-lo; as
described in section 1.4.
Section 1.3.C 6-keto-PGF-lo; Radioimmunoassay
6-keto-PGF-lo: was measured using an antibody raised in
rabbits immunized with a 6-keto-PGF-lo:-thyrogl obul i n conjugate
(Dighe, Jones and Poyser, 1978).
Method
Reagents: Diluent 3
— 1 — 1
3H-6-keto-PGF-lo; 0.24 |iCi ml (0.6 ngml ) in diluent
3.
6-keto-PGF-lo: antiserum (rabbit 1, 6th bleed) 1:1500
dilution in diluent 3
NRS 1:140 dilution in diluent 3
DARS 1:15 dilution in diluent 3.
6-keto-PGF-lo: Standard Curve and Assay
A series of standard solutions of 6-keto-PGF-lo: ranging
-1 -1
from 0.2 ngml to 5.12 ngml were made up in diluent 3.




Fig. 9 shows the standard curve for the 6-keto-PGF-la:
radioimmunoassay drawn from the results of 6 consecutive
assays (mean _+ s.e.m.). The detection limit was 40 pg
6-keto-PGF-lo: . Intra- and inter-assay coefficients of
variation were 8.2% and 9.7% respectively. The gradient of
the standard curve measured over a doubling of the concentration
of 6-keto-PGF-lO! in the tube was 12% and the working range of
the assay was 40 to 400 pg. The accuracy of the assay was
assessed by incorporating two tubes, each containing 0.32 ng
of 6-keto-PGF-la: standard into the assay. The mean value
obtained was 0.310 0.019 ng (mean _+ s.e.m.).
3
Deterioration of H-6-keto-PGF-lo: was indicated by lower
percentage binding of tracer to antibody. When this occurred,
the tracer was purified by column chromatography as described
below.
Purification of 3H-6-keto-PGF-la by Column Chromatography
Method
3H-6-keto-PGF-lQ! was purified by straight-phase, liquid-
gel partition, column chromatography on Lipidex 1000. The
column was first equilibrated overnight with the solvent mixture
hexane, 1,2 dichloroethane, ethanol and acetic acid in the
ratio 100:100:15:0.1 (Brash and Jones, 1974). Effluent from
the column was collected in a L.K.B. ultronic fraction collector.
Ten drops from the column were collected and transferred into a











The tritiated 6-keto-PGF-loi was taken to dryness at 40°C
under reduced pressure on a rotary evaporator. The tracer
residue was redissolved in 0.5 ml methanol and applied dropwise
to the top of the column. The flask containing the tracer
was then washed three times with 0.5 ml methanol and each
washing, applied to the top of the column. 500 ml of the
solvent system was added to the reservoir above the column and
-1
allowed to flow through the column at a rate of 10ml h .
Fractions were collected each containing 180 drops.
Samples (10/j1 ) of each fraction were transferred to
individual scintillation vials each containing 10 ml
scintillation fluid I and counted for 1 min on a scintillation
counter. Fig. 10 shows a histogram of the amount of
radioactivity in 17 fractions collected from the column. The
fractions containing the greatest number of c.p.m. (fractions 7,
8 and 9) were assumed to contain pure tracer and these fractions
wefe pooled and transferred to a pear shaped flask. The fraction
tubes were washed three times with 0.5 ml methanol and the
washings added to the flask. The pure tracer was taken to
dryness at 45°C under reduced pressure and the residue was
dissolved in 5 ml methanol. Two 10/il aliquot volumes were
transferred to vials containing 10 mis scintillation fluid I
and counted in a scintillation counter for d.p.m. The volume










1 2 3 4 5 6 7 8 9 >0 11 12 13 14 15
Fraction number
Figure 10. Histogram of the amount of radioactivity
in serial fractions collected during
purification of 3H-6-keto-PGF-kX. by column
chromatography on Lipidex 1000.
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Results
Following purification of 3H--6-keto-PGF-lo: by column
chromatography percentage binding of H-6-keto-PGF-lo: in zero
standards was between 60 and 70%.
Table 4 shows the cross reactivities of the 6-keto-PGF-lo:
antiserum from rabbit 1, 6th bleed with various other prostanoids
as determined by Miss I. Ramsay. Cross reactivity was measured
at 30% binding of tracer.
Conclusion
Antiserum from rabbit 1, 6th bleed raised against
6-keto-PGF-lo: shows minimal cross reactivity with other
prostanoids and is considered suitable for the measurement
of 6-keto-PGF-lo: by radioimmunoassay.
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Table 4. Cross reactivities of prostanoids with 6-keto-PGF-la
antiserum from rabbit 1, 6th bleed, measured at
-fall
30% binding of tracer.
A
Prostanoid % cross reactivity at















Section 1.3.d. TXB-2 Radioimmunoassay
Introduction
TXB-2 was measured by an antibody raised in rabbits




3H-TXB-2 0.16 ^uCiml 1 (0.6 ngml 1 ) in diluent 2.
TXB-2 antiserum (rabbit 11, 1st bleed) 1:400 dilution in diluent
2.
NRS 1:140 in diluent 2
DARS 1:8 in di1uent 2.
-1
Standard solutions of TXB-2 ranging from 0.2 ngml to 5.12 ngml
were made up and the radioimmunoassay set up as for PGE-2.
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Results
The results of 6 standard curves for TXB-2 are given in
Fig. 11 (mean _+ s.e.m.). The limit of detection was 30 pg.
Intra- and inter-assay coefficients of variation were 8.0%
and 6.1% respectively. The gradient of the standard curve was
12% as measured over a doubling of the concentration of TXB-2
in the tube. The working range of the assay was 30 to 400 pg.
The accuracy of the assay was demonstrated by adding known
amounts of TXB-2 standard (0, 50, 100, 200, 500 ng) to 20 ml
Krebs' solution, extracting the TXB-2 by the method described
in Section 1.2a and measuring the amount of TXB-2 by
radioimmunoassay. The values obtained were (0, 49 jh 2.1,
103 + 3.2, 189 + 7.9, 507 + 10.3 ng).
Table 5 shows the cross reactivities of TXB-2 antiserum
with various prostanoids as measured by Miss I. Ramsay.
Concl usion
Antiserum from rabbit 11, 1st bleed raised against TXB-2
shows negligible cross reactivity with other prostanoids and
the accuracy of the assay has been demonstrated. The assay














Table 5. Cross reactivities of prostanoids with TXB-2
antiserum from rabbit 11, 1st bleed, measured at
"(ctU un
30% binding of tracer.
A
Prostanoid % cross reactivity at
















SECTION 1.4 COLUMN CHROMATOGRAPHY AND GAS CHROMATOGRAPHY -
MASS SPECTROMETRY
Introduction
Although RIA provides a method for the determination of
picogram quantities of PGs in biological samples, the
identification of these compounds is not definitive. Extraction
of the PGs from the biological sample decreases the likelihood
of compounds present in the sample cross-reacting with the
antibody and cross reactivity studies provide further indication
of the specificity of the RIA. However, even if cross reactivity
is low, the ability of an antiserum to measure a specific
PG will depend on the relative amounts of that PG and cross
reacting substances present in the sample.
The cross reactivities of the antisera have been outlined
in the previous section and it was noted that the PGF-2ce
antiserum cross-reacts significantly with PGF-la and that the
PGE-2 antiserum cross-reacts significantly with PGA-2, PGB-2
and PGE-1.
Uterine and ovarian samples which had been assayed for
PGs and TX by RIA were therefore subjected to further analysis
by GC-MS firstly to positively identify PGE-2, PGF-2oi,
6-keto-PGF-la and TXB-2 in the samples and secondly to determine
if these samples contained significant quantities of PGA-2,
PGB-2, PGE-1 and PGF-la. Unfortunately there was insufficient
samples from median eminence or anterior hypothalamus for
analysis by GC-MS. Prior to GC-MS analysis, lipids were
separated from the tissue extracts by column chromatography.
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Section 1.4.a Purification of tissue extracts by column
chromatography
Four columns containing 4g silicic acid (Unisil 100-200
mesh) were prepared and each washed with 100 ml diethyl ether.
The extracts of one tissue type (uterus or ovaries)
were combined to provide two pooled samples. Each sample
was evaporated to dryness under reduced pressure at 45°C,
redissolved in 30 ml of 67% ethanol, washed twice with 60 ml
petroleum ether (b.p. 40°-60°) and evaporated to dryness again.
Each sample was then dissolved in 0.5 ml diethyl ether and
applied, dropwise, to the top of each column. The columns
were eluted in succession by 100 ml diethyl ether, 100 ml 80%
diethyl ether and 20% methanol, and 100 ml methanol. The second
solvent mixture elutes PGs and TX and this fraction from each
column was evaporated to dryness, and redissolved in 1 ml ethyl
acetate.
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Section 1.4b Gas chromatography - Mass spectrometry
GC-MS analysis was carried out on a VG-micromass 7070F
double focussing gas chromatogram-mass spectrometer. The column
(3m x 4 mm) was packed with 3% 0V1 on supelcoport 100-120
mesh (Supelco Inc., Bellefonte, U.S.A.). The column temperature
-1
was 275°C and the helium carrier gas flow rate was 30 ml min
Conditions for operation of the mass spectrometer were:-
Ion source temperature 250°C
Electron energy 70 eV
Accelerating voltage 4 kV
Signal amplification 2 x 1Q7 amps,
Full mass spectra were recorded on photographic paper
by a light beam oscillograph (S.E. Labs. (EMI) Ltd., Feltham,
England). A mixture of straight chain saturated fatty acid
methyl esters with 16, 18, 20, 22, 24 and 26 carbon atoms
was used to calibrate the G.C. column. By plotting the
retention times of each fatty acid against the number of carbons
in the fatty acid on a logarithmic scale, the observed retention
times of the standard PGs can be converted to carbon values.
The size and shape of the G.C. peak corresponding to each fatty
acid standard also indicates the efficiency of the G.C. column.
Derivitization of PGs for GC-MS
Introduction
Derivitization of PGs is essential to provide a molecule
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which has suitable volatility and high thermal stability which
will run on the GC column. Carboxylic acid groups on the PGs
are protected by forming methyl ester derivatives, hydroxyl
groups are protected by forming trimethylsilyl ethers and
ketone groups are protected by conversion to butyl oxime
derivatives. Butyl oximation produces two geometrical
isomers with most ketonic PGs.
Method
Two 0.5 ml aliquot volumes of each sample were evaporated
to dryness in 1 ml eppendorf tubes at 20°C under a stream of
nitrogen. Drying was completed by vacuum dessication for 15 min.
Methyl ester formation
0.5 ml of diazomethane solution (9 parts diethyl-ether:
1 part methanol) were added to the two tubes from each sample
and the contents of the tubes allowed to react for 10 min.
The solvent was evaporated at 60°C under a stream of nitrogen
and the process was repeated. Following evaporation of the
solvent again, the samples were vacuum dessicated for 10 min.
The methyl esters of standards - PGA-2, PGB-2, PGD-2, PGE-1,
PGE-2, PGF-lo:, PGF-2a , 5-keto-PGF-lo: and TXB-2 were also
prepared by this method.
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n-Butyloxime* formation
The butyloxime derivatives were prepared by adding 3
drops of 5 ng ml 1 0-butyl hydroxylamine hydrochloride in
dry pyridine to one tube from each sample and to tubes
containing PGD-2, PGE-1, PGE-2, 6-keto-PGF-la and TXB-2.
The tubes were stoppered and the contents allowed to react at
room temperature overnight. The following morning the tubes
were placed in an oven at 60°C for 15 min to complete the
reaction. The pyridine was then evaporated off under a stream
of nitrogen at 60°C and drying completed by vacuum dessication
for 15 min.
Trimethylsilyl ether formation
30jul bis (trimethyl si lyl) tri fl uoracetami de (BSTFA) was
added to all standards and 20jj1 BSTFA to all samples. After
closing the tubes and vortex mixing the tubes were heated for 15
min at 60°C.
Each standard PG was injected, in turn, into the instrument.
After noting their retention times on the GC, a full mass
spectrum was taken. Each sample was then injected into the
instrument and a mass spectrum taken at the appropriate
retention time. The mass spectra from the samples and standards
were compared. The limit of detection of the mass spectrum
is approximately 50 ng. Table 6 shows the characteristic
ions used to determine the presence of PGs and TXB-2 in
biological samples.
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Table 6. Characteristic iohs of methyl trimethylsilyl ether
(Me, TMS) and methyl trimethylsilyl butoxime








6-keto-PGF-lo; 1st isomer Me,BuO,TMS 671,656,600,598,510,508
491
PGD-2 2nd isomer Me,BuO,TMS 581,510,508,420,418,295
PGE-1 1st isomer Me,BuO,TMS 583,568,510,512,297
PGE-2 2nd isomer Me,BuO,TMS 581,566,510,508,295,225
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* Section 2.1 PGS AND OVULATION
Introduction
Ovarian PGE and PGF levels rise from late afternoon on
pro-oestrus, reach a peak at midnight and return to basal levels
within 5h. This increase in PG levels follows the surge of LH
from the pituitary gland and is a consequence of that surge
(Bauminger and Lindner, 1975).
The biochemical mechanism whereby LH stimulates PG synthesis
in the ovary is not fully understood. PG synthetase activity
in whole ovaries (Bauminger and Lindner, 1975) and in cultured
granulosa cells (Clark, Marsh and LeMaire, 1978b) increases
concurrently with the increase in PG levels at the time of
ovulation. Subsequent studies have indicated that LH stimulates
PG synthesis in the ovary by increasing PG synthetase activity
rather than by increasing the availability of arachidonic acid
for PG synthesis (Bauminger, Liberman and Lindner, 1975; Zor,
Strulovici, Nimrod and Lindner, 1977; Clark, Marsh and LeMaire,
1978). Characterization of the ovarian PG synthetase enzyme
complex indicates that the apparent Km for arachidonic acid is
not altered by hCG treatment, but that hCG increases the specific
activity of the enzyme (measured as the amount of PGE produced
min 1mg protein1). These findings suggest that hCG and
presumably LH increase ovarian PG levels either by increasing the
quantity of the enzyme complex or its catalytic efficiency
(Clark, Chainy, Marsh and LeMaire, 1980).
Experiments described in this section were performed to
elucidate further, the mechanism of the increased ovarian PG
synthesis at the time of ovulation.
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Section 2.*la Measurement of the ability of ovarian tissue
to produce PGs and TX during the oestrous cycle
Introduction
The PG synthetase enzymes form several metabolites of
arachidonic acid. In addition to PGE-2 and PGF-2o:, rat ovaries
synthesize 6-keto-PGF-lo: (ref1ecting PG1-2 synthesis), TXB-2
(reflecting TXA-2 synthesis) and PGD-2 (Poyser and Scott, 1980).
This study showed that PGI-2 is the major PG present in, and
synthesized by, rat ovarian homogenates. Ovarian 6-keto-PGF-la:
and TXB-2 synthesis did not show any daily variations, however
PG and TX measurements were only determined at 10:00h on each day
of the oestrous cycle. As PG synthesis has previously been
shown to rise and fall within a 12h period between pro-oestrus
and oestrus (LeMaire, Leidner and Marsh, 1975), such changes in
PG synthesis would have been overlooked in the experiment of
Poyser and Scott (1980).
The following experiment has involved measurement of the
synthesis of 6-keto-PGF-la and TXB-2 as well as PGE-2 and
PGF-2a by the ovary, at more frequent intervals (4-hourly)
throughout the oestrous cycle.
Method
A total of 144 mature female Albino Wistar rats weighing
between 200g and 250g were used (These animals also provided
tissue for use in experiments described in Section 2.2a and
Section 2.3a).
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The animals were housed under controlled lighting conditions
(light period 06:00h to 20:00h) and were offered both a
standard diet and water without restriction. After an initial
period of 2 days, vaginal smears were taken daily and examined
microscopically. Oestrus was determined as the day of maximum
cornification of a smear of vaginal epithelial cells, preceeding
the day of leucocyte infiltration. Only females showing at
least 2 consecutive 4-day oestrous cycles were included in the
study.
Animals were killed by a blow to the thorax and decapitation
at 02:OOh, 06:00h, 10:00h, 14:OOh, 18:OOh and 22:OOh on a
particular day of the cycle, a total of six animals being killed
for each time of the day. The ovaries from each rat were
dissected from the ovarian side of the ovarian-oviductal junction
and placed into Krebs1 solution. After drying the ovaries ,
their weight was recorded. The ovaries from each rat were
homogenized in 5 ml Krebs' solution and the resulting homogenate
added to a 50ml conical flask. The homogenizer was washed twice
with two 5m1 volumes of Krebs1 solution and the washings added
(but without 3W-tabzlj
to the flask. The homogenate was incubated, for 90 min as
>A
described in Section 1.2b. Following incubation, the pH was
adjusted to 4 with HC1 and the lipids were extracted with ethyl
acetate as described in Section 1.2.a. Samples were stored in
10 ml ethyl acetate at -20°C until they were assayed for PGE-2,
PGF-2a, 6-keto-PGF-lo; and TXB-2 content by RIA as previously
described in sections 1.3a, b,- c and d. Results were compared
initially by an F-ratio test and subsequently by Duncan's
Multiple Range test for equal variances. Significance was tested
at the 5% 1evel.
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Identification of extracted PGs by GC-MS *
Samples which had been assayed for PGE-2, PGF-2a, 6-keto-
PGF-lo; and TXB-2 by RIA were pooled, purified by silicic acid
column chromatography and the appropriate derivatives prepared
as described in section 1.4. Following derivitization, samples
were injected into the GC in IOjjI BSTFA. Full mass spectra were
taken at the appropriate retention times on the GC corresponding
to the carbon values of PGA-2, PGB-2, PGD-2, PGE-1, PGE-2,
PGF-Iq;, PGF-2qi, /6-keto-PGF-lo: and TXB-2.
Results
Analysis by GC-MS showed that PGF-2o:, PGE-2, 6-keto-PGF-lo:,
PGD-2 and TXB-2 were present in extracts from rat ovaries, by
noting the presence of their characteristic ions in the mass
spectra. PGA-2, PGB-2, PGE-1 and PGF-kwere not detected in
these extracts.
Figure 12 shows the amounts of PGE-2, PGF-2Q!, 6-keto-PGF-1o:
and TXB-2 formed from endogenous precursors in ovarian
homogenates at 4-hourly intervals throughout the oestrous
cycle. A statistical analysis of these results is given in
Table 7. The major PG produced by ovarian homogenates throughout
most of the cycle was PGI-2 (measured as 6-keto-PGF-la) with
lesser quantities in decending order of PGF-2Q!, PGE-2 and TXA-2
(measured as TXB-2). At oestrus, PGE-2 was the major PG formed. V
PGE-2 production was low throughout most of the cycle and
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Table 7. Statistical analysis of PG and TX production by rat ovarian
homogenates as shown in Fig. 12. Significance was tested by
Duncan's multiple range test for equal variances. Values
with the same superscript within each column are not significantly
different (p>0.05). Values are expressed as mean + s.e.m. ,
n=6 for each time.
Time PG producti
ng 100 mg
on PGE-2 PGF-2CX 6-keto-PGF- la TXB-2
14:OOh oestrus 138+15ab 230+22°de 230+17® 25+4®
18:OOh oestrus 114+14®** 169+25ab°d 205+17® 38+7®
22:OOh oestrus 125+23®** 128+16®** 162+23® 45+8®
02:OOh met-oestrus 108+25ab 171+22ab°d 194+22® 38+5®
06:OOh met-oestrus 130+25ab 160+12ab°d 165+32® 33+4®
10:OOh met-oestrus 116+12ab 168+20ab°d 164+20® 34+5®
14:OOh met-oestrus
ab
113+18 170+17ab°d 163+25® 35+6®
18:OOh met-oestrus 112+18ab 138+17ab 175+20® 39+8®
22:OOh met-oestrus 91+20ab 135 + 10®** 192+25® 44+7®
02:OOh di-oestrus 107+20ab 121 + 11 ^ 201+24® 38+5®
06:OOh di-oestrus 98+20ab 114+93 184+25® 38+5®
10:OOh di-oestrus 104+15ab 12 7 +17 ab 181+25® 37+4®
14:OOh di-oestrus 115+12ab 148+12ab° 178+20® 38+5®
18:OOh di-oestrus 119+20®** 17S+10ab°d 185+15® 31+ 4®
22:OOh di-oestrus 90+32ab 120+15ab 193+30® 28+5®
02:OOh pro-oestrus 125+15ab 1 26 + 1 2®** 233+36® 38+4®
06:OCh pro-oestrus 118+17ab 126+20ab 227+48® 39+7®
10:OOh pro-oestrus 115+10ab 225+18°d 250+22®b 38+7®
14:OOh pro-oestrus 84+1 7®** 240+22def 226+30® 36+7®
18:OOh pro-oestrus 75 + 9a 200+20b° 201+12® 25 + 3®
22:OOh pro-oestrus 175+35b 313+30Sf 262+12®b 24+4®
02:OOh oestrus 380+65° 320+10f 344+25b 42+2®





190+17 345+20 40 + 5®
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Production of PGE-2 increased significantly (p<0.05) between
18:OOh and 22:00h on pro-oestrus. By 02:00h on oestrus, PGE-2
production had increased 5-fold when compared to production at
18:OOh on pro-oestrus and was significantly (p<0.05) higher than
at any other time during the cycle. Within 4 to 8h, PGE-2
production had fallen to a value which did not differ
significantly from that throughout most of the cycle.
PGF-2Q! production was lowest at 06:00h on di-oestrus.
It had increased significantly by 10:00h on pro-oestrus and
like PGE-2 production had reached a maximum at 02:00h on
oestrus, although the rise and fall in PGF-2o; production was more
gradual than for PGE-2 production. By 10:OOh on oestrus PGF-2o:
production had fallen to a value which was not significantly
different from PGF-2Q! production at most other times in the
cycle. Between 18:OOh on pro-oestrus and 02:00h on oestrus PGF-2qi
production had increased 1.6-fold.
6-keto-PGF-loi production was lowest at 22:OOh on oestrus
and fluctuated, without significant differences until 22:00h on
pro-oestrus. A significant increase in 6-keto-PGF-la production
occurred between 18:OOh on pro-oestrus and 02:00h on oestrus.
This increase being 1.7 fold. Production of 6-keto-PGF-lo:
remained elevated for 8h and had decreased by 14:OOh on oestrus
to a value which was not significantly different from those
throughout most of the oestrous cycle. There were no significant




Analysis of ovarian extracts by GC-MS confirmed the presence
of PGE-2, PGF-2o;, 6-keto-PGF-lo: and TXB-2 as had been previously
estimated by RIA. PGA-2, PGB-2, PGE-1 or PGF-ltfwere not detected
in these extracts. Thus, although the antisera used in the RIA
to measure PGE-1 shows cross reactivity with PGA-2, PGB-2 and
PGE-1, and that used to measure PGF-2xshows cross reactivity with
PGF-la, it is probable that the assays measured PGE-2 and PGF-2o;
respectively since no PGA-2, PGB-2, PGE-1 or PGF-lo: were detected
in the extracts.
The major PG produced by ovarian homogenates throughout
most of the cycle was PGI-2 (measured as 6-keto-PGF-lo;) with
lesser quantities of PGF-2a, PGE-2 and TXA-2 (measured as TXB-2).
Ovulation in these rats is known to occur around 02:OOh on
oestrus. Towards the time of ovulation, production of PGE-2,
Q maximwin
PGF-2ce and 6-keto-PGF-lo; increased and reached^at 02:00h on
oestrus (or 06:00h, in the case of 6-keto-PGF-lo;). PGE-2
production showed the greatest percentage increase between 18:OOh
on pro-oestrus and 02:OOh on oestrus. Between these two times,
mean TXB-2 production also showed an increase, however, due to
the large variance associated with the data, this difference was
not significant.
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Section 2.1b Measurement of ovarian PG and TX levels at 10:OOh
on pro-oestrus and 02:00h on oestrus and PG and TX
production by ovarian homogenates incubated in the
presence of arachidonic acid
Introduction
Hitherto, the PG and TX content of extracts of ovarian
homogenates after a 90 min incubation period has been termed
'production'. In order to equate 'production' with 'synthesis'
it is necessary to determine a) that before homogenization and
incubation, the levels of PG and TX are low and b) that
metabolism of PG and TX in the homogenate is low.
Homogenization of tissues releases arachidonic acid from
cellular phospholipids (Pace-Asciak and Wolfe, 1968; Flower
and Blackwell, 1976) and incubation of tissue homogenates will
further increase arachidonic acid release (Mitchell, Poyser
and Wilson, 1977). As the level of free arachidonic acid is
rate limiting in the biosynthesis of PGs (Kunze, 1970; Flower
and Blackwell, 1976), it is important to determine if changes
in PG production by homogenates are due to changes in arachidonic
acid availabiliy.
The following experiments were performed to determine a)
that PG and TX levels in rat ovaries are low and that b)
arachidonic acid availability in ovarian homogenates at a time
of low PG production was not rate-limiting in the biosynthesis
of PGs and TX.
PG metabolism in ovarian homogenates is described in
Section 2.2.C
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Measurement of ovarian prostaglandin and thromboxane
levels at 10:OOh on pro-oestrus and 02:00h on oestrus
Method
Rats were killed (as described previously) at 10:00h
(n=3) and at 02:00h (n=3). The ovaries of each rat were removed,
weighed and homogenized in 5 ml ethanol. After transferring the
homogenate to a centrifuge tube the homogenizer was washed twice
with 5 ml ethanol and the washings added to the tube. Each
homogenate was centrifuged at 1000 x g for 15 min and the
supernatant liquid withdrawn. The precipitate was washed with
5 ml ethanol, centrifuged at 1000 x g for 15 min and the
resulting supernatant combined with the original extract.
Each extract was evaporated to dryness, under reduced pressure
at 45°C, then dissolved in 10ml distilled water, and the PGs and
TX extracted as described in section 1.2.a. Samples were stored
and assayed by RIA as described in sections 1.3.a, b, c and d.
Results were expressed as mean _+ s.e.m. and are given in




Table 8. Concentrations of PGs and TX in ethanolic homogenates
of ovaries from rats at 10:OOh on pro-oestrus and at
02:00h on oestrus (mean + s.e.m.)
^\PG concentration























* significantly different (p<0.05) from 10:OOh on pro-oestrus.
Concentrations of PGE-2, PGF-2o;, 6-keto-PGF-la and TXB-2
in ovaries were low when compared to the amounts of PGs and
TX formed during incubation of the homogenates. At 02:00h on
oestrus, ovarian PGE-2, PGF-2o: and 6-keto-PGF-lo: concentrations
were significantly increased by 160%, 54% and 102% respectively,
(p^O.05) when compared to 10:00h on pro-oestrus. Ovarian




Ovarian levels of PGs and TX were low in comparison to
PG and TX production after incubation of homogenates as shown
previously. It can be concluded therefore, that the increased
PG and TX production following homogenization and incubation
reflects fresh synthesis of PGs and TX by the ovarian tissue.
Because PGE-2, PGF-2a and 6-keto-PGF-lo: levels were significantly
higher at the time of ovulation than at 10:00h on pro-oestrus,
this suggests that these PGs may be important in the mechanism
of ovulation in the rat.
Measurement of PG production by ovarian homogenates
incubated in the presence of arachidonic acid
Method
4 rats were killed at 10:00h on pro-oestrus, the ovaries
were dissected out, homogenized and incubated as described in
section 2.2.a except that arachidonic acid was added to the
homogenate immediately prior to incubation. The final
-1
concentration of arachidonic acid was 2 jugml . Homogenates
were extracted and assayed for PG and TX by RIA as previously
described (Sections 1.2a and 1.3.a, b, c and d). Results
(shown in Fig. 13) are expressed as mean _+ s.e.m. and were
compared using Student's 1t' test.
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Figure 13
PG and TX production by ovarian homogenates
incubated in the absence [HJ (n=6) or presence
F/3 (n=4) of 2>jgmr1 arachidonic acid.
Rats were killed at 10:OOh on pro-oestrus.
1 1 2
Resul ts*
PG and TX production by homogenates of ovaries from rats
killed at 10:00h on pro-oestrus did not differ significantly
whether incubated in the absence or presence of arachidonic
aci d.
Cone! usion
Incubation of ovarian homogenates from rats killed at
10:00h on pro-oestrus with arachidonic acid did not increase
PG or TX production when compared to PG and TX production by
homogenates incubated without the addition of arachidonic acid.
Thus it can be concluded that the relatively low PG production
at 10:OOh on pro-oestrus was not due to lack of endogenous
free arachidonic acid.
Section 2.I.e. Measurement of the ability of ovarian tissue
to metabolize P6E-2 and PGF-2g
Introduction
The previous sub-sections have described experiments
which measured PG and TX production by ovarian homogenates
when incubated for 90 min, and which showed that the PGs and
TX produced reflected fresh synthesis during the incubation.
However, ovarian tissue has the ability to metabolize PGs
(Anggard, Larsson and Samuelsson, 1971; Maule Walker, Patek,
Leaf and Watson, 1977; Aizawa, Inazu and Kogo, 1980).
1 1 3
Therefore the amount of PG synthesized after 90 min may be
affected by the extent of PG metabolism in the homogenate.
PGs are metabolized by oxidation of the secondary alcohol
group at carbon atom 15 to a ketone, by 15-hydroxy prostaglandin
dehydrogenase (15 PGDH) followed by reduction of the a-13
double bond by prostagl andi n a-13 reductase. The former
conversion requires nicotinamide adenine dinucleotide (NAD+)
as a cofactor (Anggard, 1971; Samuelsson, 1972). The 15-keto-
and 13,14-dihydro-15-keto PG metabolites show greatly reduced
biological activity (Anggard, 1966; Crutchley and Piper, 1975).
Interconversion of primary PGs has also been demonstrated in
several tissues resulting in compounds of different or even
enhanced biological potency. Watson, Shepherd and Dodson (1979)
have demonstrated the existence of prostaglandin E-2-9-
ketoreductase, an NADPH dependant enzyme, which converts PGE-2
to PGF-2Q! in rat ovarian tissue, and that this conversion is
reversible.
The following experiments were performed to study the
metabolism of PGE-2 and PGF-2Q! by ovarian homogenates with and
without the addition of cofactor (NAD+) at times when PG
production by ovarian homogenates was low (10:OOh on pro-oestrus)
and high (02:00h on oestrus). The possible interconversion
of PGE-2 and PGF-2Q! in homogenates in the absence and presence
of the appropriate cofactor reduced nicotinamide adenine
dinucleotide phosphate (NADPH) or nicotinamide adenine




The ovaries were removed from rats killed at 10:00h on
pro-oestrus and 02:00h on oestrus (n=4 for each time). The
two ovaries from each rat were separated. Each ovary was
homogenized in 5 ml Krebs' solution. NAD+ was added to one
ovarian homogenate to give a final concentration of 2mM.
PGF-2a: (lOjjg) was also added to this homogenate. Each
homogenate was then incubated in the presence of 0.5pCi
3 1
H-PGF-2a (sp. act. 160yuCimmol ) for 90 min. The PGs were
extracted as described in section 1.2a. This experiment was
repeated except that lO^g PGE-2 was added to one homogenate
instead of PGF-2a, and that each homogenate was incubated in the
presence of O.^uCi 3H-PGE-2 (sp. act 160 ^iCimmol ) instead of
H-PGF-20. The extracts were evaporated to dryness by a stream
of air and the residues were redissolved each in 0.15 ml
methanol, and subjected to thin-layer chromatography. H-PGE-2,
H-PGF-2^and non-radioactive marker standards (10|ig each of PGE-2,
PGF-2Q!, 15-keto-PGE-2, 15-keto-PGF-2o:,
13,14-dihydro-15-keto-PGE-2 and 13,14-di hydro-15-keto-PGF-2o:)
were applied to silica gel precoated TLC plates (Merck, UK). All
plates were developed in the solvent system chloroform:methanol :
glacial acetic acid: water, 90: 9: 1: 0.65, to give a solvent
front 15 cm from the origin.; Standard spots on the control
plates were visualized by exposure of the plates to iodine vapour
for 30 min and the Rf values of these standard were recorded.
The silica gel was scraped off the radioactive plates in 0.5 cm
intervals into scintillation vials. After adding 0.5 ml
methanol, 10 ml of scintillation fluid I was dispensed into each
vial.
1 1 5
Radioactivity was monitored in a Phillips scintillation counter
using sample channels ratio counting. The Rf values of
radioactive peaks on the plate were compared to Rf values of
standard PGs and metabolites. Metabolism was calculated by
expressing the radioactivity associated with each PG or
metabolite as a percentage of the total radioactivity on the
plate. Radioactivity associated with metabolites was corrected
for the loss of tritium from the 15-hydroxyl group during its
conversion to a ketone group.
The possible inter-conversion of PGE-2 and PGF-2a was
studied using essentially the same method as above. Three
rats were killed at 02:00h on oestrus. The ovaries were
dissected out and processed as described previously except that
to one ovarian homogenate, NADP (2mM) and lOyjg PGF-2o: were
added. Each ovarian homogenate was incubated in the presence
of 0.5 /iCi 3H-PGF:2c*. This experiment was repeated replacing
3 3
PGE-2 for PGF-2o:, H-PGE-2 for H-PGF-2a and using NADPH (2mM)
as a cofactor. Extracts were subjected to thin layer
chromatography as above. The radioactivity was localized
using a Panax radio thin layer chromatographic plate scanner.
Results
The Rf values for the non-radioactive marker standards
are shown in Table 9. Thin layer chromography of 3H-PGE-2
and 3H-PGF-2q: had previously shown that at least 98% of the
radioactivity was associated with PGE-2 and PGF-2q: respectively.
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The percentage metabolism of PGE-2 and PGF-2q: by ovarian
homogenates at 10:OOh on pro-oestrus and 02:00h on oestrus
incubated in the absence and presence of NAD+ is shown in
Table 10 (mean _+ s.e.m. n=4).
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The % metabolism results have not been corrected for tissue
weight. However ovarian weights did not change significantly
between the two times (52 + 7.2 mg at 10:00h pro-oestrus, and
56 _+ 9.4 mg at 02:00h on oestrus).
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Table 10. Percentage metabolism of PGE-2 and PGF-2h:at 10:00h
on pro-oestrus and 02:00h on oestrus in ovarian homogenates
incubated in the absence and presence of NAD+ (mean +
s.e.m., n=4)
Time
PGE-2 Metabolites PGF-2& metabol i tes
ovary ovary
without NAD+ with NAD+
ovary ovary
without NAD+ with NAD+
10:OOh
pro-oestrus 10.1+1.02 *51.5+13.1 11.3+1.5 *19.5+3.5
02:OOh
oestrus 11.6+2.2 *30.4+1.6 9.3+1.6 *15.0+2.0
* significantly different from the percentage metabolism
without NAD+ added (p< 0.05)
Incubation of ovarian homogenates with3H-PGE-2 or
3
H-PGF-2yresulted in the formation of metabolites with Rf
values corresponding to the 15-keto- and 13,14-dihydro-15-keto-
metabolites of these PGs. The percentage metabolism of PGE-2
and PGF-2xis expressed as the sum of these two metabolites in
each case. In the absence of NAD+, the percentage metabolism
of PGE-2 and PGF-2xwas approximately 10%. This percentage
did not differ significantly between 10:OOh on pro-oestrus
and 02:00h on oestrus.
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The addition of NAD+ significantly (p<0.05) increased both
PGE-2 and PGF-20: metabolism at both times. PGE-2 and PGF-2&
metabolism in the presence of NAD+ was greater at 10:OOh on
pro-oestrus than 02:00h on oestrus. However, due to the small
numbers in the group, this difference was not significant.
The ability of the ovaries to convert 3H-PGF-2q; to
v3H-PGE-2 at 02:OOh on oestrus was undetectable whether NADP
was present in the incubation medium or not. Figure 14 shows
the thin-layer radiochromatogram obtained by use of the Panax
scanner showing the conversion of 3H-PGE-2 to 3H-PGF-2q: in
the absence and presence of NADPH in the homogenate. Similar
radiochromatograms were obtained for all 3 experiments.
Conversion of 3H-PGE-2 to JH-PGF-2o: at 02:OOh on oestrus was
less than 2% in the absence of NADPH. Addition of NADPH
increased the conversion to 6.1 _+ 1.7% for the 3 experiments.
The main metabolites of PGE-2 as identified by T.L.C. were
15-keto-PGE-2 and 13,14-dihydro-15-keto-PGE-2 and the percentage
conversion of PGE-2 to these metabolites did not differ
significantly in the absence (19.8 + 3.3%) or presence
(15.2 + 1.1%) of NADPH.
Conclusion
Metabolism of PGE-2 and PGF-2o; in ovarian homogenates in
the absence of NAD+ is low. As it has been previously
demonstrated in this section that ovarian PG levels are also low,
and that the addition of arachidonic acid does not increase PG
production by homogenates, it can be concluded that the amounts
of PGs produced by these homogenates reflects the PG synthesizing








Profiles of thin-layer radiochromatograms
from a typical experiment showing conversion of
3H-PGE-2 to PGE-2 metabolites and PGF-2o; by
ovarian homogenates incubated a) in the absence
of NADPH and b) in the presence of NADPH.
Similar radiochromatograms were obtained in all
3 experiments.
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There was no significant difference in the ability of
ovarian homogenates to metabolize H-PGE-2 or H-PGF-2a: at
10:OOh on pro-oestrus compared to 02:OOh on oestrus.
Therefore, the increase in PGE-2 and PGF-2o; production by
ovarian homogenates seen at the time of ovulation cannot be
due to decreased metabolism. PG1-2 and TXA-2 metabolism has not
been studied here but PG 1-2 is also metabolized by the NAD-
dependent enzyme^15-hydroxyl PG dehydrogenase^to form
15-keto-PGI-2 (McGuire and Sun, 1978) which is subsequently
reduced to form 6,15-diketo-13,14-dihydro-PGF-lo; (Sun and
Taylor, 1978). Likewise 15-keto-13,14-dihydro-TXB-2 has
been identified as the major product released after immunological
challenge of sensitized guinea pig lungs (Mallen, Osborne,
Cockerill, Boot and Dawson, 1978). It is likely that the
enzymes which metabolize PGI-2 and TXB-2 are the same as those
which metabolize PGE-2 and PGF-2Q! (although the affinity for the
substrates may differ) and that PGI-2 and TXA-2 metabolism
in ovarian tissue is equally as low as that of PGE-2 and
PGF-2cx.
The addition of NAD+ increased both PGE-2 and PGF-2a
metabolism and this increase tended to be greater at 10:00h
on pro-oestrus than at 02:00h on oestrus. This may suggest
that the supply of NAD+ may control PG metabolism in the ovaries,
however more experiments of this nature would be required in
order to confirm this suggestion.
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Although the existence of an ovarian enzyme PGE-2-9-keto
reductase which can convert PGE-2 to PGF-2q; has been indicated
(Watson, Shepherd and Dodson, 1979), experiments in this
section have shown that the activity of this enzyme in ovarian
homogenates in the absence or presence of NADPH is low at
02:OOh on oestrus. There was no detectable conversion of
J
H-PGF-2o: to '3H-PGE-2 at this time. Therefore, the high PGE-2
production at the time of ovulation cannot be due to conversion
of PGF-2a to PGE-2 by the reversible action of the enzyme PGE-2-
9-ketoreductase.
Section 2.1.d Measurement of the conversion of PGH-2 to
PGE-2 prior to and at the time of ovulation
Introduction
The ratio of PGE-2: PGF-2a: 6-keto-PGF-la: TXB-2
production by ovarian homogenates was approximately 3:6:6:1
at 10:00 on pro-oestrus. This ratio had changed to 8:7:7:1
by 02:00h on oestrus. Thus, at the time of ovulation the
synthesis of PGs and TX was directed towards PGE-2. Previous
experiments in this section have demonstrated that the increased
PG production at the time of ovulation was not due to alterations
in arachidonic acid availability, PG metabolism or
i nterconversion of PGF-2a and PGE-2. This suggests that there
is an increase in the conversion of the available arachidonic
acid into PGs, i.e. increased PG synthetase activity. In
addition, these experiments suggest that a mechanism exists
in the ovary which specifically converts arachidonic acid via
PGH-2 into PGE-2 at the time of ovulation.
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Following the actfon of cyclooxygenase, which converts
arachidonic acid into PGH-2, the endoperoxide is converted to
PGE-2 by PGE isomerase. The isomerase enzyme has been isolated
from bovine seminal vesicle microsomes (Ogino, Miyamoto,
Yamamoto and Hayashi, 1977). PGH-2 also decomposes in aqueous
solution into a mixture of PGD-2 and PGE-2 with a half-life
of 10 min at 37°C (Nugteren and Chri st-Hazel hof, 1979). The
increased PGE-2 synthesis at the time of ovulation could be
due to either increased cyclooxygenase activity^or increased
isomerase activity^or both. Increased isomerase activity
would be accompanied by increased conversion of PGH-2 to PGE-2.
In the following experiment the conversion of PGH-2 to PGE-2 at
10:OOh on pro-oestrus and 02:OOh on oestrus has been compared,
thus giving an index of PGE isomerase activity. Homogenization
of the ovarian tissue was carried out in the presence of
indomethacin in order to inhibit endogenous PG synthesis.
Method
Rats were killed by a blow to the thorax and decapitation
at 10:OOh on pro-oestrus (n=6) or 02:00h on oestrus (n=7).
The ovaries were dissected out and placed into Krebs1 solution
containing 50 yugml 1 indomethacin. Indomethacin was made up
as a concentrated stock solution of 2.5 mgml in ethanol and
added to Krebs' solution in 100^1 or 200/j 1 volumes of ethanol
as required. The ovaries from each rat were homogenized in
9ml Krebs' solution containing 50jjgml 1 indomethacin. The
homogenate was then divided into 3 volumes and each 3 ml of
homogenate was transferred to separate conical flasks.
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A sample of lOQul of each homogenate was taken for estimation
of protein content using the method of Lowry, Rosebrough, Farr
and Randall, (1951). One flask was suspended in a boiling
water bath for 10 min. During this period, the remaining
two flasks were kept on ice. After this 10 min period, the
flask containing the boiled homogenate was cooled on ice.
Each of the three flasks were transferred to a shaking
water bath and incubated therein for an initial period of 3 min
which allowed the temperature of the homogenates to reach 37°C.
Flasks were gassed with a mixture of 95% 02 and 5% CO2..
PGH-2 was stored in hexane: ethyl acetate at -20°C.
Before use, the solvent was evaporated in a pear-shaped flask ^
under reduced pressure^ on ice. The flask was then connected to
a vacuum pump and drying was completed under reduced pressure
on ice. The residue was redissolved in 400jj1 of ice cold
Krebs' solution. 200/il of PGH-2 in Krebs' solution was added
to the flask containing the boiled homogenate and to one other
flask. Each flask contained approximately Lug PGH-2. The
former flask measured non-enzymatic breakdown of PGH-2 and the
latter measured enzymatic transformation. The third flask
was used to check that indomethacin had effectively inhibited
cyclooxygenase activity in the homogenates. Initial experiments
of this kind involved incubating the homogenates for 5 min at
37°C. After this incubation period 0.5 ml of Stannous chloride
— 1
in ethanol (50 ^gml ) was added to flasks containing PGH-2.
Stannous chloride acts as a reducing agent in the conversion
of any PGH-2 remaining after the incubation into PGF-2C*
(Hamberg and SamueTsson, 1973).
124
All flasks were extracted for PGs as described in section 1.2.a.
Samples were stored in ethyl acetate at -20°C until
assayed for PGE-2 by RIA as described in section 1.3.a.
Results
Initial experiments showed that using the method described
above, PGE-2 synthesis from PGH-2 did not differ between
unboiled and boiled homogenates. Possible reasons for this
result include:
a) that the incubation time was too long and that non-enzymatic
transformation of PGH-2, as well as enzymatic transformation
had occurred, and
b) that the incubation temperature was too high, which would
also accelerate non-enzymatic breakdown of PGH-2 and
c) that indomethacin could be inhibiting PGE isomerase as
well as cyclooxygenase and as a consequence of this, the
enzymatic transformation of PGH-2 was inhibited.
The experiment was therefore repeated using slightly
different conditions. Indomethacin was replaced by another PG
synthesis inhibitor Froben (2-(2-fluoro-4-biphenyl)propionic
acid, Boots, Co., Nottingham ) also used at a concentration of
- n
50 yugml . Homogenates were incubated at 25°C for 1 min.
Using these conditions PGE-2 synthesis from PGH-2 was greater
in the unboiled than in the boiled homogenate. These results
are shown in Table II.
Column b shows PGE-2 synthesis expressed as ng PGE-2 mg
protein in homogenates incubated with the addition of PGH-2
and was used to measure PGH-2 to PGE-2 isomerase activity.
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Table 11. PGE-2 synthesis by ovarian homogenates using PGH-2
as a precursor.
Flask a. no PGH-2 added
b. unboiled homogenate, PGH-2 added
c. boiled homogenate, PGH-2 added.
Results are expressed as ng PGE-2 per mg protein,
(mean + s.e.m. n=6).
Flask a b c b-(a+c)
enzymic synthesis
rat ng PGE -2 mg protein 1
10:00h pro-oestrus 1 5.5 55.4 17.5 32.4
2 3.7 43.8 31.9 8.2
3 7.4 71.8 44.3 20.1
4 1.0 39.4 11.3 27.1
5 8.3 51.6 21.5 21.8
6 7.5 23.5 12.6 2.4
mean ± s.e.m. 18.6 + 4.2
02:00h oestrus 1 10.5 36.2 16.9 8.8
2 1.0 33.0 23.3 8.7
3 4.6 46.7 37.0 5.1
4 5.5 25.4 5.8 14.1
5 2.3 36.1 14.7 19.1
6 1.0 41.0 29.1 10.9
mean ± s.e.m. 11.1 + 1.8
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Column a shows PGE-2 synthesis in homogenates without the
addition of PGH-2 which gave an index of the effectiveness of
Froben in inhibiting PG synthesis in the homogenate. The
results show that Froben did not completely inhibit PGE-2
synthesis. Therefore the contribution of PGE-2 synthesis
from endogenous PGH-2 had to be subtracted from the values
in column b. PGE-2 synthesis by boiled homogenates is shown in
column c. The values given in this column represent PGE-2
produced by non-enzymic decomposition of PGH-2 and these
values were subtracted from the figures given in column b.
The last column shows the calculated enzymic synthesis of PGE-2
from PGH-2. There was no significant difference in the
calculated enzymic PGE-2 synthesis from PGH-2 between 10:OOh
on pro-oestrus and 02:OOh on oestrus.
Conclusion
As there was no significant difference in the ability of
ovarian homogenates to synthesize PGE-2 from PGH-2 at 10:00h
on pro-oestrus and at 02:00h on oestrus, this suggests that
the increased PGE-2 production by ovarian homogenates at
the time of ovulation cannot be due to increased PGH-2 to
PGE-2 isomerase activity. The limitations of this experiment
have to be realized however. A fixed volume of solvent
containing PGH-2 was used in each experiment, and although
an initial concentration was estimated by reduction to PGF-2a
followed by quantification by mass spectrometry, the exact
concentration before each experiment was unknown.
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Therefore, although PGH-2 is stable for several weeks under the
storage conditions used, slight variations in the quantity of
PGH-2 used in each experiment may have occurred. It was assumed
that Froben did not inhibit the conversion of PGH-2 to PGE-2.
Confirmation of this would require isolation of the isomerase
enzyme and ideally this experiment should be carried out.
Crude homogenates contain thiol compounds and haemoproteins
which act as reducing agents in the conversion of PGH-2 to
PGF-2a and boiling of the homogenate may even increase PGF-2ai
formation (Nugteren and Christ-Hazelhof, 1980). Thus the
transformation of PGH-2 to PGE-2 in the boiled homogenate may be
under-estimated due to increased PGF-2^formation.
In conclusion, this experiment shows that increased
PGH-2 to PGE-2 isomerase activity does not occur at the time of
ovulation in the rat. This suggests that the increase in
PGE-2 synthesis in the ovary is the result of increased
cyclooxygenase activity with a greater proportion of the
increased PGH-2 formed being converted into PGE-2.
Piscussion
Levels of PGE-2, PGF-2a in the ovary were increased at
the time of ovulation and this agrees with previous reports
(Bauminger and Lindner, 1975; LeMaire, Leidner and Marsh, 1975).
PGI-2 levels (measured as 6-keto-PGF-lo:) were also increased
at the time of ovulation, a finding which has not been previously
reported for the rat.
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In the swine, it has been demonstrated that LH will stimulate
PGI-2 production by cultured granulosa cells and that this
stimulation is susceptible to inhibition by inhibitors of
protein synthesis (Veldhuis, Klase and Demers, 1982). The
dependence of PGI-2 production on protein synthesis suggests
that the stimulation of ovarian PGI-2 production by LH is
similar to that of PGE-2 production. It is not known whether
in these experiments PGI-2 was of vascular origin or not, but
it is possible that increased PGI-2 synthesis is responsible
for the vasodilation which occurs in the walls of the
pre-ovulatory follicles prior to ovulation (Jones, 1979).
Homogenates of rat ovaries were also found to produce
PGD-2. Production of PGD-2 by the ovary shows no daily
variation when measured at 10:00h (Poyser and Scott, 1980).
It would be interesting to determine whether changes occur in
ovarian PGD2 production in the periovulatory period.
Ovarian PG synthesizing capacity was shown to increase
at the time of ovulation. The increase in synthesizing
capacity for PGE-2, PGF-2o: and PGI-2 (measured as 6-keto-PGF-lo!)
was not due to increased arachidonic acid availability. This
agrees with the results of other workers. Bauminger, Lieberman
and Lindner, (1975) showed that addition of arachidonic acid to
cultured Graffian follicles failed to enhance PG accumulation
or to act synergistically with LH in this respect. LH increases
the PGE concentration in cultures of ovarian fragments by 300%
over a 6h period with no change in the free arachidonic acid
concentration in the tissue (Zor, Strulovici, Nimrod and Lindner,
1977). Exogenous arachidonic acid increased PGE accumulation in
cultured granulosa cells only after a 5h exposure to LH.
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LH was without effect on 3H-arachidonic acid release from
pre-labelled granulosa cell lipids or on 3H-arachidonic acid
uptake into these lipids from the incubation medium (Clark,
Marsh and LeMaire, 1978$.
These experiments also showed that decreased metabolism
of PGE-2 and PGF-2oi is not responsible for the increased
synthesis at 02:00h on the day of oestrus as metabolism in
the absence of NAD+ was low and it did not differ between
10:00h on pro-oestrus or 02:00 on oestrus. This work confirms
the result of Poyser and Scott (1980) who also found that
metabolism of PGF-2o: in homogenates in the absence of NAD+
was low and that no significant daily variations occurred.
An enzyme PGE-2-9-ketoreductase has been reported to be
present in rat tissue (Watson, Shepherd and Dodson, 1979).
It is thought that this enzyme is reversible and will catalyse
the conversion of PGF-2q: to PGE-2 in the presence of NADP. More
recently it has been demonstrated that hCG administered to PMSG-
primed rats 1 day before killing, increased the activity of this
enzyme over threefold. The hypothesis that gonadotropinn can
control ovarian PGE-2 and PGF-2q: levels by altering the activity
of 9-ketoreductase would seem an attractive one. However, the
results presented here do not demonstrate any appreciable
interconversion of these two PGs. Differences in experimental
design may account for these discrepancies. Watson et al ., used
a relatively highly purified enzyme preparation and added
NADPH, glucose-6-phosphate dehydrogenase and dithiothreitol.
It is unlikely that PGE-2-9-ketoreductase could exert fine
control over the balance between PGE and PGF in the ovary in view
of the fact that it is not a PG-specific enzyme.
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Chang and Tai (1981) have classed the enzyme as a general
aldo-keto reductase which will also catalyse the reduction
or oxidation of steroids, aldo sugars, quinones and carbonyl
compounds.
Following injection of rats with LH on the morning of
pro-oestrus, Bauminger and Lindner (1975) observed a lag period
of 3h before the in vivo changes in ovarian PGs occurred. A
result of this type suggested that there might be increased
synthesis of an enzyme in the PG synthetic pathway. Resolution
of PG synthetase into cyclooxygenase and isomerase components
has been achieved by Miyamoto, Yamamoto and Hayaishio (1974).
The results presented in this section showed that no increase
in PGH-2 to PGE-2 isomerase activity occurred at the time of
ovulation. Collectively, these experiments suggest that the
control of PG biosynthesis in the ovary is exerted at the
level of the cyclooxygenase enzyme.
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Section 2.2 PROSTAGLANDINS AND GONADOTROPHS RELEASE
Introduction
In the previous section, it has been pointed out that
indomethacin will block ovulation in the rat by preventing
follicular rupture in the ovary, an action which is not
surmountable by the administration of LH (Armstrong and
Grinwich, 1972; Tsafriri et al., 1972). However, the block of
ovulation induced by a single lower dose of indomethacin given
3h before the expected LH surge, could be reversed by the
administration of LH 3h after indomethacin (Orczyk and Behrman,
1972). Moreover, Behrman, Orczyk and Greep (1972) showed that
the aspirin blockade of ovulation was reversed by LHRH
administration. These results suggest that indomethacin and
aspirin, in addition to blocking ovulation by an action at.the
ovary, can inhibit the release of LH as the result of the
inhibition of LHRH release from the brain.
The stimulatory effect of progesterone in oestrogen-primed
rats on LH release is blocked by indomethacin administration
(Ojeda, Harms and McCann, 1975) and it has been suggested that
when plasma oestrogen reaches a critical level, oestrogen-induced
release of PGs occurs within the hypothalamus, thus promoting an
LH surge (Craig, 1975). However, while there is evidence that
PGs may act in the hypothalamus to stimulate LHRH release
(Chobsieng et al., 1975; Ojeda, Wheaton and McCann, 1975, Eskay
et al., 1975; Linton et al., 1979, Ojeda, Negro-Vilar and McCann,
1979; 1982), the evidence so far accumulated in support of a
physiological role for PGs in this process is essentially
i ndirect.
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It has yet to be demonstrated that inhibition of PG synthesis
in the hypothalamus will block the LH surge in cycling rats. In
addition, the measurement of PG synthesis by the hypothalamus
us
would help^to further understand the role of PGs in LHRH release.
However, although it has been demonstrated that the PGE content
of the median eminence (ME) is much higher than that of the
medial based hypothalamus (MBH) in male and female rats (Ojeda,
Naor and McCann, 1978), no information on PG synthesis by the
hypothalamus during the rat oestrous cycle is available.
Experiments described in this section were designed to study
PG and TX synthesis by the hypothalamus throughout the oestrous
cycle and in response to treatment with oestrogen and
progesterone. The effects of 2-OH oestradiol, an oestrogen
metabolite formed by the hypothalamus (Fishman and Norton, 1974)
and NA, a neurotransmitter associated with LH release (see
Barraclough and Wise, 1982) on hypothalamic PG and TX synthesis
were also investigated. To further elucidate whether PGs play
a physiological role in LHRH and LH release, the effect of
pretreating rats with a PG synthesis inhibitor 2-(-fluoro-4-
biphenylyl) proprionic acid, on the pro-oestrus surge of LH was
studied.
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Section 2.2.a Measurement of the ability of the median eminence
and anterior hypothalamus/pre-optic area to
produce PGs and TX during the oestrous cycle
Introduction
The site of action of PGs in stimulating gonadotroph!'n
release appears to be at the hypothalamus and PGE-2 is more
potent than PGF-2o: in this respect (Harms, Ojeda and McCann,
1974; Batta, Zanisi and Martini, 1974). Ojeda, Jameson and
McCann (1975) showed that PGE-2 was most effective in causing
a rise in plasma LH levels when implanted in the AHA in the
POA and, to a lesser extent, in the ARH-ME. PGF-2xinduced LH
release when implanted in the POA or ARH-ME.
More recently, it has been demonstrated that
intraventricular injection of the endoperoxide analog 11,9-
epoxymethano-PGH-2, which is a TXA-2 mimic (Ojeda, Jameson and
McCann, 1976) and intravenous injection of PGI-2 (Kimball,
Porteus, Kirkton, Frielink, Creasy and Dayan, 1979) into
oestrogen-treated ovariectomized rats stimulated LH release.
Therefore the synthesis of PGI-2 and TXA-2, as well as PGE-2
and PGF-2a in the AH-POA and ME may be important in the control
of LH-RH release from the hypothalamus.
In the following experiments the production of PGE-2,
PGF-2q:, 6-keto-PGF-lo: and TXB-2 by homogenates of the ME and




Measurement of PG and TX production by homogenates of ME and
AH-POA
A total of 144 mature female Albino Wistar rats weighing
between 200g and 250g were used (these animals also provided
tissue for use in experiments described in Section 2.1a and
Section 2.3a). The animals were housed, fed, smeared and
killed as described in Section 2.1a. The brain was removed from
each rat and was placed on ice. Dissection of the ME and AH-POA
was carried out under a stereoscopic microscope. The ME is a
well delineated structure; it appears as an ovoid shape on the
ventral surface of the brain, and forms the floor of the IIIrd
ventricle. Using a pair of fine forceps, the remnant of the
pituitary stalk was lifted. Two longitudinal cuts oriented
forward and slightly convergent were performed using a pair of
iris scissors. A cut was made at the point where the optic
tracts enter the brain and the ME was lifted from the brain with
fine forceps. The wet weight of this structure was approximately
0.3 mg. The dissection of the AH-POA was as follows. The optic
chiasm and optic tracts were removed from the basal surface of
the brain. A cut was made 2 mm anterior to the optic chiasm.
Two lateral cuts were performed along the borders of the
hypothalamic sulci. The final transverse cut was made along the
anterior edge of the mamillary bodies.. Each of these cuts were 2




















Table 12. Statistical analysis of PG and TX production by the ME at 4
hourly intervals throughout the oestrous cycle as in Fig. 15.
Values with the same superscript within each column are not
significantly different (p>0.05). Values are expressed as
mean ± s.e.m. n = 6 each time.
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After recording the tissue weights, each was homogenized in
Krebs' solution (2 mi for the ME and 5 mi for the AH-POA) and
each transferred to conical flasks. The homogenates were
incubated for 90 min as described in Section 1.2.b. Following
incubation, the pH was adjusted to 4 and the PGs and TX
extracted as described in section 1.2.a. Samples were stored
in 2 ml ethyl acetate at -20°C until they were assayed for PGE-2,
PGF-2q:, 6-keto-PGF-lo: and TXB-2 content by RIA as previously
described in sections 1.3a, b, c and d. Results were compared
initially by an F-ratio test and subsequently by Duncan's
Multiple Range test for equal variances. Significance was
tested at the 5% level.
Results
Fig. 15 shows PG and TX production by homogenates of ME
at 4-hourly intervals throughout the oestrous cycle, and a
statistical analysis of these results is given in Table 12.
The major PG produced by the ME was PGE-2 with lesser
quantities (in descending order) of PGF-2a, TXA-2 (measured
as TXB-2) and PGI-2 (measured as 6-keto-PGF-lo:). Both PG
and TX production by the ME showed a diurnal pattern, production
being highest in the early hours of the morning (02:00h and
06:00h) and lowest in the afternoon (14:00h and 18:00h). PGE-2
production showed peaks at 06:00h on each day of the oestrous
cycle. Each value at 06:00h was significantly greater (p<0.05)
than that at 14:00h on met-oestrus, di-oestrus and pro-oestrus.
At 06:OOh on oestrus, PGE-2 production by the ME was significantly
different from that at any other time in the oestrous cycle.
0*9
PG production (ngmg"1)
















Table 13. Statistical analysis of PG and TX production by the AH-POA at
4-hourly intervals throughout the oestrous cycle as in Fig. 16.
Values with the same superscript within each column are not
Values are expressed as mean ts.e.m.significantly different (p>0.05)
Lime























































































































0 . 46+0.04®b 0.05+0.01® 0.25+0.04®b°
0.35+0.10® 0.05+0.01® 0.17+0.04®
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An additional peak in PGE-2 production ocurred at 18:OOh on
pro-oestrus. Although showing the diurnal pattern, production
of PGF-2o: and TXB-2 did not increase in amplitude on pro-
oestrus and oestrus. 6-keto-PGF-lo: production was lower (and
barely detectable on the day of oestrus) than on the other
days of the cycle. At 06:OOh on oestrus the ratio of PGE-2:
PGF-2xproduction was approximately 5:1 whereas at the same time
on other days of the cycle this ratio was only about 3:1.
Measurements of PG and TX production by the AH-POA are shown
Fig. 16 and Table 14 shows their statistical analysis.
PGF-2q; was the major PG produced by the AH-POA with lesser
quantities (in descending order) of PGE-2, TXA-2 (measured
as TXB-2) and PGI-2 (measured as 6-keto-PGF-lo:). PGE-2
and TXB-2 production tended to be greatercat 22:00h on each
day except pro-oestrus. PGF-2a production showed a similar
pattern but showed an additional peak at 22:00h on pro-oestrus.
At 22:00h on pro-oestrus, mean PGF-2a production by the
AH-POA was highest although this value was not significantly
different from that throughout most of the oestrous cycle.
PGE-2 production tended to be lower on pro-oestrus than on
other days of the cycle, the lowest value being recorded at
22:00h on pro-oestrus. This value was significantly lower
than PGE-2 production at the correspond!'ng time on oestrus,
met-oestrus or di-oestrus. On pro-oestrus the PGF-2q::
PGE-2 ratio was about 4 whereas at other times in the cycle,
was only 2. There were no significant differences in 6-keto-
PGF-la production by the AH-POA during the oestrous cycle.
On comparing Figs. 15 and 16, it is evident that PG and TX
production by the ME was approximately ten times greater than
that by the AH-POA, when expressed on a unit weight basis.
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Conclus 1 on
The pattern of PG and TX production by the ME and AH-POA
differs greatly. Firstly, the ME has a far greater capacity
to produce PGs and TX than the AH-POA. Secondly, PGE-2 is the
major PG synthesized by the ME, whereas PGF-2(X production
predominates in the AH-POA. Both tissues showed evidence of
differing diurnal rhythms in PG and TX production. In the
ME, peak PGE-2, PGF-2a, 6-keto-PGF-la and TXB-2 production
occurred at 06:OOh whereas in the AH-POA, PGE-2, PGF-2o; and TXB-2
production generally peaked at 22:00h. In the ME an extra
peak in PGE-2 production occurred at 18:OOh on pro-oestrus.
The ratio of PGE-2: PGF-2q: production by the ME at 06:OOh
on oestrus was approximately 5:1 whereas at 22:00h on pro-oestrus
in the AH-POA, this ratio was about 1:4. This may suggest
that the relative production of these PGs is important at these
times of the oestrous cycle.
After assaying the samples by RIA, there was insufficient
samples for GC-MS analysis. However, other workers have
confirmed the presence of PGE-2, PGF-2o:, TXB-2 and 6-keto-PGF-
Iq: in brain tissue by GC-MS (see discussion).
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Section 2.2.b Measurement of i) PGE and P6F levels in the
AH-POA and ii) the ability of this tissue to
synthesize PGE and PGF in the presence of
exogenous arachidonic acid
Introduction
To check that PG levels in the brain tissue were low and
that arachidonic acid availability was not rate limiting
for PG synthesis in the homogenates, PG levels in the AH-POA
and PG production by homogenates of the AH-POA incubated in the
presence of exogenous arachidonic acid have been measured.
Methods
i) 3 rats were killed at 10:00h on pro-oestrus and their
AH-POA dissected out as described in Section 2.2.a. and after
recording the tissue weights, each tissue was immediately
transferred to a petri dish containing 5 ml ethanol. Tissues
were homogenized and processed according to the method
discussed in Section 2.1.b. Samples were stored in 1 ml
ethyl acetate at -20°C until assayed for PGE-2 and PGF-2q:
by RIA as described in Sections 1.3a and 1.3b.
ii) 4 rats were killed at 10:00h on- pro-oestrus and their
AH-POA dissected out as described in Section 2.2.a. The tissues
were homogenized and incubated for 90 mins as described in
Section 2.2.a except that 0.1 ml arachidonic acid in ethanol
was added to each homogenate to give a final concentration
of 2yugml 1 .
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Each homogenate was extracted as described in Section 1.2.a.
Samples were stored in 2 ml ethyl acetate at -20°C until they
were assayed for PGE-2 and PGF-2ct: by RIA using the method
described in Sections 1.3a and 1.3b. Results were compared with
PG production by the AH-POA at 10:OOh on pro-oestrus in the
absence of arachidonic acid, by means of Student's t-test.
Results
i) Concentrations of PGE-2 and PGF-2o; measured in samples
from AH-POA tissue homogenized in ethanol were lower than
concentrations of PGE-2 and PGF-2o; measured in homogenates
incubated for 90 min in Krebs1 solution as shown in Fig. 17.
There was insufficient sample remaining to measure 6-keto- PGF-lo;
and TXB-2 levels, ii) The addition of exogenous arachidonic acid
did not significantly alter the PGE-2 or PGF-2o; concentrations in
incubated AH-POA homogenates (Fig. 17).
Conclusion
As the levels of PGE-2 and PGF-2o; in the AH-POA were
lower than production of these PGs after incubation of
homogenates of this tissue, it can be concluded that fresh
synthesis of PGE-2 and PGF-2o: occurred in the homogenate
during the incubation period. Moreover, the fact that
addition of arachidonic acid did not significantly increase
the ability of the homogenate to synthesize PGE-2 or PGF-2o;
confirms that PG synthesis was not limited to any extent by the










Concentrations □ (n=3) of PGE-2 and PGF-2a
in ethanolic homcgenates of AH-POA compared
with production of PGE-2 and PGF-2o; by AH-POA
homogenates incubated in the absence || ill (n=6)
or presence ^ (n=4) of ^ugml-1 arachidonic
acid. Values are shown as mean ± s.e.m. for
samples from rats killed at 10:00h on
pro-oestrus.
145
Unfortunately, there was insufficient tissue to carry out
similar experiments on the ME. However, in another study
-1
(Ojeda et al., 1978) PGE concentrations of about 0.1 ngmg
in the ME has been reported which is much lower than PGE-2
beshown that"
production by the ME as reported here. It remains fco arachidonic
acid availability in brain homogenates is not rate limiting
for PG synthesis.
Section 2.2.C Measurement of the metabolism of PGE-2 and
PGF-2xat 10:OOh on pro-oestrus and 02:00h on
oestrus by homogenates of ME and AH-POA
Introduction
Metabolism of PGF-2o;in rat brain has been shown to be
negligible (Wolfe, Pappius and Marion, 1976; Geese, Ottlecz
and Telegdy, 1981). These workers measured metabolism of
PGF-2q: either in cortex or whole hypothalamus. No information
is available on the ability of the ME to metabolize PGs.
The following experiment was performed to study the metabolism
of PGE-2 and PGF-2a by homogenates of ME and AH-POA at 10:OOh
on pro-oestrus and at 06:OOh on oestrus.
Method
The ME and AH-POA of rats killed at 10:00h on pro-oestrus
and 06:OOh on oestrus were dissected out, homogenized in
Krebs1 solution as described in Section 2.2.a and incubated
in the presence of 0.5 /jCi ^H-PGF-Eo; alone, or in combination
with 2 jugml1 PGF-2a and 2mM NAD+.
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6 rats were killed for each time, providing 3 incubations in
the presence of ^H-PGF^o: al one and 3 incubations in the presence
of 3H-PGF-2(X, PGF-2Q! and NAD+, for each of the ME and the AH-POA.
This experiment was repeated for the study of PGE-2 metabolism by
replacing 3H-PGE-2 for 3H-PGF-2q: and adding PGE-2 instead of
PGF-2a. The samples were processed according to the method
previously described for the measurement of PG metabolism in
tissue homogenates in Section 2.I.e. The results are expressed
as percentage metabolism of PGE-2 or PGF-2fcanCI were compared by
means of Student's t test.
Results
Table 1^- shows the percentage metabolism of H-PGE-2 and
"3H-PGF-2q: in homogenates of' ME and AH-POA in the absence and
presence of NAD+ at 10:OOh on pro-oestrus and at 06:00h on
oestrus.
The % metabolism results have not been corrected for tissue
weight. However tissue weights did not change significantly
between the two times (0.3 + 0.03 mg at 10:00h on pro-oestrus and
0.3 + 0.02 mg at 02:00h on oestrus for the ME, 17.6 + 2.5 mg at
10:OOh on pro-oestrus and 18.1 + 2.9 mg at 02:OOh on oestrus for
*. •' 1 •"?. •.- ~•. •?,% Y'VY-.Y' . 'J*
the AH-POA).
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Table 14. Percentage metabolism (mean + s.e.m. of 3
observations) of ^H-PGE^ and ^H-PGF^o; in homogenates
of HE and AH-POA in the absence and presence of NAD+
at 10:00h on pro-oestrus and at 06:00h on oestrus.
Tissue Time PGE-2 metabolites PGF-2a metabolites
no NAD+ with NAD+ No NAD+ with NAD+
10:OOh
pro-oestrus




17.7+3.4 9.8+1.0 1^8+2.9 14.8+2.2
10:00h
pro-oestrus




8.1+1.5 7.1+1.2 12.0+2.1 11.6+0.9
3H-PGE-2 (Rf = 0.26) was metabolized by the ME and AH-POA
into mainly its 15-keto-metabolite (Rf = 0.42) with little of
the 13, 14-dihydro, 15-keto-metabolite (Rf = 0.43) in the
absence or presence of NAD+. ^H-PGF-2o: (Rf.= 0.14) was
metabolized by the ME and AH-POA into approximately equal
amounts of the 15-keto- (Rf = 0.25) and 13,14-dihydro,15-keto-
metabolite (Rf = 0.35).
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The 'percentage metabolism of PGE-2 and PGF-2o: into these
two metabolites is expressed as a single figure. Table 14
shows that the percentage metabolism of PGE-2 and PGF-2a by
the ME and AH-POA is low in the absence and presence of NAD+
ranging from 7% to 18%.
There were no significant differences in PGE-2 or PGF-2Q!
metabolism by these tissues between 10:00h on pro-oestrus and
06:OOh on oestrus.
Cone!usion
As metabolism of PGE-2 and PGF-2o: in the homogenates of
ME and AH-POA is low, the measurement of PG synthesis by the
homogenates is unlikely to be altered by metabolism. It can
also be concluded that as metabolism of PGE-2 or PGF-2o;did not
vary between the two times studied, it is unlikely that the
changes in PGE-2 and PGF-2cx production by homogenates of ME
and AH-POA during the oestrus cycle are due to changes in
PG metabolism.
Although PG 1-2 and TXA-2 metabolism has not been studied
here, it is likely that, as the same enzymes are involved
(see Section 2.1.c) that metabolism of these compounds is also
1 ow.
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Section 2.2.d. The 'effect of oestrogen and progesterone on
PG and TX production by the ME and AH-POA
Introduction
The pre-ovulatory surge of LH depends upon the increase
in plasma concentration of oestradiol that precedes the
surge (Schwartz, 1969). The stimulatory effect of
oestradiol is enhanced in the rat by ovarian progesterone
secreted in response to LH (Mann and Barraclough, 1973)
and this facilitatory effect of progesterone only occurs in
oestradiol-primed rats (Brown-Grant and Naftolin, 1972).
It has been suggested (Craig, 1975) that when plasma
oestrogen reaches a critical level, oestrogen-induced
release of PGs occurs within the hypothalamus and the PGs
stimulate the ovulatory surge of LH. This concept is supported
by the observation that indomethacin blocks the
progesterone-induced LH release in oestrogen pre-treated
rats (Ojeda, Harms and McCann, 1975). Ovariectomy was shown
to decrease the synthesis of PGF-2o; by the hypothalamus and,
while combined administration of oestrone and progesterone
did not alter PGF-2q: synthesis, it increased the synthesis
of PGE-2 by the hypothalamus (Geese, Ottlecz and Telegdy, 1981).
In the latter study on the effects of ovarian steroid hormones
on hypothalamic PG synthesis, the animals were treated with
steroids either alone,' or in combination, on every alternate day
over a 14-day period. Thus the authors made no attempt to
mimic the cyclical changes in circulating ovarian steroid
concentrations in their experiments.
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Experiments described in this section tfere performed to study
the effect of pre-treating ovariectomized rats with oestrogen
followed by progesterone on PG and TX synthesis by the ME
and AH-POA.
One model which has been designed to simulate the changes
in plasma steroid concentrations that occur before and during
the LH surge, (Karla, Fawcett, Krulich and McCann, 1973) was
used. Rats which have been ovariectomized on di-oestrus are
given oestradiol benzoate on that day followed by progesterone
on the following day. The other model which was used to study
the stimulatory effect of progesterone (Caligaris, Astrada
and Taleisnik, 1968) involves injecting progesterone 72 hr after
injecting oestradiol benzoate into long-term ovariectomized
rats. In both of these models, a surge in plasma LH occurs
5h after the injection of progesterone.
Methods
Mature female Albino Wistar rats weighing between 200 and
250g were maintained under controlled conditions as described
in Section 2.1.a. These rats also provided tissue for use in
experiments described in Section 2.3.d. Twelve rats were
ovariectomized between 09:00h and 10:OOh on di-oestrus (Group I).
Ovariectomy was performed under Althesin (Glaxo, U.K.)
anaesthesia (0.5ml lOOg 1 body weight i.p.). Six of these
animals received lOyug oestradiol benzoate -in 0.5 ml arachis oil
as a subcutaneous (s.c.) injection. The other six animals were
injected with the same volume of arachis oil alone.
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On the following day (the expected pro-oestrus) the animals
were injected with 2 mg progesterone s.c. in 0.5 ml arachis oil
at 12:OOh.
Another group of 22 rats (group II) were ovariectomized
under Althesin anaesthesia. For these rats, the stage of the
oestrous cycle at which ovariectomy was performed was unknown.
Six weeks after ovariectomy, eleven of the rats received an s.c.
injection of l&ig oestradiol benzoate in 0.5 ml arachis oil
at 12:OOh followed by 2 mg progesterone s.c. in 0.5 ml arachis
oil 72h later. The eleven 'control' rats received s.c.
injections of arachis oil alone at the above times. At 17:00h,
five hours after the progesterone injection, the rats from both
groups were killed and their ME and AH-POA dissected out,
weighed, homogenized, incubated and extracted for PGs and TX
as described in Section 2.2.a. The samples were stored in 2 ml
ethyl acetate at -20°C until their content of PGE-2, PGF-2o:,
6-keto-PGF-lo: and TXB-2 was determined by RIA as described in
Section 1.3.a, b, c and d. Results were compared by means
of Student's t-test.
Results
Fig. 18 shows PG and TX production by homogenates of ME
and AH-POA from either acute ovariectomized (Group I) or
long-term ovariectomized (Group II) oestrogen and progesterone
treated rats. Combined treatment with oestrogen and progesterone
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Production of PGE-2, PGF-2a: and 6-keto-PGF-lcx was significantly
(p<0.05) increased in the AH-POA of acutely ovariectomi zed
rats treated with oestrogen and progesterone, whereas TXB-2
synthesis was unaltered by treatment.
PGE-2 production by the ME of long-term ovariectomized rats
was significantly increased by steroid treatment while production
of PGF-2a, 6-keto-PGF-la and TXB-2 was unaffected. Although the
treatment of long-term ovariectomized rats did not affect PGF-2a,
6-keto-PGF-lo: or TXB-2 production by the AH-POA, it did increase




Oestrogen and progesterone treatment of long-term
ovariectomized rats increased PGE-2 production by the ME and
AH-POA. Although the latter increase was not significant,
it can be concluded that ovarian steroid treatment of the
long-term ovariectomized rat can modulate PGE-2 synthesis
by the hypothalamus and apparently in a selective manner.
In acute ovariectomized rats, PG and TX production by
the ME was unaffected by treatment with oestrogen and
progesterone. However, production of PGE-2, PGF-2o; and
6-keto-PGF-lo: by the AH-POA was significantly increased by
the steroid treatment. These findings suggest that the
stimulatory effect of ovarian steroids is in the AH-POA
and not in the ME of acute ovariectomized rats.
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It has not been established in these studies whether the
stimulatory effects of the treatment on PG and TX production
were due to decreased metabolism or increased arachidonic
acid availability. However, other workers have shown that,
after ovariectomy and hormone treatment^neither 15-hydroxy-PG
dehydrogenase norA-13-PG reductase activity could be detected
(Gesce, Ottlecz and Telegdy, 1981) and that arachidonic acid
availability in homogenates of hypothalamus is sufficient to
completely saturate the brain cyclooxygenase enzyme (Wolfe,
Pappius and Marion, 1976). Therefore the changes in PG and
TX production observed are probably not due to changes in
PG metabolism and/or arachidonic acid availability.
Section 2.2.e. Measurement of the in vitro effect of
noradrenaline and catechol oestrogen on PG
and TX production by the ME and AH-POA
Introduction
Although the ability of oestrogen to influence PG
production by various tissues, including the uterus and
hypothalamus, has been demonstrated in vivo (Ham, Cirillo,
Zanette and Kuehl , 1975; Geese, Ottlecz and Telegdy, 1981),
this effect has rarely been observed in vitro. Naylor and
Poyser, 1975 were able to show that in vitro oestradiol
stimulated PGF-2a synthesis by homogenates of guinea pig
uterus but this effect was small in comparison to the effect
of in vivo oestradiol. These experiments suggest that a
transformation of oestradiol to a more active metabolite is
required in vivo for its action.
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Metabolism of oestrogens into their catechol derivatives
by hydroxy]ation at the C2 position is known to occur in the
liver and brain (Fishman and Norton, 1974; Ball, Haupt and
Knuppen, 1978). Kelly and Abel, (1981), have reported that the
uterus can hydroxylate oestrogens at the 2 position and that
catechol oestrogen stimulates PG production by rat uterine
homogenates. Recently, catecholoestrogens have been proposed as
mediators of the oestrogen-induced LH surge in the rat (Naftolin,
Morishita, Davies, Todd and Ryan, 1975; Fishman, Norton and Krey,
1980; Rodriguez-Sierra and Blake, 1982). . In a study of the
distribution of 2-hydroxylase activity within the brain, the
highest activity was observed in the hypothalamus (Fishman
and Norton, 1975) and Fishman, Norton and Krey, 1980, have shown
a sharp increase in 2-hydroxylase activity in brain between
di-oestrus and pro-oestrus in cycling rats.
In view of these findings, it was decided to investigate
the ability of the catechol oestrogen 2-hydroxyoestradiol
(2-OH oestradiol) to stimulate PG and TX production by the ME
and AH-POA in vitro. This was studied at two times during
the oestrous cycle, i.e. 18:OOh both on di-oestrus and on
pro-oestrus. At these times the activity of the brain
2-hydroxylase enzyme is low and high respectively (Fishman,
Norton and Krey, 1980). As the structure of the 2-OH oestradiol
resembles noradrenaline in that they both have a catechol group
present, it was decided to compare the effect of 2-OH oestradiol




2-OH oestradiol was checked for purity by thin layer
o
chromatography. The compund (10/jg) was spotted on to a silica
gel plate in 50yul of hexane. 10 ^g of oestrogen was also applied
to the plate. After allowing the spots to dry, the plate was
developed in hexane: ethyl acetate (60:40). The spots were
visualized by spraying with phosphomolybdic acid followed by
incubation of the plate in an oven at 60°C.
The ME and AH-POA from 10 rats which had been killed at
18:00h on di-oestrus and 10 rats killed at 18:OOh on pro-oestrus
were removed, weighed and homogenized as described in Section
2.2.a. Five homogenates of each type of tissue at each time were
incubated for 90 min in the presence of 100/jM 2-OH oestradiol.
The other five homogenates of each type of tissue at each time
were incubated in the presence of 1OQuM noradrenaline bitartrate
and 0.06 mM ascorbic acid. Following incubation, the homogenates
were extracted for PGs and TX using the method described in
Section 1.2.a. Samples were stored in 2ml ethyl acetate at -20°C
until they were assayed for PGE-2, PGF-2o; and TXB-2 by RIA as
described in Sections 1.3a, b and d. Results were compared by
Student's t-test.
Results
Analysis by thin layer chromatography showed that the
2-OH oestadiol and oestradiol ran as single spots with
differing Rf values (0.08 and 0.2 respectively). Thus the
catechol oestrogen was not contaminated with oestrogen and
was free from other impurities.
The effect of 2-0H oestradiol and noradrenaline on
PGE-2, PGF-2Q! and TXB-2 production by homogenates of ME and
AH-POA at 18:OOh on di-oestrus and pro-oestrus is shown in




The results have been compared with PG and TX production by
these tissues as determined in experiments described in
Section 2.2.a. There was no significant difference between
PG or TX production by homogenates of ME incubated in the
presence or absence of 2-OH oestradiol either at 18:00h on
di-oestrus or pro-oestrus (Fig. 19). Noradrenaline
significantly increased PGE-2 (p<0.05), PGF-2Q! (p<0.02) and
TXB-2 (p<0.05) production by the ME at 18:OOh on di-oestrus
whereas at 18:00h on pro-oestrus, noradrenaline had no
significant effect. As in the ME, 2-OH oestradiol had no
effect on PGE-2 or PGF-2qi production by AH-POA homogenates
from rats killed at 18:00h on di-oestrus or pro-oestrus.
(Fig. 20). There was an apparent decrease in TXB-2 production
by AH-POA homogenates from rats killed at 18:00h on di-oestrus
(p<0.05) when incubated in the presence of 2-OH oestradiol.
However, this effect was not observed in homogenates from rats
killed at 18:OOh on pro-oestrus. In contrast, noradrenaline
significantly increased PGE-2, PGF-2a and TXB-2 production at
18:00h on di-oestrus and at 18:OOh on pro-oestrus. The percentage
increase in production in the presence of noradrenaline is shown
in Fig. 20. This shows that noradrenaline is more effective in
stimulating PG and TXB-2 production by the AH-POA at 18:OOh on
pro-oestrus than at 18:00h on di-oestrus.
Conclusion
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Whereas noradrenaline stimulates PG and TX production by
the ME and AH-POA in vitro, 2-OH oestradiol has no effect.
Noradrenaline was more effective in stimulating PG and TX
production by the ME at 18:OOh on di-oestrus than at 18:OOh on
pro-oestrus, this increase being between 200% and 250%. In
contrast, noradrenaline was more effective in stimulating PG and
TX production by the AH-POA at 18:OOh on pro-oestrus than at
18:OOh on di-oestrus. An effect of ascorbic acid on PG and TX
production cannot be ruled out as no incubations with
noradrenaline were carried out in the absence of ascorbic acid.
However, ascorbic acid has been reported to have an inhibitory
effect on PG production by the guinea pig uterus (Pugh, Sharma
and Wilson, 1975). Consequently, the stimulatory effect is
probably due to NA. The lack of effect of 2-OH oestradiol on PG
and TX production cannot be due to contamination with oestrogen,
or impurity of the substance, as this was checked before the
experiment. It is possible that, as no antioxidant was added to
the incubations with 2-OH oestradiol, the catechol oestrogen was
inactivated by oxidation. However, Kelly and Abel, 1980 have
reported that ascorbic acid reduces the effect of 2-OH oestradiol
on PG synthesis and for this reason, ascorbic acid was not
included in the 2-OH oestradiol incubations.
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Section 2.2.f. The effect of Froben on the pro-oestrous
LH surge
Introduction
If PGs are involved as mediators or modulators of
gonadotroph!'n release from the hypothalamus, it should be
possible to demonstrate that inhibition of hypothalamic PG
synthesis results in altered gonadotroph!'n secretion. Although
it has been demonstrated that indomethacin given daily for
5 days will depress serum LH levels in ovariectomized rats
(Sato, Jyujo, Hirono and lesaka, 1975) and that 5-, 8-, 11-,
14- eicosatetracynoic acid (TYA), a PG synthesis inhibitor,
and indomethacin, administered intraventricular^ also decrease
the post-castration rise in plasma LH levels (Ojeda, Harms
and McCann, 1975) it has yet to be shown that PG synthesis
inhibitors will affect the pro-oestrous LH surge. Tsafriri,
Koch and Lindner (1973) reported /that indomethacin given as
a single injection either at 08:30h or 14:30h failed to
prevent the pro-oestrous LH surge, and likewise, indomethacin
injected at 13: OOh on pro-oestrus had no effect on serum LH
levels in cycling rats (Sato, Taya, Jyujo and Igarashi,
1974). In the last study, however, rats treated with
indomethacin on pro-oestrus ovulated and, after oestrus,
di-oestrus persisted for 5 to 12 days suggesting that
indomethacin may have had some effect on gonadotroph!'n release.
The lack of effect of indomethacin in blocking the pro-oestrous
LH surge may be due to the inability of the drug to penetrate
the central nervous system (Hucker, Zacchei, Cox, Brodie and
Cantwell, 1966; Goodman and Gillman, 1975).
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The possibility also exists that a PG synthetase isoenzyme
exists in the hypothalamus and that indomethacin is a
relatively poor inhibitor of this form of the enzyme.
The effect of a new PG synthesis inhibitor 2-(2-fluoro-
4-biphenylyl )proprionic acid (Froben) on the pro-oestrous LH
surge has been the subject of the experiment described in this
section. This inhibitor was used on the basis that it is more
potent as an antipyretic agent than either aspirin,
meclofenamic acid, paracetamol or phenylbutazone (Van Miert and
Van Duin, 1977) and thus may be more effective in inhibiting PG
synthesis in the hypothalamus.
Method
Twelve rats weighing between 200g and 250g were used
in the experiment. The rats had been housed fed and smeared
as described in Section 2.1.a. Between 08:OOh and 10:00h
on pro-oestrus, rats were anaesthetized with halothane.
Each rat was prepared with a jugular cannula for collection
of blood samples for the estimation of plasma LH. After
exposing the right jugular vein, the wall of the vessel was
cut with iris scissors and a cannula, filled with heparinized
_ 1
saline (50 I.U.ml ), passed along the inside until blood
could be seen to well back into the cannula. This event
marked the entry of the cannula into the right atrium. The
cannula was secured with ligatures placed along a 0.4mm
section of cannula which had been strengthened by placing
a hollow metal tube inside.
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The cannula was exteriorized at the back of the neck to a
length of approximately 3 cm. After flushing the cannula with
heparinized saline, the open end was stoppered with a brass pin.
The rats recovered consciousness within 10 min of removal from
the halothane. Six rats prepared in this way acted as controls
and received 0.5 ml saline intra-peritoneally (i.p.) at
09:00h and again at 13:OOh intravenously (i.v.). The remaining
six animals were given Froben at 09: OOh i.p. and at 13: OOh i.v.
Froben was injected in 0.5 ml saline at a dose of 2 mgkg-''.
Blood samples 0.4 ml were collected, via a 50cm extension cannula
at 12:OOh, 15:OOh, 16:00h, 17 :OOh, 18:00h, 19:00h and 20:00h.
The samples were stored on ice until they were centrifuged
at 4°C for 20 min at 1300 x g on an MSE Cool spin centrifuge.
The plasma was transferred to plastic tubes and stored at
-20°C until assayed for LH. After collection of the last
blood sample each rat was killed and the M E and AH-POA
dissected out, weighed, homogenized in Krebs' solution,
incubated and extracted for PGs and TX as described in
Sections 1.2.a and 2.2.a. The samples were stored at -20°C
until assayed by RIA for PGE-2 using the method described
in 1.3. a.
Plasma was assayed for LH content by RIA according to
Niswender, Midgley, Monroe and Riechart (1968). The assistance of
Ms L. Nairn and Ms A. Horn of the MRC Brain Metabolism Unit,
Edinburgh with this assay is acknowledged. Standard curves were
based on triplicate estimates at 9 dose levels of ovine standard
LH (NIH-LH-S13). Purified ovine LH was iodinated with i'* and an
antibody (GDN#5) against ovine LH was used at a dilution of




The lower limit of sensitivity of the assay was lngml in
terms of the LH standard.
Results
Froben decreased the concentration of PGE-2 in samples
of ME and AH-POA from a mean of 5.15 _+ 0.5 ngmg 1 and 0.25 _+
0.02 ngmg 1to 1.22 _+ 0.35 ngmg-1and 0.08 _+ 0.04 ngmg-1
respectively.
All of the rats given saline alone showed a- surge of
LH which peaked between 16:OOh and 18:OOh (Fig. 21a). Of
the rats treated with Froben, two showed no LH surge and the
remaining 4 rats each showed a surge in LH which occurred
between 17:OOh and 19:00h (Fig. 21c). The mean values of plasma
LH from control and from the treated rats which showed an LH
surge are shown in Fig. 21b. Froben appears to delay the
peak in plasma LH by 2 hours. However, the mean values of
plasma LH at either 17:OOh or 19:OOh did not differ
significantly between control and treated rats.
Conclusion
Froben treatment inhibited LH release in 2 out of the
6 rats. In the remaining 4 rats, the LH peak was delayed
by up to 2 hours. Froben treatment therefore inhibited or
delayed the appearance of the LH surge. As Froben
significantly reduced PGE-2 levels in the ME and AH-POA, it
is possible to speculate that inhibition of PG synthesis by
Froben resulted in inhibition or delay of the LH peak.
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However, if PGE-2 produced by the brain is essential for LH
release, Froben treatment should have prevented the LH surge in
all 6 rats. The dose of Froben used, though, only reduced
PGE-2 levels by 70%, therefore PG synthesis may not have been
completely inhibited and sufficient synthesis of PGE-2 may
have occurred in 4 of the 6 rats to cause the delayed release
of LH. Further experiments are therefore required using a
larger dose of Froben and/or an additional injection at 15:OOh
(i.e. l-3h before the LH surge) in order to establish if PGs
are essential for the LH surge.
Pi s'cussi on
The results presented in this section confirm earlier
observations on the presence of PGs in rat brain. Wolfe,
Rostworowski and Pappius, (1975), have shown that rat brain
synthesizes PGF-2o; and PGE-2 from endogenous precursors in
a ratio of approximately 3:1. Homogenates of rat cerebral
cortex synthesize TXB-2 in similar amounts to PGF-2oi (Wolfe,
Rostworowski and Marion, 1976). 6-keto-PGF-la could be
identified in rat brain homogenates but was a minor component
in relation to PGD-2, PGE-2 and PGF-2o: (Saeed Abdel-Halim,
Lunden, Cseh and Anggard, 1980). The major PG produced by
rat brain homogenates is PGD-2 (Abdel-Halim, Hamberg, Sjoquist
and Anggard, 1977). In a study on the distribution of PGD-2
in the rat brain, Narumiya, Ogorochi and Hayaishi (1982)
have shown that the distribution is wide, with higher
concentrations being found in the pituitary gland and
hypothalamus.
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PGD-2 synthesis has not been studied here due to the lack of
an RIA for this compound. It would be interesting to study its
production by the hypothalamus during the oestrous cycle.
Although the samples were not analyzed for the presence of
cross reacting substances, such as PGE-1 and PGF-lot, it has
been reported that the rat brain lacks eicosatrienoic acid,
the precursor of the I-series PGs (Baker and Thompson, 1972).
Therefore the antibodies were probably measuring the PGs of
the 2-series to which they had been raised.
The ratio of PGF to PGE concentrations in the medial
hypothalamus measured by bioassay is approximately 2:1 whereas
in the ME, this ratio is reversed (Cseh, Szabo, Lang and
Palkovits, 1978). Furthermore, these workers report that the
ME contains more than 10 times as much PGE-2 and 6 times as
much PGF-2o: as the medial hypothalamus. Ojeda, Naor and
McCann (1978) have also found that PGE concentrations in the
ME exceed those in the MBH by 4- to 5-fold. These results
are in agreement with those presented in this section. The
present results also show that the increased concentration
of PGE and PGF in the ME is due to increased synthetic
capacity of the tissues for them. PG and TX production by
the ME showed a diurnal rhythm. PGE-2 production by the ME
increased at the time of the LH surge (i.e. between 14: OOh and
18'-00h on pro-oestrus). This increase in PGE-2 production is
unlikely to be due to increased arachidonic acid availability in
the tissue as the addition of exogenous arachidonic acid to
hypothalamic homogenates did not increase PGE-2 production.
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Metabolism of PGE-2 by the ME and AH-POA did not change
significantly betwen 10:OOh on pro-oestrus and 06:00h on
oestrus and so the increased PGE-2 production seen on these two
days cannot be due to a decrease in its metabolism.
Peak PGE-2 production by the ME occurred at 06:OOh on
oestrus, a time when LH levels would have returned to basal.
It cannot be ruled out therefore, that PGE-2 synthesis by the
ME is related also to the release of other hypothalamic
releasing factors. A surge in growth hormone (GH) occurs
in the early hours of light (Martin, Tannenbaum, Willoughby,
Renaud and Brazeau, 1975) and PGE-2 will stimulate GH release
by acting within the hypothalamus (Ojeda, Negro-Vilar, Arimura
and McCann, 1980). There are however, no reports of a diurnal
variation in LHRH or LH release in the rat.
A diurnal rhythm exists in plasma progesterone
concentrations (mainly of adrenal origin) during the oestrous
cycle of the rat (Mann and Barraclough, 1973). Plasma levels
of this steroid are at a nadir between 10:00h and 14:00h and
peak during the early morning hours (01:00h to 05:00h) on
each day of the cycle. Since the peak production of PGE-2
by the ME follows these peak levels of progesterone, a causal
relation appears to exist between the diurnal rhythm in adrenal
progesterone output and PGE-2 synthetic capacity of the ME.
There is an extra peak in progesterone between 17:OOh on
pro-oestrus and 01:OOh on oestrus due to increased ovarian
secretion which may be responsible for the peak in ME PGE-2
production at 18:00h on pro-oestrus.
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Further support for a stimulatory effect of progesterone on
PGE-2 synthesis by the ME came from the observation that
injecting long-term ovariectomized oestradiol-primed rats with
progesterone increased PGE-2 production by the ME. This
treatment is known to induce a surge in plasma LH within
5h of the progesterone injection (Caligaris, Astrada and
Taleisnik, 1968). Unfortunately, no reports are available to
show that the LH surge is coincident with a surge in LHRH.
Nevertheless these results suggest that progesterone may
facilitate an increase in LH release by firstly stimulating
PGE-2 synthesis in the ME which would, in turn, cause LHRH
release into the hypophyseal portal vessels (see Introduction).
It is not clear, however, why treatment of short-term
ovariectomized rats with oestrogen and progesterone had no
effect on PGE-2 production by the ME.
Correlations of PG and TX synthesis in the AH-POA
with plasma concentrations of ovarian steroids (as shown in
Fig. 3) shows that a high ratio of PGF to the other PGs and
TX occurs when plasma progesterone concentrations are high.
However, treatment of either long-term or short-term
ovariectomized rats with oestrogen and progesterone did not
preferentially increase PGF production by the AH-POA.
Indeed, it can be said that the steroid treatment which was
designed to simulate the changes in plasma steroid
concentrations that occur before and during the LH surge did
not result in simulating the changes in PG and TX production
by the AH-POA occurring at that time in cycling animals.
The significance of these results is not clear.
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In future experiments it would be interesting to study
the effect of progesterone given separately to test whether
priming with oestradiol affected the PG and TX synthesis by
the brain in response to progesterone.
Although Kelly and Abel (1980) were able to show that
2-OH oestradiol stimulated PGE-2 and PGF-2q: production by
rat uterine homogenates, this effect was not seen in either
the ME or AH-POA at a similar dose (i.e. lOOpM) in the
experiments described here. However, in order to conclude
that catechol oestrogen does not affect PG synthesis by the
hypothalamus a wider range of doses of this compound would
require to be tested. The stimulatory effect of NA on
PGE-2 and PGF-2Q: production by brain tissue confirms the
results of Hillier and Roberts, 1976; Wolfe, Pappius and
Rostworski, 1976 and Ojeda, Negro-Vilar and McCann, 1979.
The mechanism of action of catecholamines in stimulating
PG production is unknown but it is possible that they act as
reducing agents in the conversion of PGH-2 to PGF-2q: or act
as free radical scavengers, thereby preventing cyclooxygenase
inactivation during PG synthesis (To, Smith and Carpenter, 1980).
Ojeda, Negro-Vilar and McCann (1982) have shown that the
stimulatory effect of NA on PGE-2 and LHRH release from the ME
in vitro is blocked by phentolamine and thus involves
participation of an a-adrenergic receptor. Therefore the
differing responses to NA with respect to PG production by
the ME between 18:OOh on di-oestrus and 18:00h on pro-oestrus
observed in experiments described in this section, may reflect
cyclical changes in the number of oi-receptors in the ME.
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Changes in PGE-2 release by the ME in response to NA throughout
the oestrous cycle hatealso been reported by De Paolo, Ojeda,
Negro-Vilar and McCann (1982). They observed a diurnal
variation in responsiveness, being high at 13:00h and low at
16:OOh. When progesterone was given several hours before
the normal ovulatory increase, the onset of the LH surge as
well as the increased response of the ME to PGE-2 were advanced
(De Paolo et al., 1982). Therefore, as it has been suggested
in this section that progesterone may increase the synthetic
capacity of the ME for PGE-2, it would be interesting to
speculate that progesterone increases the responsiveness of
the ME to NA by increasing the ability of the ME to synthesize
PGE-2.
The final experiment described in this section which was
designed to study the role of hypothalamic PG production, showed
that Froben prevented the release of LH in 2 out of 6 animals and
appeared to delay LH release in the other 4. These results
do not fully support the results of Tsafriri et al., (1973)
or Sato et al., (1974) who showed that indomethacin did
not affect the pro-oestrous surge of LH and suggested that
hypothalamic PG synthesis is not essential for the LH surge.
Because of the increase in pituitary responsiveness to LHRH on
pro-oestrus, it is possible that only a very small increase in
LHRH (and PG) release from the ME is required for a surge in LH.
The effect of Froben on the pro-oestrus surge in LHRH requires
studying.
Further experiments are required, therefore, in order
to clarify the role of PGs in LHRH release.
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As peak PGE-2 production by the ME occurred at the time .of the
ovulatory surge of progesterone, it would be interesting to
study the effect of progesterone on PGE-2 synthesis by the ME.
In particular the activity of the cyclooxygenase and isomerase
enzymes involved in hypothalamic PGE-2 synthesis requires
investigation.
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Section 2.3 PROSTAGLANDIN PRODUCTION BY THE UTERUS
Introduction
PGs produced by the uterus have been implicated in the
regulation of several processes in the female reproductive tract
of the rat. It has been suggested that they mediate the
vascular changes at blastocyst implantation sites (Kennedy,
1979b) as well as the uterine hyperaemia which occurs in response
to oestrogen (Ryan, Clark, Van Orden, Farley, Edvinson, Sjoberg,
Van Orden and Brody, 1974). A number of investigations suggest
the involvement of endogenous PGs in uterine contractions
(Vane and Williams, 1973; Phillips and Poyser, 1981a). PG
production by the uterus fluctuates during the oestrous cycle
(Ham, Cirillo, Zanetti and Kuehl 1975; Poyser and Scott, 1980;
Van Orden, Goodale, Baker, Farley and Bhatnagar, 1980).
However, the physiological significance of uterine PG
production during the oestrus cycle is unknown at present.
The following experiments describe PG and TX production
by the rat uterus throughout the oestrous cycle. PG and TX
by the endometrium and myometrium and the effect of ovarian
steroids on uterine production of PG and TX have also been
studied.
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Section 2.3.a Measurement of the ability of uterine tissue to
produce PGs and TX during the oestrous cycle
Introduction
The rat uterus synthesizes 6-keto-PGF-lo; in addition to
PGE-2 and PGF-2Q! (Fenwick, Naylor, Poyser and Wilson 1977;
Pace-Asciak and Rangaraj, 1977). In the same year, Williams
and Downing showed that microsomes from the pregnant rat
uterus can convert 3H-AA into small amounts of TXB-2. Small
quantities of TXB-2 (3 to 5 nglOOmg ) were detected in the
uterus of the cycling rat by GC-MS assay (Poyser and Scott,
1980) but, due to the relatively low sensitivity of this
assay method, accurate measurements of TXB-2 production
during the oestrous cycle were not possible in their study.
In the majority of studies on PG production by the uterus
of the cycling rat (Ham et al., 1975; Poyser and Scott, 1980;
Van Orden et al., 1980; Thaler-Dao, Saintot, Ramonatxo, Chavis
and Crastes de Paulet, 1982) determinations were made only
once or twice per day. The following experiments have
examined uterine PG and TX production at 4-hourly intervals
during the oestrous cycle.
Method
Rats weighing between 200g and 250g were killed at
02:00, 06:OOh, 10:00h, 14:OOh, 18:OOh and 22:OOh on each day
of the cycle. These animals also provided tissue for use in
experiments described in Sections 2.1a and 2.2a.
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The uterus from each rat was dissected out and any cervical
tissue removed. After weighing the uterus it was homogenized
in 5 ml Krebs' solution in a Fisons glass homogenizer. The
homogenate was transferred to a 50ml conical flask and the
homogenizer was washed twice with 5ml Krebs' solution, the
washings being added also to the flask. Each flask was
incubated for 90 min at 37°C as described in section 1.2b
and, following incubation, the PGs and TX were extracted
according to the method given in Section 1.2.a. Samples were
stored in 10ml ethyl acetate at -20°C until being assayed for
PGE-2, PGF-2Q!, 6-keto-PGF-la: and TXB-2 content by RIA as
previously described in Sections 1.3a, b, c and d.
The results from the rats killed at 4-hourly intervals
during the cycle were compared using Duncan's Multiple Range
test for equal variances. Where comparisons were being made
between means having differing variances, as determined by a
F-ratio test, then significance was tested by the method of
Fisher and Behrens. Significance was tested at the 5% level.
Identification of extracted PGs by GC-MS
Samples which had previously been assayed for PGs and TX
by RIA were pooled, purified by silicic acid chromatography
and the appropriate derivatives prepared according to the
method described in Section 1.4. The samples were injected
in lOyul BSTFA into the GC and full mass spectra taken at the
retention times on the GC corresponding to the carbon values




GC-MS analysis confirmed the presence of PGE-2, PGF-2Q:,
6-keto-PGF-lo: and TXB-2 in the uterine samples as previously
shown by RIA. PGD-2 was also present in these samples. Neither
PGA-2, PGB-2, PGE-1 nor PGF-la were detected in the samples.
Fig. 22 shows the amounts of PGE-2, PGF-2o:, 6-keto-PGF-lo:
and TXB-2 formed from endogenous precursors by rat uterine
homogenates at 4-hourly intervals throughout the oestrous cycle.
A statistical analysis of these results is given in Table 15.
Homogenates of the whole uterus synthesized mainly
6-keto-PGF-lo: with smaller amounts (in descending order) of
PGF-2Q!, PGE-2 and TXB-2. Production of al 1 3 PGs and TXB-2
showed little variation on met-oestrus and di-oestrus but a
comparison throughout the cycle shows production tending to be
lowest on the day of di-oestrus. Between 06:00h and 14:OOh
on pro-oestrus PG and TX production started to increase. At
02:OOh on oestrus, production of 6-keto-PGF-la, PGF-2a and
TXB-2 reached peak values. These values were significantly
different from the values at 10:OOh on pro-oestrus for the
corresponding PG or TXB-2. Between 10:OOh on pro-oestrus and
02:00h on oestrus TXB-2 production showed the greatest
percentage increase, i.e. 225% compared to 50% for 6-keto-PGF-lo;
and 97% for PGF-2a. At 02:00h on oestrus, uterine TXB-2
production was significantly greater than at any other time
in the cycle. By 14:00h on oestrus, production of PGF-2o: and
TXB-2 had declined to values which did not differ significantly
from those on met-oestrus. 6-keto-PGF-lQ! production remained
elevated at 14:OOh on oestrus, but showed a gradual decline
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Table 15. Statistical analysis of PG and TX production by rat uterine
homogenates as shown in Fig.22. Significance was tested by Duncan's
multiple Range test or Fisher Behrens test*. Values with the same
superscript within each column are not significantly different
(p>0.05). Values are expressed as mean + s.e.m., n = 6 for
each time.
PG production
ng 100 mg~ PGE-2 PGF-2Q; 6-keto-PGF- la TXB-2
Time
14.OOh oestrus 42.2+4.8efgh 91.4+6.3de 230+17jk 36.2+3.Qbcdef9
18:OOh oestrus 35.1+7.0bcde 79.7+10.0Cd 203+15hlj 36.4+3.lcdefg
22:OOh oestrus 39.6+4.0defg 84.0+6.0Cde 207+171^k 40.8+3.6fgh
02:OOh met-oestrus 37.1+3.4Cdef 84.9+7.0Cde 183+1ldefghl 34.1+6 .-0bcdef
06:OOh met-oestrus 32.1+4.8abcd 86.5+8.lCdS 178+32Cdefghi 27.2+6.7abcde
10:OOh met-oestrus 38.2+6.0def 88.0+7.9de 158+19abcdef 30.1+7.0abcdef
14:OOh met-oestrus 46.3+6.2fgb 97.5+13.0ef 192 + 14efgMj 39.8+6.7efgh
18:OOh met-oestrus 33.3+2.4abcde 75.4 + 11.2bCd 137+21abC 26.6+6.labcd
22:OOh met-oestrus 39.2+5.5defg cd79.9+6.9 188+26efghi:' 38.6 + 5 .1efg
02:OOh di-oestrus 26.'2+7.2^ 57.0+5.0a 161+23abcdefg 27.3M.9abcde
06:OOh di-oestrus 32.8+6.5abcde 62.0+3.7ab 164+13abcdef9h 22.3+2.3a
10:OCh di-oestrus 32.9+5.4abcd 58.7+6.0ab 146+16abCd 20.2+2.5a
1 4: OOh di-oestrus 29.4+8.iabC 57 . 7+6.03 145+20abcd 19.5+2.73
18:OOh di-oestrus 26.0+3.0a 55.4+3.2a 135+27ab ab23.7+4.0
22:OOh di-oestrus 28. 6+4 . 0ab<" 55.5+3.^ 127+13 a 22.3+2.9a
02:OOh pro-oestrus 29.2 + 3. 5^"" 56.6+4.6® 156+25abcde 24.8+1.iabC
06: OOh pro-oestrus 24.3+5.0a 53.3+5.2® 153+33abcde 20.4+3.3a
10:OOh pro-oestrus 28.8+2.4SbC 76.0+14.4bcd 167+27abcdefgh 31.8+7.2abcdef
14: OCh pro-oestrus 24.1+2.43 83.2+4.8Cde 170+25bcdefghi 26.5+5.0abcd
18:OOh pro-oestrus 28.0+5.3^° t>c74.3+9.9 173 +29bcdefghi 28.4+4.1abcdef
22:OOh pro-oestrus 47.7+4.0gb qh138.0+15.6 197 + 24fgh;Lj 51.7+8.8hl
02:OCh oestrus
oh
47.9+7 . 5 151.0+9.5h 251+28k 103.5+25.7j*
06:OOh oestrus 49.5+6.7h 121.0+12.99 175+19bcdefghi 47 .6+5.09hl
10:OOh oestrus 38.8+5.2def9 113.0+4.9f9 202+22ghlj 60:7+7.01
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PGE-2 production by the uterus showed a slightly different
trend. Like the other PGs, production of PGE-2 was lowest
on the day of di-oestrus. However, production of PGE-2
increased significantly between 18:OOh and 22:00h on
pro-oestrus (by 77%) and remained constant at this elevated
level between 22:OOh on pro-oestrus and 06:00h on oestrus
before showing a slight decline. There was no discernible
peak at 02:OOh on oestrus. Also, in contrast to production
of 6-keto-PGF-lo:, PGF-2a and TXB-2, PGE-2 production remained
relatively high on met-oestrus before decreasing to its
lowest value on the day of di-oestrus. The ratio of
6-keto-PGF-la;: PGF-2cx:TXB-2: PGE-2 production changed from
4.4:1.8:0.6:1 at 02:00h on di-oestrus to 5.2:2.9:1.6:1 at 02:00h
on oestrus.
Cone!usion
Since the presence of PGE-2, PGF-2o:, 6-keto-PGF-lo:and TXB-2
in uterine samples was confirmed by GC-MS analysis and neither
PGA-2, PGB-2, PGE-1 nor PGF-lo: were detected, it can be
concluded that the antibodies used in the RIA probably measured
PGE-2, PGF-2q:, 6-keto-PGF-lo: and TXB-2 in the samples.
There is an increase in the ability of the uterus to
synthesize PGE-2, PGF-2o:, 6-keto-PGF-lo: and TXB-2 on pro-oestrus.
Peak PG and TXB-2 production occurred at 02:00h on oestrus,
this being the time of ovulation and the time of maximum PG and
TXB-2 production in the ovary (see Section 2.1 ). TXB-2 showed
the greatest percentage increase between 10:00h on pro-oestrus
and 02:00h on oestrus which may suggest that TXA-2 synthesis
by the uterus is important at the time of ovulation.
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Since the ratios of the production of PGE-2, PGF-2Q!, 6-keto-PGF-la
and TXB-2 changed during the oestrus cycle, this indicates that
their synthesis may be controlled independently of each other.
Section 2.3.b Measurement of i) PG and TX levels in the
uterus and ii) the ability of the uterus to
synthesize PG and TX in the presence of
exogenous arachidonic acid
Introduction
In order that production of PGs and TX by the uterine
homogenates can be taken as a reflection of PG and TX
synthesis for reasons described in Section 2.1.b, PG and TX
levels in, and PG and TX production by uterine homogenates
incubated in the presence of arachidonic acid has been
measured.
Methods
i) 3 rats were killed at 10:OOh on pro-oestrus and their
uteri dissected out as described in Section 2.3.a. Tissues
were weighed and homogenized in 5 ml ethanol and further
processed according to the method given in Section 2.1.b.
Samples were stored in 5 ml ethanol at -20°C before being
assayed for PGE-2, PGF-2a, 6-keto-PGF-lo: and TXB-2 by RIA as
described in sections 1.3a, b, c and d.
ii) The uteri from 4 rats killed at 10:OOh on pro-oestrus
were dissected out, homogenized and incubated for 90 min in
-1
Krebs' solution containing 2pgml arachidonic acid.
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The homogenates were extracted for PGs and TX as described in
Section 1.2.a. Samples were stored in 10ml ethyl acetate at
-20°C until they were assayed for PGE-2, PGF-2o:, 6-keto-PGF-la
and TXB-2 by RIA using the method described in Sections 1.3a,
b, c and d.
Results were compared with PG production at 10:OOh on
pro-oestrus in the absence of arachidonic acid, by means of
Student's t-test.
Results
i) Uterine concentrations of PGE-2, PGF-2a, 6-keto-PGF-la
and TXB-2 were low in comparison to the amounts of PGs and
TX formed during incubation of the homogenates, (Table 16).
Table 16. Concentrations of PGs and TX in ethanolic homogenates
from rats killed at 10:OOh on pro-oestrus and 02:00h
on oestrus (mean ± s.e.m.)
PG 1 evel s
^^Vng lOOmg
T i me













* denotes values significantly different from those at 10:OOh
on pro-oestrus, (p<0.05).
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The major PG present in the uterus at 10:OOh on pro-oestrus
was PGF-2oi whereas at 02:00h on oestrus, 6-keto-PGF-lo: was the
predominant one. At 02:00h on oestrus, uterine concentrations
of PGF-2a, 6-keto-PGF-lo: and TXB-2 were significantly increased
from their correspond!'ng values at 10:00h on pro-oestrus,
ii) the addition of arachidonic acid had no significant effect
on PG or TX production by uterine homogenates from rats killed
at 10:00h on pro-oestrus (Fig. 23), although 6-keto-PGF-lo;
production tended to be higher.
Conclusion
Levels of PGE-2, PGF-2a, 6-keto-PGF-lo; and TXB-2 are low
in comparison to the amounts produced after incubation of
homogenates. Therefore synthesis must have occurred during the
homogenization and incubation procedures. As the levels of
PGF-2o:, 6-keto-PGF-lo; and TXB-2 were higher at 02:00h on
oestrus than at 10:00h on pro-oestrus, and an increase in
synthetic capacity was observed between these times, this
suggests that the increased levels are the result of the increase
in the ability of the uterus to synthesize PGF-2a,6-keto-PGF-lQ!
and TXB-2 at 02:00h on oestrus. Addition of exogenous
arachidonic acid to homogenates of uteri from rats killed at
10:00h on pro-oestrus did not increase the ability of the tissue
to synthesize PGs or TX. It can therefore be concluded that the
relatively low synthetic capacity of uterine homogenates for PGs
and TX seen at 10:OOh on pro-oestrus, was not due to a lack of
free arachidonic acid in the homogenates.
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Figure 23
PG and TX production by uterine homogenates incubated
(n=4)in the absence EH (n-6) or presence
of 2>igml"1 arachidonic acid. Rats were killed at
10:OOh on pro-oestrus
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This suggests that the increased synthetic capacity between
pro-oestrus and oestrus is due to changes in the activity of the
PG synthetase enzyme complex.
Section 2.3.c. Measurement of the ability of the uterus to
metabolize PGE-2 and PGF-2o:
Introduction
Existing studies show that the ability of the uterus of
the swine (Anggard, 1971), human (Kierse, Williamson and
Turnbull, 1975), guinea pig (Maule, Walker and Poyser, 1978)
and rat (Poyser and Scott, 1980) to metabolize PGs is low.
However, in the last study, significant changes in the
metabolism of PGF-2c*:into 15-keto-PGF-2a: and 13,14-dihydro-15-
keto-PGF-2o; were observed during the oestrous cycle. Metabolism
was significantly higher on pro-oestrus and oestrus than on
met-oestrus or di-oestrus. This suggests that PG metabolism
may be modulated by ovarian steroid hormones as plasma oestradiol
levels are increased on the days of pro-oestrus and oestrus
(see Fig. 3). However, it has been reported that oestradiol
decreases prostaglandin dehydrogenase activity in kidneys from
ovariectomized rats (Blackwell and Flower, 1975).
The following experiments were performed to determine
whether changes in PG and TX metabolism by the uterus could
account for the increased production which occurred between
10:00h on pro-oestrus and 02:OOh on oestrus.
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Methods
The uterus was removed from rats killed at 10:OOh on
pro-oestrus (n=4) and 02:00h on oestrus (n=4). After separating
|5DimC) of
the two uterine horns,^each horn was homogenized in 10ml
Krebs' solution. NAD+ (2mM), and PGF-2a (2^igml~^) were added to
one uterine horn homogenate from each rat. All homogenates were
3
incubated in the presence of 0.5 /jCi H-PGF-2Q! for 90 min. The
extracts were further processed using the method described in
Section 2.I.e. This experiment was repeated for the study of
uterine PGE-2 metabolism by replacing JH-PGF-2a; with 3H-PGE-2
and adding PGE-2 in place of PGF-2a. The results are expressed
as percentage metabolism of PGE-2 or PGF-2o; and were compared
using Student's t-test.
Results
The uterus metabolized 3H-PGF-2a (Rf=0.14) and 3H-PGE-2
(Rf=0.26) into a mixture of the corresponding 15-keto-metabolites
(Rf=0.25 and 0.42 respectively) and 13,14-dihydro-15-keto-
metabolites (Rf=0.35 and 0.43 respectively). Table 17 shows
the percentage metabolism of PGE-2 and PGF-2q: into these
metabolites expressed as a single figure.
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Table 17. Percentage metabolism (mean + s.e.m.^of 4
observations) of 3H-PGE-2 and 3H-PGF-2o?in
homogenates of uteri in the absence and presence
of NAD+ from rats killed at 10:00h on pro-oestrus
and 02:00h on oestrus
TIME PGE-2 metabolites PGF-2xmetabolites
No NAD+ NAD+ present No NAD+ NAD+ present
10:OOh
pro-oestrus 6.7+0.2 26.6+10.2 11.8+3.4 11.9+3.6
02:OOh
oestrus 16.5+3.5* 30.2+5.6 4.7+1.2* 12.8+4.2
In the absence of NAD+ the percentage metabolism of PGE-2
and PGF-2o; is relatively low (from 7 to 20%). The presence of
NAD+ increased the percentage metabolism to between 12 and 35%.
In the absence of NAD+, PGE-2 metabolism was significantly
(p<0.05) greater at 02:OOh on oestrus than at 10:00h on
pro-oestrus. In contrast, PGF-2o: metabol ism was significantly
lower at 02:00h on oestrus than at 10:00h on pro-oestrus.
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Cone 1usion
In the absence of NAD+, metabolism of PGE-2 and PGF-2qi in
uterine homogenates is relatively low. Therefore the amounts
of PGs produced during incubation of homogenates can be taken
to reflect the synthetic capacity of the uterus. Although
metabolism of PGF-2cedid decrease at 02:OOh on oestrus by
approximately 7%, this is unlikely to account for the 97%
increase in uterine PGF-2a production occurring between 10:OOh
pro-oestrus and 02:OOh on oestrus. PGE-2 metabolism increased
between these times and, therefore, the synthetic capacity at
02:00h on oestrus may be limited slightly by this change in
metabolism.
It is assumed that, as the same enzymes are involved
(see Section 2.1.c) that metabolism of PGI-2 and TXA-2 by the
uterus is also low.
Section 2.3.d. Measurement of PG and TX production by the
endometrium and myometrium at 10:OOh on
pro-oestrus and at 02:00h on oestrus
The uterus consists of two tissue types. The outer
layer, or myometrium, contains smooth muscle cells arranged in
distinctly oriented layers, while internally, the endometrium
contains predominantly epithelial cells and glandular tissue.
Evidence is accumulating which shows that PGs and TX synthesis
is unevenly distributed between these two layers. In the
pregnant rat, the endometrium is the major site of PGF-2cy
synthesis (Williams, Sneddon and Harney, 1974).
1(8 8
The same is true of the human endometrium, which also synthesizes
PGE-2 and PGD-2 (Abel and Kelly, 1979). However, in the pregnant
rat uterus (Williams, Dembinska, Zmuda and Gryglewski, 1978;
Downing and Williams, 1980) and human uterus (Abel and Kelly,
1979), PGI-2 synthesis predominates in the myometrium.
Two reports exist which disagree on the main site of
uterine TXA-2 synthesis. While Downing and Williams 1980, found
that in the pregnant rat uterus only the endometrium converted
arachidonic acid into TXB-2, Campos, Liggins and Seamark, (1980)
found that in superfusates from uteri of oestrogen-treated
ovariectomized rats, the major source of TXB-2 was the
myometriurn.
Since no information is available on PG and TX production
by the endometrium and myometrium of the cycling rat, the
following experiment was designed to study this. PG and TX
production by these two tissues was studied at times of high
(02:00h oestrus) and low (10:00h pro-oestrus) production by
whole uterine homogenates.
Method
The uteri from 6 rats killed at 10:OOh on pro-oestrus
and from 7 rats killed at 02:00h on oestrus were removed and
weighed. The endometrium was separated from the myometrium
by scraping with a microscope slide (this was initially
demonstrated by Dr. I. Downing). The efficiency of removal
of endometrium by this method has been tested (Downing, 1979).
The myometrium was weighed and thus the weight of the
endometrium was calculated by difference.
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Following separation, the two layers were homogenized in
Krebs' solution (2 ml for the endometrium and 15ml for the
myometrium) and the homogenates transferred to 25ml conical
flasks. Each homogenate was incubated for 90 min at 37°C
as previously described in section 1.2.b. and the PGs and TX
extracted according to the method given in section 1.2.a.
Samples were stored in 2 ml (endometrium) or 10ml (myometrium)
ethyl acetate at -20°C until being assayed for PGE-2, PGF-2Q!,
6-keto-PGF-lo: and TXB-2 using the method described in Sections
1.3.a, b, c and d. The results were compared by Student's
t-test.
Results
Table 18 shows the production of PGE-2, PGF-2o:, 6-keto-
PGF-lo! and TXB-2 on a unit weight basis by endometrial
honogenates and myometrial homogenates from rats killed at
10:OOh on pro-oestrus and at 02:00h on oestrus. At both times,
PGF-2o: was the major product of the endometrium whereas 6-keto-
PGF-lo: predominated in the myometrium. Between 10:00h on
pro-oestrus and 02:OOh on oestrus, production of PGF-2cy, TXB-2
and 6-keto-PGF-lo' by the endometrium increased significantly
(p<0.001) by 480%, 270% and 166% respectively. Although the
•mean production of PGE-2 had also increased, this was not
significant. PGE-2 production by the myometrium showed a
significant decrease between 10:00h on pro-oestrus and 02:OOh
on oestrus (p<0.02) while myometrial production of PGF-2o: and
6-keto-PGF-lo; significantly increased (p<0.02). Myometrial
TXB-2 production showed no change between the two times.
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Table 18. Production of PGE-2, PGF-2QJ, 6-keto-PGF-lO and TXB-2
(mean +. s.e.m.) by endometrial and myometrial homogenates











170+61 504+127 126+27 183+72






18.0+3.1 24.2+5.0 45.0+5.8 16.0+1.9
★ ★
11.1+lto 37.3+3.1 78.2+8?9 17.3+1.0
Results are significantly different ** p<0.02 and *** p<20.001 from PG or
TX production at 10:OOh on pro-oestrus
Table 19. Total production of PGE-2, PGF-2<X 6-keto-PGF-la and TXB-2
(mean + s.e.m.) by endometrial and myometrial homogenates from










39.3+8.4 141+24.5 29.7+5.6 43.4+8.4






77.2+11.8 92.8+37-9 185+18.5 56.8+8.1
52.4+3.9 152+10.8 312+38?5 74.6+8.4
Results are significantly different * p<0.05, ** p<0.02 and
*** 0.001 from PG or TX production at 10:OOh on pro-oestrus
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Between 10:OOh on pro-oestrus and 02:OOh on oestrus ratios of
PGF-2o:: TXB-2:PGE-2:6-keto-PGF-lo: production by the endometrium
had changed from 4.5: 1.6 : 1.5 : 1 to 10 : 2.1 : 0.9 : 1.
Thus, endometrial PG production is directed towards PGF-2a: and
TXB-2 at 02:00h on oestrus. At 10:OOh on pro-oestrus ratios of
PGF-2C*: TXB-2: PGE-2 : 6-keto-PGF-lcwere 0.5 : 0.3 : 0.4 : : 1 in
the myometrium, and by 02:00h on oestrus this had changed to 0.5
: 0.2 : 0.2 : 1.
Since the weights of the endometrium and myometrium vary
considerably (1:20) the total PG and TX production by the whole
endometrium and the whole myometrium is shown in Table 19.
The myometrium produced more 6-keto-PGF-la and PGE-2 in total
than the endometrium. Total PGF-2o: production was greatest in
the endometrium whereas total TXB-2 production was equally
distributed in the two tissues. Between 10:00h on pro-oestrus
and 02:00h on oestrus, there were significant increases in total
PGF-2a (p<0.001) and TXB-2 (p<0.02) production by the
endometrium. In the myometrium, total PGE-2 and PGF-2Q! (p<0.05)
and 6-keto-PGF-lo: (p<0.02) production was significantly
increased at 02:00h on oestrus.
It was decided to examine whether co-incubation of the
homogenized endometrium and myometriurr^as opposed to incubating
homogenates of these tissues separately^affected PG and TX
production. The total production of PGE-2, PGF-2o:, 6-keto-PGF-lo:
and TXB-2 produced by the endometrium and myometrium incubated
separately has been divided by uterine weight and these values
have been compared with the respective PG and TX production by
whole uterine homogenates at 10:00h on pro-oestrus and at 02:00h
on oestrus as determined in Section 2.3.a.
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These results are shown in Fig. 24. Production of PGE-2,
PGF-2gi and TXB-2 was significantly greater (p<0.02, p<0.001,
p<0.05 respectively) by homogenates of whole uterus than the
total production by the endometrium and myometrium incubated
separately at 02:00h on oestrus, but not at 10:00h on
pro-oestrus. 6-keto-PGF-la production by homogenates of
whole uterus was significantly greater (p<0.001) than the total
6-keto-PGF-lo: by the endometrium and myometrium incubated
separately at both 10:OOh on pro-oestrus and 02:00h on
oestrus.
Cone! u'si on
The ability of the uterus to synthesize PGE-2, PGF-2a,
TXB-2 and 6-keto-PGF-lo:, expressed on a unit weight basis,
resides chiefly in the endometrium. However, because of the
vastly differing weights of the endometrium and myometrium,
expressing PG and TX production on a unit weight basis affects
the pattern of results obtained. As the myometrium constitutes
the greater part of the uterine mass, it can be concluded that
this is the major site of 6-keto-PGF-la production as this tissue
produced greater amounts of 6-keto-PGF-lo: in total than the
endometrium. In contrast, the endometrium is the major site of
uterine PGF-2a production as this tissue produced more PGF-2a in
total than the myometrium.
It was noted in Section 2.3.a. that the ability of the
uterus to synthesize PGs and TX increased between 10:OOh on


















In the case of PGE-2 and TXB-2 this increase is mainly due to
increased endometrial synthesis as myornetrial TXB-2 production
did not change between these times, and myometrial PGE-2
production actually decreased. However, the increase in uterine
PGF-2q: and 6-keto-PGF-loi production is due to increases in both
endometrial and n\yometrial production although PGF-2Q! production
in the endometrium showed a far greater percentage increase
between these two times.
There may be an interaction between the two uterine layers,
as evidenced by a greater PG or TX production by whole uterine
homogenates when compared to the sum of PG or TX production by
the endometrium and niyometrium incubated separately. Indeed
these results suggest that the endometrium may provide enzymes
or substrate for myometrial PG and TX synthesis or vice versa.
Section 2.3.e. The effect of oestrogen and progesterone on PG
and TX production by the uterus
Introduction
The effects of ovarian steroids on uterine PG production
have been reviewed (see Introduction). There is, however,
considerable variation in experimental results. Oestradiol
increased uterine PG production and PG release into the uterine
vein (Ham et al., 1975; Castracane and Jordan, 1975). However,
in the former study, PGF synthesis increased at the expense
of PGE synthesis while the latter study showed a parallel
increase in PGF and PGE in uterine venous plasma.
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In contrast, other workers report that oestradiol decreased
PGE-2 production while having no effect on PGF-2CX production
in ovariectomized rats (Thaler-Dao, Rarnonaxto, Saintot,
Chaintreuil and Crastes de Paulet, 1982b).
The influence of progesterone on uterine PG synthesis is
also inconclusive. Castracane and Jordan (1975), reported that
progesterone enhances the effect of oestradiol on uterine
PGF and PGE output whereas Ham et al., (1975) found that
progesterone had no effect on uterine PGF levels and actually
depressed PGE levels.
An inhibitory effect of oestradiol on PGI-2 release
(Gimeno, Borda, Lazzari and Gimeno, 1980) and 6-keto-PGF-la
production (Thaler-Dao et al., 1982b) by the rat uterus has been
reported.
The variation in these experimental results can be
ascribed to the different timing and dosage of steroids
administered to the animals. Often these experiments did not
mimic the in vivo situation (see General Introduction). The
experiments described in this section have examined the effects
of progesterone acting upon an oestrogen-primed uterus, on the
production of PGE-2, PGF-2ai, 6-keto-PGF-lo; and TXB-2 in the
ovariectomized rat.
Methods
Twelve rats were ovariectomized between 09:00h and
10:OOh on di-oestrus (Group I), under Althesin anaesthesia
(5mlkg~''). At 12:OOh on that day, six animals received
lOug oestradiol benzoate in 0.5ml arachis oil (s.c.). The
other six animals were injected with 0.5 ml arachis oil.
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♦ On the following day (the expected day of pro-oestrus) the
animals were injected s.c. with 2 mg progesterone in 0.5 ml
arachis oil at 12:00h.
Twenty-two rats (Group II) which had been ovariectomized
under Althesin anaesthesia 6 weeks previously, were divided
into two groups. Eleven of the rats received an s.c.
injection of lOpg oestradiol benzoate in 0.5 ml arachis oil at
12:OOh followed by 2 mg progesterone s.c. in 0.5 ml arachis oil
72h later. The remaining eleven rats received s.c. injections
of arachis oil alone at the above times.
The animals from both treatment groups were killed five
hours after the progesterone injection and their uteri removed,
weighed, homogenized, incubated and extracted for PGs and TX
as described in Section 2.3.a. The results are expressed per
unit wet weight of tissue. In addition protein determinations
(using the method of Lowry et al ., 1956) were made on 11
uterine homogenates from each of control and treated rats.
In this way, PG production expressed per mg wet weight could
be compared with that expressed per mg protein.
Results
Treatment with oestrogen and progesterone increased
uterine protein content from 22.5 jt- 2.9 mg (control) to
32.9 _+ 5.9 mg. Table 20 shows that treatment of long-term
ovariectomized rats with oestrogen and progesterone
significantly (p<0.05) increased PGF-2o: production by the
uterus, expressed on a unit weight basis or per mg protein.
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The percentage increase in PGF-2o; production calculated per
A
mg wet weight was greater than when expressed as per mg protein,
but the difference was not great.
Table 20. A comparison of PGF-2Q! production by uteri of
oestrogen and progesterone treated rats with those
of untreated rats when expressed on a unit weight
basis or per mg of protein (mean +_ s.e.m.)
ng PGF-2Q; production Control Treated % Increase
n = 11 n = 11
per mg wet weight 5.9+0.07 10.6+1.1* 79
per mg protein 65+7.4 110+8.2* 69
* significantly different from control p<0.05.
Treatment of acute ovariectomized rats with oestrogen
and progesterone had no significant effect on uterine
production of PGE-2, PGF-2oi, 6-keto-PGF-lo: or TXB-2 on a
unit weight basis (Fig. 25a). Production of PGF-2o; and TXB-2
was significantly (p<0.05) increased by treatment of long-
term ovariectomized rats with oestrogen and progesterone whereas







PGE-2 PGF-2o£ TXB-2 6-keto PGP4o6
Figure 25
Effect of oestradiol and progesterone treatment
of Group I) acute ovariectomized rats (n=6) and
Group II) long-term ovariectomized rats (n=ll)
on PG and TX production by uterine homogenates
expressed as nglOOmg-1 tissue. Values are shown
as mean + s.e.m.












When total PGE-2, PGF-2ct,6-keto-PGF-lo: or TXB-2 production by
each uterus is considered, the treatment of both acute, and
long-term ovariectomized rats with oestrogen and progesterone
significantly (p<0.001) increased production of all PGs and
TXB-2 (Fig. 26a and b).
Cone!usion
There is little difference between expressing uterine
PGF-2a production on a unit weight, basis or per mg protein
with respect to the percentage increase in PGF-2a production
following oestrogen and progesterone treatment of ovariectomized
rats. Thus it would have been of no advantage to express
the results according to uterine protein content. Due to the
increase in uterine weight following oestrogen and progesterone
treatment, PG and TXB-2 production expressed on a unit weight
basis did not change (with the exception of PGF-2Q! and TXB-2
production in uteri of long-term ovariectomized rats) in
contrast to total uterine production which was significantly
increased by treatment.
The difference between the effects of oestrogen and
progesterone treatment of acute and long-term ovariectomized
rats may be due to the fact that in the former case, oestrogen
was allowed to act for 24h before progesterone injection, whereas
in the latter 72h, separated the oestrogen and progesterone
injections. The experiment described in section 2.3.a. showed
that between 10:00h on pro-oestrus and 02:OOh on oestrus,
PGF-2a and TXB-2 production increased by 100% and 200%
respectively whereas 6-keto-PGF-bt and PGE-2 production showed
much smaller percentage increases.
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A similar response to oestrogen and progesterone treatment
of long-term ovariectomized rats was observed, with the effect
on uterine PGF-2<y and TXB-2 production being much greater
than on 6-keto-PGF-ly. or PGE-2 production. Thus the sequential
action of oestrogen and progesterone may be the stimulus for the
increased ability of the uterus to synthesize PGs and TX which
occurs towards the time of ovulation.
The effects of oestrogen and progesterone could be due
to decreased PG and TX metabolism in the homogenates. However,
as uterine metabolism of PGE-2 and PGF-2ot (and presumably TXA-2
and PGI-2) was between 5 to 15%, even complete inhibition of this
factor could not result in the increase in PGF-2ot and TXB-2
production after treatment with oestrogen and progesterone.
Piscussion
The endogenous concentrations of PGs and TX in the uterus,
are low, and metabolism of PGE-2 and PGF-2od in the absence of
NAD+ is also low. The addition of arachidonic acid to
homogenates of uteri from cycling rats does not alter PG or
TX production. Therefore the amounts of PGs and TX produced
by uterine homogenates incubated in vitro reflect the
relative abilities of the components of the PG synthetase
complex to convert free endogenous arachidonic acid released
during the homogenization and incubation, into PGs and TX.
202
Uterine production of PGE-2, PGF-2a, 6-keto-PGF-loi and
TXB-2 increased on pro-oestrus and reached a peak at 02:00h
on oestrus. The timing of the peak uterine PG and TX production
coincides with ovulation. Other workers also report an increase
in uterine PG production but there is disagreement on the
timing of peak uterine PG levels and production. A pro-oestrous
peak in uterine PGE-2 and PGF-2xlevels has been reported by
Ham et al., (1975), by Van Orden et al., (1980) and by Thaler-Dao
et al., (1982), while Ishikawa and Fuchs (1978) and Poyser and
Scott (1980) report highest PG levels and PG production on
oestrus. These discrepancies can be attributed to the frequency
of sampling employed in each study. The experiments described
in this section and in section 2.1.a. show that the ability of
the uterus and ovary to synthesize PGs and TX can change
markedly in a 4-hour period and that peak production occurs
around 02:OOh in both tissues and this present study demonstrates
the need for carrying out frequent measurements of PG levels
or production by tissues.
An additional peak in PGE-2 production by the uterus was
found on di-oestrus by Thaler-Dao et al., (1982). This finding
was not confirmed in this study. They also did not find any
significant differences in PGI-2 production during the oestrous
cycle but a rather insensitive radiochemical assay was used by
them- to measure PGI-2 production.
There are no reports on uterine TXA-2 synthesis during
the oestrous cycle although the uterus of the pregnant rat
at term has been shown to release significant quantities of
TXB-2 (Phillips and Poyser, 1981a, Dubin et al., 1982).
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In the present study, the origin of uterine TXB-2 was not
determined. It is possible that platelets trapped within the
uterus is the source of TXB-2 and that the increased production
reflects an increased blood volume at oestrus. It would be
interesting therefore to see if the uterus retained the ability
to synthesize TXB-2 after perfusion of its blood vessels with
saline to remove any blood elements.
Evidence against the possibility that the platelets
may be the source of uterine TXA-2 comes from the fact that
total TXB-2 production by the endometrium and myometrium were
similar. If the platelets were the only source of uterine
TXA-2 it would be expected that the myometrium, due to its
greater size, and therefore greater blood volume, would produce
more TXA-2 but this was not found to be the case. Since
TXB-2 production showed the greatest percentage increase
between 10:00h on pro-oestrus and 02:OOh on oestrus, TXA-2
synthesis by the uterus at the time of ovulation may be of
physiological importance. In this regard, recent reports
show that TXA-2 is highly potent in causing contractions of the
non-pregnant human uterus in vitro (Wi1helmsson, Wikland and
Wiqvist, 1981) and of the pregnant rat uterus (Dubin et al.,
1982). While little is known of the uterine motility at the
time of ovulation in the rat, increased uterine TXA-2
synthesis may increase uterine motility at that time. Sperm
transport into the rat oviduct is most rapid around the time
of ovulation (Shanghi and Kracier, 1978).
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Moreover, gap junction formation, which is thought to be
essential for synchronous uterine contractions (Garfield,
Sims, Kannan and Daniel, 1978), is inhibited by indomethacin
and restored by TXA-2 mimic 11,9-epoxymethano-PGH-2 but not by
PGE-1, PGE-2, PGF-2a or TXB-2 (Garfield, Kannan and Daniel,
1980). The effect of a specific TXA-2 synthesis inhibitor
or TXA-2 receptor antagonist on the uterine motility and the
fertility of rats requires investigation.
In agreement with the present study, Downing and Williams
(1980) report that the endometrium .was the major source of
TXB-2 in the uterus of the pregnant rat. However, Campos
et al., 1981 find that the myometrium releases more TXB-2.
Certain differences in experimental design account for these
divergent results. In the latter study, the endometrium and
myometrium were peri fused by a method which enabled their
anatomical relationship to be left intact. The authors claimed
that their method gave a true indication of endometrial and
myometrial PG and TX production by finding similar results
when perfusing each of these tissues separately. However,
their dissection of the uterus yielded two tissues of
approximately equal weight. Hence, their calculation of
endometrial weights must have been over-estimated considerably,
since in the present study the endometrium accounted for only
about 5% of the uterine weight. Also, Campos et al ., (1980)
used ovariectomized rats which had been given rather high
doses (1 mg per day for 3 days) of oestradiol and this would
also contribute further to the differences in results.
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Previous reports on PGE-2, PGF-2a and 6-keto-PGF-lo.
production by the endometrium and myometrium agree with the
results presented here, which show that the endometrium is
the main source of uterine PGF-2a and that uterine 6-keto-PGF-l<%
production predominates in the myometrium (Williams, Sneddon
and Harney, 1974, Williams et al., 1978; Abel and Kelly, 1979).
The relatively large increases in uterine PGF-2a and TXB-2
production seen at the time of ovulation can be attributed to
the relatively large increase in endometrial synthesis of these
two compounds (480% and 270% respectively).
An important finding was that the separated endometrial
and myometrial homogenates synthesized less PGs and TX than
when homogenized together. This finding agrees with the results
of Abel and Kelly, (1979) who found that the human endometrium
was rich in cyclooxygenase and enzymes which convert PGH-2 into
PGs and TX, but that the myometrium contained little
cyclooxygenase. Thus, when the tissues are homogenized together,
the endometrium provides cyclooxygenase for conversion of
archidonic acid into PGH-2, and then the PGH-2 is acted upon by
enzymes from both the endometrium and myometrium to produce
the various PGs and TX. Although the authors extrapolated this
to the in vivo situation by suggesting that the endometrium
provides endoperoxides as substrate for the myometrium, this
is unlikely to occur in vivo due to the instability of PGH-2.
Correlations of uterine PG and TX synthetase as
determined here with plasma concentrations of ovarian steroids,
show that peak PG and TX production occurs when plasma
oestradiol and progesterone levels are maximal (Shaikh and
Shaikh, 1975; Thaler-Dao et al., 1982).
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Furthermore, oestradiol and progesterone treatment of long-term
ovariectomized rats increased PGF-2<% and TXB-2 production
significantly. This suggests that the increased PGF-2a and
TXB-2 production on pro-oestrus and oestrus occurs in response
to oestrogen and progesterone. In contrast to the results of
Ham et al ., (1975) who found that oestradiol treatment increased
uterine PGF-2a production at the expense of PGE, the results
presented here show that the synthesis of one arachidonic
acid metabolite did not occur at the expense of any other.
However, Ham et al., (1975) used differing experimental
conditions from those used here. They added exogenous
arachidonic acid and the cofactors hydroqinone and reduced
glutathione which promote PGE synthesis, whereas in this study
neither arachidonic acid nor cofactors were added.
Unfortunately, time did not permit the study of either
oestrogen and progesterone treatment alone. It is possible
that oestradiol given alone is sufficient to increase uterine
PG synthesis as Kogo, Yamada and Aizawa (1977) found this to be
the case. However, uterine PG and TX production increased
little between 10:00h on di-oestrus and 10:OOh on pro-oestrus,
when oestradiol levels are already high. Rather, they increased
from the afternoon of pro-oestrus when the ovulatory surge of
progesterone occurs (see Fig. 3). Other studies support the
view that progesterone is necessary for maximum uterine PGF-206
production in the sheep (Barcikowski, Carlson, Wilson and
McCracken, 1974; and in the guinea pig (Blatchley and Poyser,
1974).
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Since oestrogen and progesterone increase the ability of
the uterus to synthesize PGs and TX this is presumably due to
increasing the amount of PG synthetase present in the uterus.
However, Castracane and Jordan (1976) found that the increase
in uterine PGF and PGE synthesis is unaffected by administration
of an oestrogen antagonist or protein synthesis inhibitors.
Thus, the action of the ovarian steroids on uterine PG and
TX synthesis may be indirect. For example, the effect may be
due to a catechol oestrogen (Kelly and Abel, 1981) or to
catecholamines (Van Orden et al., 1980) which may act as
co-factors during PG synthesis. A role for LH cannot be ruled
out, as oestrogen and progesterone treatment causes LH release
from the pituitary gland. Peak PG and TX production in the
uterus coincided with peak ovarian PG production which is due
to the action of LH on PG synthetase (see General Introduction).
However, no studies concerning the effect of LH on uterine
PG synthesis have been performed.
It was noticed that uterine PG and TX ratios changed
during the oestrous cycle which may suggest that their
synthesis is controlled independently. Therefore the
synthesis of PGE-2, PGF-2a, 6-keto-PGF-l£X and TXB-2 by the
endometrium and myometrium from PGH-2 requires investigation.
In conclusion, an increase in uterine PGE-2, PGF-20C,
6-keto-PGF-la and TXB-2 production occurs on pro-oestrus and
reaches a peak at the time of ovulation. This increase
occurs in the endometrium in the case of PGE-2, PGF-20C and
TXB-2 and in the myometrium for 6-keto-PGF-10t. While oestrogen
and progesterone treatment of ovariectomized rats was found to
mimic these changes to some extent, their exact mechanism of
action is unknown at present.
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It is speculated that the peak in uterine PG and TX production
at 02:OOh on oestrus may be associated with changes in
uterine motility at that time.
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Section 2.4. THE EFFECT OF AGEING ON UTERINE PG AND TX SYNTHESIS
Introduction
The failure of the uterus to support pregnancy may be one
of the factors to contribute to the decline in reproductive
capacity which accompanies ageing. In support of this suggestion
it has been demonstrated that transplantation of morulae and
blastocysts from young animals into aged recipients resulted
in their resorption, whereas a higher proportion survived and
implanted when transplanted into young recipients (Blaha,
1964; Talbert and Krohn, 1966).
Since these initial studies, the impaired decidualization
of uterine stromal cells in response to artificial stimuli
has been documented in the aged mouse (Finn, 1966; Shapiro
and Talbert, 1974), rat (Maibenco and Krehbiel, 1973) and
hamster (Blaha, 1967). Differences in circulating levels of
steroid hormones cannot account for these effects of ageing
as these studies were generally carried out on ovariectomized,
steroid-primed animals.
Decidualization (which can be brought about experimentally
by chemical or mechanical irritation of the endometrium) can
only be obtained when the uterus has previously been primed by
oestrogen and progesterone (O'Grady and Bell, 1977). According'
to measurements of circulating progesterone in the ageing
pregnant rat (Miller and Riegle, 1978), the hormonal milieu in
these animals is adequate to support normal decidual development.
It is possible then, that a reduced response to the hormonal
stimulus occurs in the aged animal.
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Uterine decidualization is preceded by and possibly
dependent on, increased capillary permeability (Psychoyos,
1973) which has also been shown to be reduced in ageing
pregnant hamsters (Parkening and Soderwall, 1973). Since there
is evidence (see Introduction) that PGs are implicated in the
control of endometrial vascular changes and in the decidual
cell response, defective production of these compounds may
explain the reduced decidual cell response in ageing uteri.
The experiments to be described in this Section were
designed to study PG and TX production by the uterus of young
and aged ovariectomized rats in response to treatment with
oestrogen and progesterone, using a regimen designed to mimic
pre-implantation endometrial development. Aged animals were
used at 13-14 months. At this time a loss of fertility is
evident but longevity exceeds 24 months on average. Three
parameters of the response have been measured, i.e. PG and TX
synthetic capacity in incubated uterine homogenates, PG and TX
levels in ethanolic uterine homogenates and PG release from the
superfused uterus.
Methods
Preparation and treatment of animals
Virgin Sprague-Dawley rats were housed under controlled
lighting conditions (Lights on 05:00h, Lights off 19:OOh) and
allowed free access to food and water. Young rats were used at
4-5 months and aged rats at 13-14 months. They weighed 230-31Og
and 270-350g respectively.
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Rats were bilaterally ovariectomized under ether anaesthesia,
this being used to induce anaesthesia during all surgical
procedures. The day of ovariectomy was designated as day 1 of
treatment. On day 8 a silastic tubing implant (Dow & Corning,
inner diameter 0.1550 cm, outer diameter 0.3125 cm, length
2 cm) either containing crystalline oestradiol-17/3 (treated
rats) or empty (control rats) was inserted subcutaneously
between the scapulae. All implants were preincubated overnight
at 37°C in phosphate-buffered saline (pH 7.1) and after being
filled with steroid, were sealed with silicone adhesive type A
(Dow & Corning). On day 11, the oestradiol implants were removed
and replaced by implants containing crystalline progesterone. A
replacement empty implant was exchanged for the empty implant in
control animals. At this stage, a blood sample was withdrawn by
cardiac puncture from 4 animals from each of the groups, for
estimation of plasma oestradiol by RIA. (The RIA for oestradiol
was performed by Dr. H.M. Fraser, MRC Reproductive Biology Unit,
Edinburgh). On day 14, animals in the treatment group received a
subcutaneous injection of oestradiol-17/3(0. ^ugkg~1) in a vehicle
composed of benzyl benzoate and arachis oil (1:9, v:v) at 12:OOh,
while control animals received vehicle alone. Animals were
killed on day 15, 21-23h after the oestradiol injection, and
blood was withdrawn by cardiac puncture for estimation of plasma
progesterone levels by RIA. (The RIA for progesterone was also
performed as above).
Analysis of plasma oestrogen and progesterone levels showed
them to be in the physiological range for early pregnancy
"" 1 — *]
(Oestradiol, 50-100 pgml ; progesterone, 15-60ngml ).
Preparation of animals in this way was carried out by Dr. R.G.
Gosden of the Department of Physiology, University of Edinburgh.
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Rats which had been sensitized in this way were then
assigned to one of the experiments described in the following
sub-sections. However, some animals provided tissue for use in
more than one experiment.
Presentation of results
In each set of experiments uterine PG measurements are
presented both as total per uterus, and also on a unit protein
basis. The two ways of expressing the data are employed as
part of the increase in uterine protein content in the aged
animal can be ascribed to the accumulation of collagen in the
uterus of the aged rat (Schaub, 1964). Since collagen is an
extracellular protein, and PG synthetase is intracellular (Smith,
Rollins and Dewitt, 1981), expressing the data on a unit protein
basis alone may be misleading.
Section 2.4.a. Measurement of the effect of treatment on
the capacity of the uterus of young and aged
rats to produce PGs and TX
Method
A total of 20 young and 20 aged rats were used. From each
group, 10 animals were treated with oestrogen and progesterone
as described previously, while 10 animals served as controls.
On day 15 of treatment the animals were killed and each uterine
horn was dissected out and homogenized in 5 ml Krebs' solution.
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A sample of the homogenate (lOQjul ) was taken for protein
estimation using the method of Lowry et al., (1956) and then each
homogenate was added to a flask. Flasks were incubated as
described in Section 2.1.a and extracted for PGs and TX as
described in Section 1.3.a. Samples were stored at -20°C in
ethyl acetate, until they were assayed for PGE-2, PGF-2a,
6-keto-PGF-l# and TXB-2 content by RIA using the methods
described in Sections 1.3a, b, c and d.
The results have been expressed as mean ± s.e.m. and were
examined by two-way analysis of variance (Anovar) and Student's t
test, to provide information about the effects of treatment, age
and their interaction.
Results
The major PG produced by young and aged animals was
6-keto-PGF-lct with lesser quantities of (in descending order)
PGF-2&, PGE-2 and TXB-2. Uterine protein content (Table 21,
Panel A) was significantly increased (p< 0.001) with age and
by treatment with oestrogen and progesterone (pc0.05).
On a unit protein basis (Table 21, Panel A) production of
PGs and TXB-2 was significantly lower in ageing than in young
uteri and was increased by steroid treatment, the sole exception
was 6-keto-PGF-loc which just failed to reach an acceptable level
of statistical significance (p=0.05). There was no effect of
age or treatment on the proportions of PGs or TX produced with
respect to one another.
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Interactive effects of age and treatment revealed by Anovar
were significant for PGF-2CC (p<0.025) and TXB-2 (p<0.01) and
was also significant when the data for all the PGs and TXB-2 were
nested and transformed to logarithms (p< 0.025). Although
steroid treatment significantly increased the production of
these compounds in young animals (p< 0.01 by Student's t test)
there was no such effect in the ageing groups.
In contrast to these results, production of PGs and TXB-2
expressed per uterus was unaffected by ageing (Table 21, Panel B)
although there was a significant stimulation of production
following steroid treatment (p<0.025) and a significant
interactive effect of age and treatment for PGE-2 (p < 0.05).
Cone!usion
On a unit protein basis, PG production was diminished in
the uteri of aged animals, but when expressed as total
production per uterus, it was unaffected by age. The two ways
of expressing the data were employed as there is evidence that a
proportion of the increased uterine protein in aged animals
is extracel1ular and presumably therefore is not associated with
PG synthetase which is an intracel1ular protein. Accordingly,
when expressed per mg of protein, the reduced PG and TX
production in the aged animal may reflect a 'dilution' due to
increased collagen. However, the significant interactive effect
of age and treatment implies that the responsiveness of the
aged uteri to treatment was diminished and this conclusion is not
subject to the same limitations in interpretation as above.
Furthermore, a parallel increase in uterine protein content in
response to treatment occurred in young and aged animals and
yet PG and TX production increased only in young animals.
Section 2.4.b. Measurement of the effect of treatment on uterine
PG levels in young and aged rats
Method
A total of 7 rats in each of the groups were used in this
experiment. Rats were killed and their uteri dissected as
before." The two uterine horns were divided and only one horn
used in this experiment. Each uterine horn was homogenized
in 5 ml ethanol and lOQul taken for estmation of protein
content as before. After transferring the homogenate to a
centrifuge tube, the homogenizer was washed twice with two
5 ml volumes of ethanol and the washings added to the centrifuge
tube. The homogenate was centrifuged at 1000 x g for 5 min.
Following centrifugation, the supernatant was transferred to a
flask and evaporated to dryness under reduced pressure at 45°C.
The residue was resuspended in 10ml Krebs1 solution and the
extraction of PGs proceeded as described in Section 2.1.a. The
samples were stored at -20°C in ethyl acetate until they were
assayed for PGE-2 and PGF-20C content by RIA .using the method
described in Sections 1.3a and b.
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Res u11 s
Uterine PG levels were an order of magnitude lower than in
the incubated homogenates above. The levels of PGE-2 were
slightly higher than those of PGF-2ctand, when expressed per mg
protein, were found to be significantly greater in young compared
to ageing uteri (Table 22, Panel A, p<0.001). The results
for PGF-2awere not significant but indicated a similar trend
to that of PGE-2. As in Section 2.4.a, the effect of age was
lost when results were expressed as total amounts per uterus
(Table 22, Panel B). Steroid treatment did not affect the
levels of PGs in either young or ageing animals.
Cone!usion
Since uterine levels of PGE-2 and PGF-2a were an order
of magnitude lower than PG production as determined in
Section 2.4.a, it is likely that PG production by the incubated
uterine homogenates reflects fresh synthesis. The reduced levels
of PGE-2 in ageing uteri parallels the reduced PGE-2 production
in ageing animals. In contrast, however, reduced PGF-2ct
production in aged animals was not accompanied by reduced PGF-206
levels in aged uteri.
Although treatment with oestrogen and progesterone increased
synthetic capacity for PGE-2 and PGF-2a in young animals
(Section 2.4.a) PG levels were unaffected by this treatment.
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Section 2.4.C. Measurement of the effect of treatment on the
capacity of the uterus of young and old rats
to release PGs
Method
Uterine horns (n=4 for each group) were opened
longitudinally and cotton threads were attached to either end.
One end of the thread was secured to the base of a 20ml
open ended chamber. The upper thread was attached to a
pivoted arm which was calibrated to provide a tension of lg.
The tissues were superfused with Krebs1 solution at 37°C
-1
at a rate of 5m 1 min . After an initial equilibration period
of 1h, the superfusate was collected for lOmin, and, after
another 20 min, a further 10 min collection was made. The
superfusates were extracted for PGs as described in Section
1.2.a. and the samples stored at -20°C in ethyl acetate until
they were assayed for PGE-2, PGF-2a as described in sections 1.
and b. After the last collection of superfusate, each uterine
horn was homogenized in 5ml Krebs' solution and lOOjul of the
homogenate taken for estimation of protein concentration.
Results
The amounts of PGE-2 and PGF-2CC released by superfused
uteri showed considerable variation between individuals but
were approximately comparable.
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Release of PGE-2 but not PGF-2Ctwas significantly less in
ageing compared to young uteri (Table 22, Panel A, p<0.05).
The effects of treatment appeared to be slight or possibly even
negative in the case of PGE-2 where the statistics approached
significance (0.05<p< 0.10).
Cone!usion
The small numbers employed in this experiment together with
considerable variability in PG release limits the interpretation
of the results. The reduced release of PGE-2 from superfused
tissue in aged animals together with reduced PGE-2 levels in
unincubated tissue, suggest that the reduced amounts of PGs
produced by incubated homogenates reflect a physiological
change. Although steroid treatment increased synthetic capacity
for PGE-2 and PGF-2ain young animals (Section 2.4.a) the same
treatment did not result in increased release of these compounds
from superfused tissue.
Piscussion
Production of PGs and TXB-2 per unit weight of protein
was reduced in aged uteri when compared to young animals under
comparable endocrine conditions. The pattern of results was
generally similar for all 4 compounds measured although was
perhaps more marked for PGE-2. Moreover, although steroid
treatment significantly increased the production of PGs and
TX in young animals there was no such effect in the ageing
groups. However, steroid treatment did not affect PG levels
or release by young or aged animals.
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Providing that the availability of arachidonic acid within
the homogenates was not limiting for PG and TX synthesis, these
results provide evidence of a reduced capacity to synthesize PGs
and TX in the aged animal.
Changes in the pattern of synthesis may reflect changes
in the mass and in the cellular composition of the tissue, and
this limits the interpretation of the data. The uterus continues
to grow throughout life and accumulates collagen (Shaub, 1964-65)
at a disproportionate rate. The increasing amount of
extracellular protein would lead to values of PG production in
aged animals for example, being lower than in young animals
when expressed per mg protein.
Despite these limitations in interpretation of the reduced
PG production, levels and release in aged animals, the
interpretation of the reduced responsiveness to steroid treatment
in these animals is not limited in this way. Expressing the data
as total PG and TX production or PG levels and release per uterus
highlighted the effect of treatment. These results imply that
the major effect of treatment was to stimulate growth of the
uterus rather than the amount of PGs and TX produced per unit
protein mass.
The details of the growth promoting effects of steroids
upon the various sub-populations of cells are likely to be
very complex and presently there are no improvements available
for the two methods of presentation of the data. Although
there was no evidence that uterine protein production in response
to treatment was reduced in aged compared with young animals,
it is possible to explain the reduced PG production in aged
animals as the result of a decreased growth response of some
uterine cells.
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Following steroid treatment of young rats, the amounts of
PGE-2, PGF-2(Xand 6-keto-PGF-10t were similar to those previously
reported for rats on day 5 of pseudopregnancy (Fenwick et al.,
1977; Phillips and Poyser, 1981b). TXB-2 production by uteri
of young rats was also increased. However, no reports on
TXB-2 synthesis relating to the time of implantation are
avaiTable.
At first sight it seems difficult to reconcile the fact
that treatment of young rats increased synthetic capacity
for PGs and TX while levels and release were unaffected by the
same treatment. It is possible that the steroid treatment of
young animals increases PG synthetic capacity but that PG
synthesis has to be stimulated either artifically or by
blastocyst implantation, in order to reveal this increased
capacity as increased levels of PGs in the uterus. Several
studies have demonstrated increased uterine PG levels in response
to deciduogenic stimuli (Rankin et al., 1979; Kennedy, 1979,
1980; Kennedy, Barbe and Evans, 1980). These studies measured
PG levels after sensitization of the uterus with oestrogen
and progesterone, which is similar to the method used here.
However, in contrast to the experiments reported here, PBSG
or sesame oil was injected as an additional artificial
decidualizing stimulus by these workers. Artificial
deciduogenic stimuli cause tissue damage (Finn, 1977; Lundqvist, .
Ljunqkvist and Nilsson, 1977) and tissue damage is known to
stimulate arachidonic acid release and PG synthesis (Ramwell and
Shaw, 1970; Piper and Vane, 1971). In the physiological
situation, the close contact of the blastocyst with the
endometrial surface may cause a similar type of tissue damage
(Psychoyos, 1973). It is proposed then, that steroid treatment
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increases the activity of PG synthetase but that arachidonic
acid release is required to express the increased enzyme activity
as increased PG levels or release.
The diminished response to oestrogen and progesterone may
be the result of decreasing concentrations of uterine cytosolic
steroid receptors (Holinka, Nelson and Finch, 1975; Saiduddin
and Zassenhaus, 1979; Gessell and Roth, 1981). However, the
reduced amounts of PGE-2 in unincubated tissue and the reduced
release of PGE-2 from superfused tissue in aged animals suggests
that the reduced amounts of PGs produced in incubated homogenates
reflect a physiological change in the PG synthetic pathway.
In this regard it is interesting to note that the PG synthesizing
capacity of the liver and its stimulation by phenobarbitol is
reduced with ageing in rats (Murota and Morita, 1980). In their
study, reduced PG synthesis was accompanied by increased uptake
of arachidonic acid into cellular phospholipids. This
suggests that there is a decline in phospholipase activity
during the process of ageing. The study of phosjahol ipase
activity in the uterus of the aged animal merits investigation.
Reduced tissue concentrations of PGs (and possibly
TXB-2) may have significant implications for fertility in
ageing uteri. Decreased PGE-2 and PGI-2 concentrations may
result in impaired hyperaemia and endometrial vascular
permeability and perhaps together with reduced PGF-2CX
concentrations, may cause the impaired decidual response.
It is of interest that Soderwall and Smith (1962) found
that Vitamin E treatment improved the development of implantation
sites in aged hamsters. Vitamin E, an antioxidant, is a
potent inhibitor of soya bean lipoxygenase (Pangan amala,
Miller, Gwebu, Sharma and Cornell, 1977). Fatty acid
hydroperoxides produced during the 1ipoxygenation reaction
have been reported to inhibit PG synthesis (Gryglewski, Bunting,
Moncada, Flower and Vane, 1976). It is also known that excessive
lipid peroxidation secondary to free radical formation occurs
during the process of ageing (Slater, 1972). Therefore the
beneficial effect of Vitamin E on the development of implantation
sites in aged animals may be by virtue of its protective effect
against inhibition of PG synthesis by hydroperoxy fatty acids.
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GENERAL DISCUSSION
The experiments described in this thesis have addressed the
questions of the physiological significance of PG and TX
synthesis in the ovary, hypothalamus and uterus and of how this
synthesis is regulated.
Several of the multiple stages involved in the PG
synthetic pathway have been examined viz., PG synthetase
activity, PG metabolism and PGE-2-9-ketoreductase activity.
PG and TX production by the ovary, hypothalamus and uterus
varied throughout the oestrous cycle. Since in each case,
these variations were not due to alterations in arachidonic
acid availability or PG metabolism it was concluded that they
were due to changes in the activity of PG synthetase. The
regulation of PG synthetase activity therefore constitutes
an important stage for regulation of PG and TX synthesis.
The dominant pathway for PG and TX synthesis varied
among different tissues. This observation may reflect the
presence of differing amounts of enzymes in different cell
types.
In each type of tissue homogenate the ratios of PGs
and TX produced were not constant during the oestrous cycle
which suggests that there is specific control of the
individual enzymes producing PGs and TX from PGH-2. However,
despite this suggestion, it was concluded that in the ovary,
LH controls PG synthesis by acting at the level of the
cyclooxygenase enzyme.
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It was proposed that LH could stimulate cycl ooxygenase thereby
increasing PGH-2 availability which would result in a
preferential increase in PGE-2 synthesis. Several studies
in other tissues support this proposal. Fig. 27 illustrates
the effect of increasing substrate (PGH-2) concentrations
on the formation of TXB-2 and 6-keto-PGF-lct by rabbit lung
microsomes as reported by Sun, Chapman and McGuire (1977).
2 5 7 5 12-5
[>GH-2] x 106M
Figure 27. Effect of substrate concentrations on the
formation of TXB-2 and PGI-2 by rabbit lungmicrosomes. Two ml of rabbit lung microsomes(2 mg/ml) were incubated with various concentrationsof C-PGH-2 for 2 minutes at 37°C. (From Sun,Chapman and McGuire, 1977).
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Clearly low substrate concentrations favour 6-keto-PGF-ia
synthesis while higher concentrations of PGH-2 favour TXB-2
synthesis. This study illustrates how a directional stimulation
of one PG or TX could be brought about solely by increasing
cyclooxygenase activity. It is proposed that a similar
mechanism accounts for the preferential increase in PGE-2
production at the time of ovulation in the rat.
Smith and Lands (1972) have provided evidence of two
separate types of cyclooxygenase - a 'slow* enzyme which provides
basal levels of PGs and another 'rapid' enzyme which requires
activation. In the ovary, the 'slow' enzyme may provide basal
PG and TX levels, and, when activated by LH, the 'rapid'
cyclooxygenase could provide elevated levels of PGH-2.
Obviously, the effect of changing PGH-2 concentrations on
ovarian PG and TX synthesis requires investigation.
In the studies on ovarian PG and TX synthesis, homogenates
of whole ovaries were used. However, the granulosa cells
within the ovarian follicles appear to be the main site of
ovarian PG synthesis (Clark, Marsh and Le Mai re, 1978 ;
Erickson, Challis and Ryan, 1977). In future experiments
on the control of ovarian PG synthesis, separation of ovarian
follicular cell types will be required. Nevertheless, there
may be an interaction between follicular cell types as LH
will stimulate PG production by whole rabbit follicles
in organ culture, (Moon, Zamecnik and Armstrong, 1974), whereas
rabbit granulosa cells and thecal tissue grown separately, fail
to respond consistently to LH (Erickson et al., 1977).
The physiological significance of ovarian PGE and PGF synthesis
is well established in that they are essential for ovulation in
many species, with the possible exception of humans although more
studies are required in women.
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The present study showed th'at in addition to PGE and PGF, 6-keto-
PGF-la synthesis was elevated at the time of ovulation implying
that PGI-2 may have a role in the ovulatory process. Although
the precise site of PGI-2 synthesis was not determined it is
possible that the increased synthesis of PGI-2 is responsible for
the vasodilation occurring in ovarian follicles just prior to
ovulation (Jones, 1979). PGE-2 may be involved in causing
vasodilation also.
An unexpected finding was that a peak in uterine PG and
TX production occurred simultaneously with peak in ovarian PG
production. The production of PGF-2aand TXB-2 increased between
pro-oestrus and oestrus to a much greater extent than the
production of PGE-2 and 6-keto-PGF-la. This pattern of synthesis
was mimicked by treatment of long-term ovariectomized rats with
oestrogen and progesterone suggesting that ovarian steroids may
directly stimulate uterine PG and TX synthesis. However, these
steroids also cause an LH surge which may have affected uterine
PG and TX synthesis. The fact that peak uterine PG and TX
production coincided with peak ovarian production suggests that
they may have a common stimulus. Since LH is the stimulus for
ovarian PG synthetase, it would be interesting to examine the
possibility that uterine PG synthetase is another 'target' enzyme
for LH.
Separation of uterine tissue into the endometrium and
myometrium again highlighted the fact that the dominating
pathway in the synthesis of PGs varies between cell types.
In the endometrium the major PG produced was PGF-2ct, while in the
myometrium 6-keto-PGF-liX predominated. However, an interaction
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between the two tissues was apparent in that PG and TX production
was greater when they were homogenized and incubated together.
As suggested by Abel and Kelly (1979) it is possible that
in vivo the endometrium supplies PGH-2 as substrate for
conversion into PGs and TX by myometrial enzymes. While this
interaction could occur at the interface between the two
tissues, the instability of PGH-2 would indicate that
diffusion of active PGH-2 between the tissues is unlikely.
The physiological significance of the cyclical
variations in uterine PG synthesis is unknown at present.
It is speculated, however, that the approximately 3-fold
increase in uterine TXB-2 production (reflecting TXA-2
production) at the time of ovulation may be involved in the
genesis of uterine contractions at that time. Increased
uterine activity could account for the accelerated sperm
transport into the oviduct close to, or just after
ovulation in many species (see Hunter, 1981). Studies
with specific TXA-2 receptor antagonists or TXA-2 synthesis
inhibit ors promise to elucidate further the physiological
significance of uterine TXA-2 synthesis.
A disruption of uterine PG and TX synthesis was observed
in the aged animal. PG and TX production was reduced in aged
rats but this effect was most striking in the case of PGE-2.
Since PGE-2, PGF-20C and PGI-2 are implicated in the vascular
changes which precede uterine decidualization (see General
Introduction) it was suggested that the reduced capacity to
synthesize PGs (and TX) may explain the decline in the
capacity of the aged uterus to support blastocyst implantaton.
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It was demonstrated that the reduced PG and TX production*
was due to the reduced ability of the PG synthetase to
convert arachidonic acid into PGs and TX. In agreement
with a decreased PG synthetase activity^an age-related
decrease in PGI-2 synthesis from PGH-2 occurs in aortic
smooth muscle (Chang, Murota, Nakao and Orimo, 1980).
However, decreased PG synthetase activity may occur in
parallel with decreased phospholipase activity as this has
been demonstrated in the liver of aged rats (Morita and
Murota, 1980).
It was proposed that the accumulation of high levels
of lipid hydroperoxides in ageing tissue (Slater, 1972)
may account for the observed decrease in PG and TX synthesis.
During PG synthesis the generation of high levels of lipid
hydroperoxides and free radicals causesinactivation of
cyclooxygenase. This emphasizes another control mechanism
for PG synthesis in that cyclooxygenase is a self-1imiting
enzyme (Lands, 1981) and therefore regulation of the inactivation
could alter the amounts of PGs and TX synthesized by tissues.
Antioxidants, which are capable of scavenging free radicals
have the potential to modulate the activity of the cyclooxygenase
enzyme. It was therefore proposed that this may explain
the stimulatory effect of NA on PGE-2, PGF-2a and TXB-2
synthesis in the ME and AH-POA.
Stimulation of hypothalamic PG synthesis by NA may be •
of importance in the control of LHRH release as an increase
in NA turnover occurs between 11:OOh and 17:OOh on pro-oestrus
and this overlaps with a peak in PGE-2 synthesis in the ME
(Barraclough and Wise, 1982).
231
Furthermore, it has been demonstrated that the ME releases
PGE-2 in response to NA and that inhibition of PG synthesis
suppresses the release of LHRH elicited by NA (Ojeda et al.,
1979). Collectively, these results suggest that the
stimulatory effect that NA exerts on LHRH release (Negro-Vilar
et al., 1979) is mediated by increased PGE-2 synthesis.
Whether PG synthesis is within or in the vicinity of the
LHRH containing neurones, requires investigation. In
addition to NA stimulating PGE-2 synthesis, PGE-2 may in
turn stimulate NA release from hypothalamic neurones
(Roberts and Hillier, 1976). Thus the stimulatory effect of
PGE-2 on LH release may arise by potentiation of adrenergic
neurotransmi ssion in the hypothalamus.
A case has been put forward for regarding progesterone
as a stimulus for the increased PG production in the ME.
Plasma levels of this hormone (Mann and Barraclough, 1973)
closely resemble the diurnal variation in PGE-2 production by the
ME. Moreover, progesterone treatment of oestrogen-primed
long-term ovariectomized rats increased PGE-2 production by the
ME. This hypothesis is supported by the work of Labhsetwar and
Zolovick (1973) who showed that aspirin, injected into the
hypothalamus, blocked the stimulatory effect of progesterone on
ovulation. Since this effect of progesterone on ovulation is
transmitted through anct-adrenergic pathway in the hypothalamus,
these workers suggested that PGs potentiate hypothalamic
adrenergic neurotransmission. However,OL -receptor antagonists
do not block PGE-2-induced LH release (Harms et al., 1976).
Therefore an alternative interpretation is that progesterone
stimulates NA release and that NA is the stimulus for PG
synthesis.
If progesterone and NA are physiological stimuli for
an increase in hypothalamic PG synthesis, then a mechanism must
exist which directs ME PG synthesis towards PGE-2 on pro-oestrus
and oestrus. As was suggested for the ovary, the availability
of PGH-2 may determine which PG is formed. The effect of
changing PGH-2 concentrations on the ratios of PGE-2,
PGF-2&, TXB-2 and 6-keto-PGF-lct production by the
hypothalamus requires investigation.
.stuciy oj~
The.effect of Froben treatment on the pro-oestrus
LH surge was inconclusive, probably for two reasons.
Firstly, the effects of the drug on the release of LH may
be complicated by changes in pituitary responsiveness. If Froben
increased pituitary responsiveness to LHRH it would be difficult
to determine whether the drug could inhibit the LH surge. The
effect of Froben on the pro-oestrous surge in LHRH would overcome
this problem and this experiment requires investigation.
Secondly, PG synthesis in the hypothalamus was not completely
inhibited by Froben and sufficient levels of PGs may have
remained which allowed a full LH surge. Conclusive evidence of a
physiological role for PGs as mediators of LHRH release must
await the demonstration that complete inhibition of hypothalamic
PG synthesis blocks the pre-ovulatory LHRH surge.
In conclusion, these studies have provided further evidence
that PGE-2 is involved in the processes of LHRH release and
ovulation. It is proposed that LH controls ovarian PG synthesis
by altering the availability of PGH-2 to the PG synthetase enzyme
complex. The process of ovulation may be closely related to the
increase in uterine PG synthesis at that time. Finally, reduced
uterine PGE-2 synthesis may be a significant factor contributing
to the reduced fertility in the aged animal.
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